

## The Standard Documents of tender to specialist Sectors Buying the Medicine

**Contracting Entity:** Ministry of Health / Environment / The  
State Company For Marketing Drugs  
Medical Appliances (kimadia )

**Project Reference/Tender:** Contract For The Supply of  
medicine will arranged on the recent balance

**The Project Name/Tender:** Med / 1 /2020

**Title of the Task:** buying the medicine

Date: issued in date( day)... 19 /1 / 2020.

## The Standard Documents of tender to specialist Sectors

### General Tender Buying the Medicine

Tender: Med /1 /2020

Reference Tender: recent Iraqi Federal Budget

Date: 19 / 1 /2020

## Invitation for Bids (IFB)

### **Tender: General Tender to Buying the Medicine**

**Tender No.:** Med/ 1 /2020 on the recent Iraqi Federal Budget

**IFB Number:** 1 .....

1. The Ministry of Health / Environment / The State Company For Marketing Drug AND Medical Appliances (kimadia

) invites the a bidders qualified to present the tenders that sealed & signer for contracting on supplying of medicine

2. will be adoption measures of public bidding in the process of tender where allowed to take part of all bidders from countries eligible legally as specified in the document of bidding.

3. Interested eligible bidders may obtain further information's from Ministry of Health / Environment / The State Company For Marketing Drug and Medical Appliances (kimadia )/ **Drug Media Department & the Public Relations**- 5<sup>th</sup> floor , position of MOH (Ministry of Health), E-mail (dg@kimadia.iq ) & Kimadia website is ([WWW.kimadia.iq](http://WWW.kimadia.iq) ) and inspect the bidding documents at the address given below from ( 8:30 AM) to (2:30 PM) at Baghdad time.

4. Bidders must meet the requirements of qualifications including: the legal, technical and financial requirements as mentioned in Bidding Document. A margin of preference for the pharmaceutical will be adopted from suppliers/ national factories goods . Additional details shall be specified in the Bidding Documents (see the clause(30) priority national from the Instructions To Bidders & clause (30) from Bid informations sheet.

5. the interested bidders could purchase the complete set of Bidding Documents in English or Arabic Language upon submission of a written application to the address below and after payment of a non-refundable fee with lump sum as follows:

a- (1.000.000) one million Iraqi Dinar of the tender that less than (1.000.000) Dollars .

b- (2.000.000) two million Iraqi Dinar for the tender that more than (1.000.000) Dinar.

Otherwise the offer will be neglected.

The way of payment this duty will be cash & the Bidding Document will be sent as state in ITB (Instruction To Bidders ) & the bidder who is previously participated in the re-announced bid to submit the previous purchasing receipt with the tender documents

6. Announcement date of this tender will be on 19 / 1 /2020 and The date of conference convening will be on 17 / 2 /2020 for responding the inquire of the participants against the tender.

Bids must be delivered at or before the end of formal work on 23 / 2 / 2020]. The late bids will be rejected. Bids will be opened in the presence of the bidders' representatives who choose to attend in person at the address below .

The date of opening the tender will be the day after closing date in Kimadia and in publicly form.

. All bids must be accompanied by a Bid Security at ratio 1% from the estimated cost on condition issued from Iraqi dependable bank according to report issued from the Iraqi central bank for the bank financial performance & it depend on

a- Bid Bond shall only be accepted if presented as a bank guarantee or legalize check or svtjh & the swift of a guarantee letter or direct bond are not accepted.

b-Bid Bond should submit by the bidder or any of the share holders of the company or companies participate under contract for the benefit of contracting party as mentioned in attached sample in Bidding Forms/part 4<sup>th</sup>.

c-Public companies exempt from submitting the bid bond & letter of guarantee good execution stipulated by instruction of implementation the contracts (no.2) year 2014.

d-the bond issued from company which contracted with it or with its legal authorized for issuing the bond under formal & certified authorization.

e-the submitting of bond should attached with litter of legalized issuing (private & secret) send to Ministry of Health / Environment / The State Company For Marketing Drug Medical Appliances (kimadia ) by the bank who issued the bond.

f-the bond should not conditional & for the favor of The Ministry of Health / Environment / The State Company For Marketing Drug Medical Appliances (kimadia )

g-the bond must issued by two languages (Arabic & English).

h-the primary insurance will be confiscated for who to be the successful upon his abstain for signing the contract after the notification with awarding matter & all other legal procedures will be taken against him that indicated in these instructions & confiscate the bid bonds for those who referred to him the tender when withdraw its bid during the period of validity after the closing of tender or refused correction on his calculations mistakes in tender & its reflection or awarding decision & take legal actions set forth in the instructions of implementation the Government contracts against him.

i-Final bid bond expiration date be valid until after the end of validity tender specified in the documents of tender.

7. The address(es) referred to above is Baghdad/bab-Almadhm Ministry of Health / Environment / The State Company For Marketing Drug Medical Appliances (kimadia )/6<sup>th</sup> floor/Financial Dept. to submit the bid bond or Receipt & Opening the offers to submit the tenders

Tel.4157667, Mobil:707705419074, switchboard:8,7,5,4158401 (switchboard with 4line)

**Contracting Entity** The Ministry of Health / Environment / The State Company For Marketing Drug Medical Appliances (kimadia) **Contracting Authority:** PH.MUDHAFAR ALI ABBAS

**Title:** Director General of The State Company For Marketing Drug Medical Appliances (kimadia )

**Signature:** { signed }



---

**MED/ 1 /2020**  
لتوفير احتياج عام 2021

- All human products must be of human recombinant origin wherever these are available in the markets.
- For oral solution it is preferable: Syrup then Suspension and then Elixir
- Caution To be written if the products contain metabisulphite as following (Caution: this product contain metabisulphite may cause broncho spasm in atopic & Asthmatic subjects)
- It doesn't matter of all tablets that approved in the national list as scored tab to be plain tab (Not scored).
- The measuring unit of medicinal milk powder weight is 400gm up to 1000gm (as upper limit)
- لا تزيد نسبة الكحول الموجودة في الشرابيات (بشكل عام) عن 10% .N.M.T.
- فيما يخص شرابيات الاطفال.. يفضل بدون كحول أو بنسبة ضئيلة 5% .N.M.T.
- يجب استخدام soft gelatin Cap لمستحضرات (Oily prep)
- يحل الغاز الدافع CFC – free (HFA 134a) محل CFC.
- وحدة قياس الحليب الطبي (بودرة) باعتماد الوزن هي ٤٠٠ غم لغاية ١٠٠٠ غم كحد اعلى
- note:Trade name is mentioned as an Example only and not limited to the trade name mentioned beside the item.**

ملاحظة: ان الكلفة التخمينية هي للتعينة اما الاحتياج الكلي فهو للوحدة الواحدة  
Note : The estimated cost is per packing size while the total need is for unit dose

	national code	Item	Total NEED 2021 (for unit dose)	PACK SIZE	MEAN BRAND Price (\$) / pack size	GENERIC European 70% mean price (\$) / pack size	GENERIC Asian including Arabic 45% mean price(\$)/ pack size	GENERIC Far East 25% mean price (\$) / pack size
1	01-AA0-004	Digoxin 250 mcg scored Tablet	1575863	100 tab	2.5	1.25		
2	01-AA0-006	Digoxin 250 mcg/ml inj (2ml) Ampoule	50848	6 amp of 2ml	2.63	1.84	1.18	0.66
3	01-B00-005	Frusemide I.V, I.M/or Slow I.V , I.M. inj 20mg/2ml Ampoule	3097433	amp	0.30	0.22	0.17	0.1
4	01-C00-012	Labetalol 5mg/ml inj. (20ml) Ampoul or vial للتخدير من قبل وحدات التخدير مع امكانية استخدامها "وتستخدم ايضا على الشكل التالي لعلاج حالات ارتفاع ضغط الدم الحلمي pregnancy intiated hypertention IV ملغم خلال دقيقة وبعد خمس دقائق وكحد اعلى 200 ملغم -1 الحقن الوريدي (50) ملغم /ساعة وتضاعف الجرعة بعد 20 ( IV infusion ) عن طريق-2 ملغم/ساعة وتعتبر من ادوية الخط الاول 160 نصف ساعة وكحد اعلى لعلاج حالات ارتفاع ضغط الدم الحلمي وقد اقر البروتوكول العلاجي من قبل اللجنة الاستشارية للنسائية والتوليد	21491	5 amp of 20ml	43.430	30.4	19.54	10.858
5	01-C00-017	Metoprolol tartrate 1mg/1ml I.V. inj (5ml) Ampoule SEE 1C تستخدم ايضا للتخدير من قبل وحدات التخدير	103292	5 amp	6.3	4.41	2.84	1.58
6	01-C00-023	Propranolol Hcl 1mg/ml slow IV inj (1ml) Ampoule (ويؤخذ بنظر الاعتبار استخدامه في التخدير ( ٩٧٦ )	24115	10 amp of 1ml	3.063	2.144	1.378	0.766
7	01-D00-001	Amiodarone Hcl inj 50mg/ml (3ml) Ampoule SEE 1D (976) يؤخذ بنظر الاعتبار ضمن قائمة التخدير	187386	6amp	6.00	4.2	2.7	1.5

8	01-D00-014	Phenytoin sodium 50mg/ml I.V inj (5ml) Ampoule الطوارئ ادويه	40859	5 AMP			12	
9	01-D00-022	Verapamil Hcl inj 2.5mg/ml, slow I.V. (2ml) Ampoule	54245	amp of 2ml			0.300	
10	01-D00-027	Adenosine inj. 3mg/ml (2ml) Vial OR Amp	40004	6 amp	17.30	12.1	5.45	3.03
11	01-D00-034	Lignocaine Hcl 2% 20mg /ml 2ml Ampoule (CCU) SEE 1D يستخدم في وحدة العناية المركزة بدرجة ضمن قوائم التخدير	91366	amp of 2ml	0.486	0.340	0.219	0.122
12	01-E00-014	Hydralazine Hcl inj 20mg/Amp. I.V infusion or slow I.V injection	90421	5 amp	16.00	11.20	7.20	4.00
13	01-E00-018	Lisinopril (as base) or Lisinopril (anhydrous),Lisinopril (as dihydrate),the same drug( with or without water of hydration) 10mg Tablet	3926544	28 tab	5.40	1.10		0.85
14	01-E00-063	Tamsulosin-HCL 0.4mg equivalent 0.367mg Tamsulosin modified release Capsule or tab ( يحصراستخدامه لجراحة المسالك البولية	531039	30 cap	12.77	6.65	4.78	3.70
15	01-E00-088	Bosentan(as monohydrate) 125 mg tablet أ- Pulmonary arterial hypertension. ب- Systemic sclerosis with ongoing digital ulcer disease يحصراستخدامه في مراكز امراض القلب في العراق ج/٩٨٩ الغاء النسب	427449	56 tab	1,891.70	1324.20	300.00	471.94
16	01-F00-024	Glyceryl trinitrate 0.5mg sublingual Tablet	33807399	100 tab	4.90	3.44	2.20	1.22
17	01-F00-035	Isosorbide dinitrate 20mg (s/r) capsule or Tablet ج/١٠١٢	611003	56 tab	3.23	2.26	1.45	0.81
18	01-F00-060	Nimodipine 30mg Tabet للمراكز الجملة العصبية وردهات الامراض العصبية	140536	30 tab	9.80	6.86	4.41	2.45



19	01-F00-069	Glyceryl trinitrate 1mg/1ml (10ml) Ampoule في حالة عدم توفر أو تسجيل المادة بالتركيز 1 mg/ 1ml يتم تجهيز المادة بالتركيز القديم (5mg/10ml) وتعتبر غير ملغية لحين توفر التركيز الجديد(1mg/ml) يمكن اعتماد احتياج التركيز (1mg/1m 10ml amp) بنفس احتياج التركيز (5mg/ml 5ml Amp) احتياج واحد مع code 01-F00-073 ويؤخذ بنظر الاعتبار استخدامه ضمن قوائم التخدير	74096	10ml amp	2.98	2.09	1.34	0.75
20	01-F00-073	Glyceryl trinitrate 5mg/ml(5ml)Ampoule في حالة عدم توفر أو تسجيل المادة بالتركيز 1 mg/ 1ml يتم تجهيز المادة بالتركيز القديم (5mg/10ml) وتعتبر غير ملغية لحين توفر التركيز الجديد(1mg/ml) يمكن اعتماد احتياج التركيز (1mg/1m 10ml amp) بنفس احتياج التركيز (5mg/ml 5ml Amp) احتياج واحد مع code 01-F00-069 ويؤخذ بنظر الاعتبار استخدامه ضمن قوائم التخدير	74096	5ml amp	10.88	7.62	4.90	2.72
21	01-G00-001	Dobutamine (as Hcl) i.v infusion 250 mg/vial OR Amp(12.5 mg/ml 20 ml) يتم الاخذ بنظر الاعتبار استخدامه في قوائم التخدير	47629	20-ml vial	3.45	2.42	1.55	1.00
22	01-G00-002	Dopamine Hcl inj 40mg/ml, (5ml) Ampoule OR vial يتم الاخذ بنظر الاعتبار استخدامه في حالات (التخدير والقلبية والسوموم )	164679	10 amp of 5ml			5.00	3.40
23	01-G00-009	Ephedrine Hcl inj 3% 30 mg / ml, slow I.V. injection 1ml ampoule ( hypotension prevention in epidural/spinal anaesthesia) لا يستعمل الا بعد التخفيف use in 14DB--وتستخدم في القلبية ايضا	108741	1-ml amp	3.98	2.78	1.79	0.99
24	02-B00-001	Atropine sulphate 0.6mg/ml, (1ml) Ampoule SEE 2B "وتستخدم في القلبية ايضا"	1307865	1 amp.				0.04

25	02-C00-013	<p>Misoprostol 200 mcg (synthetic prostaglandin analogue) Scored or plain Tablet</p> <p>يقتصر استعماله في اقسام النسائية والتوليد في المستشفيات (التعليمية وغير التعليمية) ٢-يستعمل في حالات اقل من ١٣ اسبوع (اسقاط منسي, اسقاط جراحي, اسقاط ناقص) ٣- يعطى العلاج (٤٠٠) مايكروغرام عن طريق الفم او المهبل وتعاد الجرعة كل اربع ساعات ولمدة (٢٤) ساعة كحد اقصى</p> <p>26- في حالات الحمل من (١٣) اسبوع 4- . اسبوع يستعمل كالاتي : أ-١٣-١٧ اسبوع (٢٠٠) مايكروغرام مهلي كل ٦ ساعات وبواقع اربع جرع فقط. ب- ١٨-٢٦ اسبوع (١٠٠) مايكروغرام مهلي كل (٦) ساعات وبواقع اربع جرع فقط . ملاحظة: يشترط عدم وجود عملية قيصرية سابقة او اي عملية في (الرحم بالنسبة للفقرة ٤, ٣) وان وجدت حينئذ cytotic tab الخط الثاني من العلاجات التحفظية تشكل لجنة طبية للبت في الموضوع . ٥- في حالة النزف بعد الولادة يعتبر الخط الاول وتكون الجرعات هنا (٨٠٠) مايكروغرام عن طريق (oxytocin وال methergin ) الفم او تحت اللسان او في المقعد حيث يعد ال</p>	586982	28 TAB	6.50	4.55	2.93	1.63
26	02-C00-025	<p>ml) Ampoule ٢) Ranitidine as Hcl 25mg/ml</p> <p>تعدل طريقة اعطاء المادة لتكون كالاتي : I.M -</p> <p>- الزرق الوريدي البطيء slow Intravenous Injection و يخفف في ٥٠ mg في 20 ml % 0.9 NaCl or ليصبح التركيز للمادة بعد التخفيف ٢.٥ mg/ml ويمكن تخفيفه ايضا في محلول Lactate Compound Sodium ويعطى بالوريد ببطيء (خلال ثلاث دقائق)</p> <p>- يمكن اعطائه بطريقة التسريب الوريدي Intravenous infusion . (Slow I.V , I.M) - (Or )</p>	3580962	2ml AMP		0.23	0.16	0.15
27	02-C00-035	<p>Omeprazole (as sodium salt) 40mg/ vial powder for reconstitution ,intravenous infusion or plus solvent</p> <p>يعطى ٤٠ . Inj . IV دقائق او خلال ٥ infusin خلال ٢٠-٣٠ دقيقة مع الاسعار مع مادة تخضع لقاعدة اقل code 02 -C00-038 مع كل من PPIS استعمال</p>	642398	1 VIAL	4.50	3.15	1.38	0.92



34	03-A00-001	Aminophylline dihydrate 250mg/10ml equivalent to Aminophylline base 197 mg/10 ml (I.V) inj . (10ml ampoule) (plastic or glass amp.) ( aminophylline مع العبوة من البلاستيك ) انفا مع العبوة المنتجة بتقديم ما يثبت عدم تفاعل المادة الشركة مطالبة البيطية المصنوعه من البلاستيك او الزجاج ويعطى بالزرق الوريدي ج1030	454041	10ml AMP	0.31	0.22	0.14	0.08
35	03-A00-024	Salbutamol nebules (Respirator solution) 0.5% w/v (20ml) Note: Home Nebuliser (port Neb home compressor Nebuliser with solution (salbutamol) (as sulphate ) salbutamol دستوريا ان يكون باشكالها الصيدلانية وحسب المقرر المادة لامانع من اعتماد as sulfate or as base لمستحضرات الفعالة بشكل (as sulphate or as base) ١٠٠ يعادل mcg	363465	20 ML			1.22	
36	03-I00-006	Phospholipids 25 mg ( derived from bovine lung lipid extract) Beractant + NaCl 9mg .. in water for inj/1ml (single dose vial of -4ml ) intratracheal use only (For Intensive care unites for children) - تطلب شهادات خلو المادة من TSE ( جنون البقر ) - تستعمل المادة في ردهات حديثي الولادة والخدج في المستشفيات - :-التعليمية التي يوفر فيها الاتي ا نابيب القصبات في مختلف الحجم (٢/٢، ٥/٣) *جهاز ناظور الحنجرة * بمختلف القياسات (صفر، ١) . * جهاز قياس غازات الدم جهاز التنفس الصناعي للخدج * .او كسجين & Ambu bag للخدج لقاعدة اقل الاسعار مع تخضع code 03-I00-007	7823	4 ML VIAL	210.00	147	94.50	52.50
37	03-I00-007	Calfactant 35mg/ml ( 3 ml ) intratracheal suspension لقاعدة اقل الاسعار مع تخضع code 03-I00-006	7550	3ml vial	218.92	153.24	98.50	54.73
38	04-A00-041	Chloral Hydrate 500mg/5ml oral solution (Bottle of 200 ml )	11862		16.70	11.69	7.52	4.18
39	04-B00-004	Chlorpromazine Hcl 100mg Tablet	880486	28 TAB	3.39	2.38	1.53	0.85

40	04-B00-008	Chlorpromazine Hcl 25mg/ml, I.V , I.M (2ml) Ampoule يستعمل للزرق العضلي العميق بمعدل ٢٥ - ٥٠ مغ كل ٦-٨ ساعات ويستعمل للزرق الوريدي بصوره مخففه وبطينة للحالات المعندة Nausea , Hiccups,Tetanus , Vomitting والمصاحبة للجراحة	52549	2 ML AMP	0.94	0.66	0.42	0.23
41	04-B00-018	Fluphenazine decanoate depot 25mg/ml, (1ml) Ampoule	148077	10 AMP of 1ml		8.63	7.60	6.76
42	04-B00-023	Haloperidol 5mg Tablet	804789	100 TAB			1.20	
43	04-B00-025	Haloperidol 5mg/ml Injection (1ml Ampoule)	30905	1 ML AMP	0.62	0.44	0.28	0.16
44	04-B00-082	Risperidone liquid 1mg/ml oral solution	17553	100 ML	34.60	24.20	15.60	8.65
45	04-CA0-007	Clomipramine Hcl 25mg Tablet	764144	30 TAB	4.14	1.20	1.86	1.03
46	04-CC0-002	Fluoxetine as HCl 20mg film coated tab or Capsule	1255244	14 CAP	3.00	0.69	0.44	0.40
47	04-CD0-001	Mirtazapine 30mg Tablet للمستشفيات التخصصية في الطب النفسي فقط	172414	14 TAB			2.05	
48	04-F00-016	Ondansetron 8mg lyophilisates Oral Tablet	837998	10 TAB		11.00	12.50	

49	04-F00-025	<p>Aprepitant capsule pack contains (Aprepitant 125 mg one hard capsule + Aprepitant 80 mg hard capsule (2 capsules)</p> <p>على الشركة المجهزة ان تلتزم بتوفير (٥٠%) من الاحتياج الكلي للعراق كبضاعة مجانية على ان لا يكون السعر المقدم في المناقصة اعلى من الكلفة التخمينية او سعر التسجيل ويحصر (highly emetogenic potential chemotherapy): والتي تشمل استخدامه مع</p> <p>1-Taxol + carboplatim combination 2-Adriamycin + endoxan combination 3-Cisplatin 4-Dactinomycin 5-Dcarbazine 6-high dose of Endxan 7- Lumastin 8- ifosphamide</p>	62985	Aprepitant 125 mg one hard capsule + Aprepitant 80 mg hard capsule (2 capsules)	66.94				
50	04-G00-037	<p>Paracetamol 10 mg/ml I.V. Infusion (50ml vial) يستعمل للكبار بطريقة الاسترواء الوريدي خلال ١٥ (دقيقة وللصغار حسب وزن الطفل يستعمل لحديثي الولادة والرضع والاطفال الذي تكون اوزانهم اقل من ٢٣ كغم</p>	479465	50ml vial	1.25	1.00			
51	04-H00-003	<p>Morphine sulphate 10mg (s/r) cap or Tablet (في المراكز السرطانية تحديد صرفها)</p>	30571	60 TAB	7.63	5.34	3.43	1.90	
52	04-H00-012	<p>Tramadol Hcl I.M.;S.C.,slow iv.iv. Infusion inj 50mg /ml (2ml amp) بالامكان ان تكون جميع هذه الطرق مذكورة على المستحضر وتستخدم حسب ما مثبت في (او بشكل منفصل) جزء منها النشرة الداخلية للمستحضر</p>	2078672	10 AMP		3.42		3.40	
53	04-I00-004	<p>Pizotifen as hydrogen maleate 0.5mg Tablet و العصبي للمستشفيات التخصصية في الطب النفسي</p>	52620	30 TAB	3.25	2.28	1.46	0.81	

54	04-J00-017	Phenobarbitone sod. 200mg/ml (1ml) . Ampoule المادة دواء طوارئ ولا يعطى الا بالوريد بعد التخفيف بنسبة ماء للزرق واحد في عشرة(مل واحد يخلط مع ١٠ مل وحسب المراجع)	189568	1 amp	1.70	1.19	0.76	0.42
55	04-J00-031	Sodium valproate solution 200mg/ml Drop	143322	40 ML	3.12	2.18	1.40	0.78
56	04-J00-034	Sodium valproate 200mg Tablet or (enteric coated) tab	20348087	40 TAB	3.60	2.52	1.50	0.90
57	04-J00-053	Gabapentine 300mg capsule or Tablet	3399021	50 cap	24.00	7.25	5.90	4.60
58	04-J00-061	Sodium valproate (Powder) 400mg Vial with 4ml ampoule water For inj	6631	4 VIAL	18.80	13.16	8.46	4.70
59	04-K00-016	Procyclidine Hcl 5mg Tablet يستخدم (لمرض الشلل الرعاشي ) مرض باركنسن	1581014	100 TAB	6.00	4.20	2.70	1.50
60	04-M00-001	Baclofen 10mg Tablet للمرضى الشلل والمعاقين	565290	50 TAB	4.34	2.78	1.95	1.00
61	04-Q00-001	Memantine Hcl 10mg Tablet (for moderate & sever dementia in ALZHEIMERS disease )	126333	28 TAB	21.00	14.70	7.22	1.10
62	04-R00-001	Fingolimod as Hcl 0.5 mg capsule يستخدم كعلاج ثاني في حاله فشل علاج الخط الاول وحسب الضوابط العالمية المعتمدة لتحديد الفشل (EMA & Rio C riteria (AAN) ٢- يستخدم كعلاج خط اول في الحالات الحصرية الاتية ١- رهاب الحقن الاكيد ب-بعض حالات التصلب العصبي الشديد جدا وحسب الضوابط العالمية المعتمدة لتحديد المرض الشديد (EMN & Rio(AAN) ريوكداينيريا يحدد صرف المادة في مركز تصلب الاعصاب في دائرة مدينة الطب ومركز تصلب الاعصاب في اربيل ومركز تصلب الاعصاب في النجف الاشرف,و الرصافة	187517	28 tab	1,886.45	1320.50	660.00	471.60
63	05-AA0-069	Tazobactam as sodium salt 250mg + piperacillin as sodium salt 2gm inj.vial I.V infusion(with or without EDTA)	143290	1 VIAL	9.75	2.24		

64	05-AA0-071	Tazobactam as sodium salt 500mg + piperacillin as sodium salt 4gm I.V infusion (with or without EDTA)	93773	1 VIAL	16.70	3.16	6.50	
65	05-AB0-024	Ceftazidime as pentahydrate inj. 1g I.V. Injection +solvent water for inj.	775775	1 VIAL			1.55	
66	05-AC0-001	Amikacin as sulphate inj. 250mg/ml, (2ml) Vial OR Amp I.M , slow I.V or I.V infusion	1634060	2 ML VIAL		1.34	0.50	0.28
67	05-AC0-005	Gentamicin as sulphate inj 10mg/ml, (2ml vial OR Amp) I.M , I.V	1391860	2-ml vial			0.20	
68	05-AG0-015	Meropenem (as trihydrate or anhydrous) inj 500mg I.V.,I.V Infusion Vial  بحسب الاحتياج ٦٠ % من احتياج دواء ( يستعمل meropenem في المراكز التخصصية في دار التمريض الخاص بصرف infections in neutropenic patients to be reserve antibiotics يحصر استخدامه في المستشفيات الحكومية المركزية والمراكز التخصصية عمليات جراحية في الصدر مراكز الحروق، المراكز التي يتم اجراء) (والقلب والدماغ والجهاز الهضمي والعناية المركزة)	783596	1 VIAL	14.70	3.20	5.60	3.40
69	05-AG0-059	Meropenem (as trihydrate)1gm Vial I.V , I.V infusion	782367	1 VIAL	29.22	4.40		
70	05-AG0-063	Vancomycin as Hcl 1gm Vial.	512517	1 VIAL		3.20		0.00
71	05-AH0-001	Capreomycin as sulphate 1g/ Vial (1g=million unit) deep IM Inj or iv infusion injection( حسب تقدير الحاجة)	6240	1 VIAL	20.01	14.01	9.01	5.00
72	05-AH0-002	Cycloserine 250mg Tablet	108000	100 CAP	503.29	352.30	226.48	125.82
73	05-AH0-003	Ethambutol Hcl 400mg Tablet	320000	100 TAB				2.69
74	05-AH0-006	Ethionamid 250mg Tablet	108000	100 TAB				8.00



75	05-AH0-039	Rifampicin 150 mg + Isoniazid 75mg +Ethambutol 275mg+pyrazinamide 400mg (RHEZ)=KIT حصر تداوله في المراكز الصحية المعنية(المراكز التخصصية للأمراض فقط ومنع تداولها في القطاع الخاص (الصدرية)	2040000	672 tab (24*28)					78.06
76	05-AH0-040	Rifampicin 150 mg + Isoniazid 75mg (RH)=KIT حصر تداوله في المراكز الصحية المعنية(المراكز التخصصية للأمراض فقط ومنع تداولها في القطاع الخاص (الصدرية)	4008000	tab or cap	0.03	0.02	0.01	0.01	
77	05-AH0-046	Ethambutol Hcl 100mg film coated tab.	96000	56 tab	14.40	10.08	6.48	3.60	
78	05-AH0-051	Rifampicin60mg + Isoniazid 30mg or Rifampicin 75mg + Isoniazid 50mg((tab or dispersable tab) حصر تداوله في المراكز الصحية المعنية(المراكز التخصصية للأمراض فقط ومنع تداولها في القطاع الخاص (الصدرية)	192000	30 tab	1.170	0.82	0.527	0.29	
79	05-B00-001	Acyclovir as sodium salt 250mg I.V. Infusion Vial	223296	1 VIAL			1.50		
80	05-B00-003	Acyclovir 200mg/5ml Suspension	23924	bottle			4.50		
81	05-B00-004	Acyclovir 400mg Tablet	400300	56 TAB		4.80	4.80		
82	05-B00-007	Ganciclovir 500mg I.V. Infusion Vial	7168	1 VIAL	40.80	28.56	18.36	10.20	
83	05-B00-053	Palivizumab 50 mg vial injection مع ضوابط الصرف الواردة في كتاب د.ا.ف المرقم ٤٣٢/٢/٢/٥ في ٢٠١١/٣/٢٧ ان هذا العقار يستعمل للوقاية من التهاب الجهاز التنفسي بسبب وخلال فترة الموسم ويعطى شهريا بالعضلة كما ويعطى (RIV)فايروس لحديثي الولادة من الخدج الذين يكون عمرهم الحظي اقل من (٣٥ اسبوع) يستعمل لوحدها حديثي الولادة _ ويعطى خلال ال ٦ اشهر الاولى (الخدج) في العناية المركزة لحديثي الولادة في المستشفيات التعليمية	2940	1 VIAL	482.13	337.49	216.95	120.53	
84	05-B00-058	Oseltamivir (as phosphate) for reconstitution with water 30mg/5ml suspension	41428	65 ml bottle	12.84	8.99	5.78	3.21	



87	05-C00-035	<p>Voriconazole 200 mg vial: 1 vial powder for solution for infusion <math>\equiv</math> to 10 mg/ml when reconstituted as recommended</p> <p>على ان تكون النسبة المطلوبة من مضادات الفطريات تقسم بنسبة ٢٥% بنوعية و المقرتان Amphotericin منهما و ٥٠% تعطى لمادة لكل بقاعدة اقل الاسعار ضمن المستوى الاول</p> <p>• يكون البروتكول المعتمد لاستخدام الادوية المضادة للفطريات كمايلي</p> <p>A- First line in the treatment of undiagnosed causing agent in neutropenic fever or in the RCU:-  1- Amphotericine ; whether lipid complex or liposomal  2- If the patient can not tolerate or has renal toxicity , the second choice will be caspofungin and the other choice is Voriconazole</p> <p>B- When the fungal micro- organism is known  1- in mucormycosis ; the first choice will be Amphotericine ( any one of them ) ,  2- In Aspergillosis ; the first choice will be the voriconazole , alternative is Amphotericine  3- In case of candidiasis ; the first choice will be caspofungin and Amphotericine is the alternative choice .  ج ١٠١٥</p>	18310	1 vial	100.00	70.00	45.00	25.00
----	------------	---	-------	--------	--------	-------	-------	-------

88	05-C00-036	Amphotericin lipid complex 100mg vial تكون على قاعدة اقل الاسعار مع code 05-c00-041 على ان تكون النسبة المطلوبة من مضادات الفطريات Amphotericin تقسم بنسبة ٢٥% لكل منهما و ٥٠% تعطى لمادة . بقاعدة اقل الاسعار ضمن المستوى الاول بنوعية و المقرتان (Amphotericin 50mg per Vial I.V.infusion) تستورد المادة مع مادة - - تصرف %يتم تثبيت الاحتياج بنسبة ٢٥ المادة من قبل مركز نخاع العظم ومراكز زرع الكلى ومراكز ودهات - يستعمل في علاج حالات الخمج بفطريات الكانديدا . امراض الدم الشديدة والخمج الناتج عن الفطريات المتغلغله والتي لا تستجيب لدواء الامفوترسين العادي او للادوية المضاده الاخرى او عندما تتعارض تأثيرات الامفوترسين العادي الجانبيه لذلك او عند وجود عجز كلوي لدى المريض.	30240	20 ML VIAL	172.85	121.00	77.78	43.20
89	05-C00-041	Liposomal Amphotericin B 50 mg vial تكون على قاعدة اقل الاسعار مع code 05-c00-036 على ان تكون النسبة المطلوبة من مضادات الفطريات تقسم تعطى لمادة %50 بنسبة ٢٥% لكل منهما و بقاعدة اقل الاسعار بنوعية و المقرتان ضمن المستوى الاول	38072	vial	86.00	60.20	38.70	21.50
90	05-D00-001	Chloroquine250mg as sulphate or phosphate tab= Chloroquine 150mg base	55784	6 tab		3.19		
91	05-D00-023	Sodium stibogluconate inj equivalent to pentavalant. antimony100mg/ml (100ml vial) or sodium antimony gluconate 100mg/ml	7121	100 ml vial	108.75	76.13	48.94	27.19
92	05-D00-026	Spiramycin 3000000 IU Tablet	170021	10 tab	6.172	4.321	2.777	1.543
93	06-AA0-001	Insulin (human) Isophane (NPH) 100units/ml injection 10 ml /vial subcutaneous injection. يتم صرفه ضمن ادوية الامراض المزمنة في العيادات عيادات السكري في المستشفيات الشعبية و المراكز التخصصية و العامه. على الشركات المنتجة للانسولين بالوفاء بالتزاماتها التي تعهدت بها (875للوزارة)	1658204	10ml vial	2.50	1.75	1.13	0.63

94	06-AA0-002	Insulin (Human) neutral (soluble) 100 units /ml injection 10 ml/vial subcutaneous injection, intravenous infusion, intramuscular injection. حسب الحاجة- يتم صرفه ضمن ادوية الامراض المزمنة في العيادات المستشفيات العامة الشعبية و المراكز التخصصية و عيادات السكري في على الشركات المنتجة للانسولين بالوفاء بالتزاماتها التي تعهدت بها ( للوزارة ٨٧٥ ) Soluble Insuline or Neutral insulin من الممكن اعطاه عن طريق I.V, I.M, S.C او حسب الحاجة I.V Infusion	1795216	10 ML VIAL	2.50	1.75	1.13	0.63
95	06-AA0-003	Insulin (human) biphasic 30% soluble , 70% isophane 100 units/ml injection 10 ml vial subcutaneous injection . يتم صرفه ضمن ادوية الامراض المزمنة في العيادات الشعبية - ( 814 ) و المراكز التخصصية و عيادات السكري في المستشفيات العامة على الشركات المنتجة للانسولين بالوفاء بالتزاماتها التي تعهدت بها (875) للوزارة	2602864	10ml vial	2.75	1.93	1.24	0.69
96	06-B00-001	Glucagon 1mg (equivalent to 1 I.U as Hcl Biosynthetic )/ml with solvent I.V. I.M. S.C inj Vial	18798	1 vial+pfs solvent	10.00	7.00	4.50	2.50
97	06-C00-006	Desmopressin acetate 4 mcg/ml, (1ml) (I.V or I.M or s.c) Ampoule تدرج ضمن قائمة التخدير	1571	1 ML AMP	1.65	1.16	0.74	0.41
98	06-C00-018	Vasopressin 20 units/ml, (aqueous) (1ml) Ampoule for hospital only يؤخذ بنظر الاعتبار قائمة ادوية التخدير	1656	1 ML AMP	40.18	28.13	18.08	10.04
99	06-C00-021	Recombinant human choriogonadotropin alfa (250mcg)/0.5 ml = (6500 IU )pre-filled syring S.C inj بتقديم الادلة والاثباتات الشركة المجهزة من مصدر بشري على ان تلتزم خلو المنتج من الفيروسات والبكتيريا :العلمية والتقنية في كل ما ياتي (priuns) والبروتينات الغريبة filled by mass الكفاءة على ان تقاس بطريقة- يستعمل في حالات قصور الغدة النخامية وبعض حالات العقم لدى الكبار تخضع لقاعدة اقل الاسعار مع code 06-C00-46 الاخذ بنظر الاعتبار الفقرة ٧ في ج ١٠٤٨	66423	1 PFS (human)	16.20	11.34	7.29	4.05

100	06-C00-043	<p>Desmopressin acetate 150 mcg/dose nasal spray : A 2.5 ml bottle containing 1.5 mg/ml with spray pump capable of delivering 25 doses. - - يخصص هذا التركيز للأمراض النزفية الوراثية فقط ضرورة توفر الفحوصات المختبرية المرفقة بكتاب دائرة مدينة الطب ٢٩٤٥٤ في ٢٠١٢/٩/١١ وحسب الجلسة ٨٢٨ - - Patients with hemophilia A with Factor VIII coagulant activity levels greater than 5% . - Mild to moderate classic von Willebrand's disease ( Type I) with factor VIII levels greater than 5% . Warning - Hyponatremia - Pediatric &amp; geriatric patients. - Habitual or psychogenic polydipsia. -Type IIB vonWillebrand's disease .( 828)</p>	2629	2.5 ML spray	414.00	289.80	186.30	103.50
101	06-C00-044	<p>٧٥ Urinary gonadotrophine (FSH)...highly purified reconstitutions for IU , vial , amp,I.M, S.C. powder solution with solvent or من مصدر بشري على ان تلتزم الشركة المجهزة بتقديم الادلة والاثباتات العلمية والتقنية في كل ما ياتي: خلو المنتج من الفايروسات والبكتيريا (والبروتينات الغريبة) priuns -الكفاءة على ان تقاس بطريقة الfilled by mass</p>	79206	1 vial + solvent	7.80	5.46	3.51	1.95
102	06-C00-045	<p>Urinary gonadotrophine (FSH/LH)...highly purified powder for .vial , amp,I.M, S.C , IU/75 IU ٧٥ solvent or solution reconstitutions with من مصدر بشري على ان تلتزم الشركة المجهزة بتقديم الادلة والاثباتات العلمية والتقنية في كل ما ياتي: خلو المنتج من الفايروسات والبكتيريا (والبروتينات الغريبة) priuns -الكفاءة على ان تقاس بطريقة الfilled by mass</p>	77898	1 vial + solvent	12.35	6.90	4.40	2.46

103	06-C00-046	Urinary human chorionic gonadotrophin (HCG)...highly purified 5000 IU , vial , amp,I.M, S.C. powder for reconstitutions with solvent or solution بتقديم الادلة الشركة المجهزة من مصدر بشري على ان تلتزم ( خلو المنتج من الفايروسات :العلمية والتقنية في كل ما ياتي والاثباتات priuns والبكتيريا والبروتينات الغربية filled by mass الكفاءة على ان تقاس بطريقة- يستعمل في حالات قصور الغدة النخامية وبعض حالات العقم لدى الكبار تخضع لقاعدة اقل الاسعار مع code 06-c00-021	79420	1 vial + solvent	10.00				
104	06-D00-001	Carbimazole 5mg Tablet	3571186	100 TAB	4.22	2.95	3.00	1.00	
105	06-D00-007	Thyroxine sodium or anhydrous Levothyroxin Sodium tab 50mcg.	2770185	100 TAB	3.10	2.70	1.40	0.78	
106	06-D00-008	Thyroxine sodium or anhydrous Levothyroxin Sodium tab 100mcg.	4741537	100 TAB	4.56	3.00	2.05	1.15	
107	06-E00-009	Dexamethasone phosphate as di sodium salt or (as sod. salt ) inj 8mg/2ml (2ml Amp OR Vial) I.V . I.M or I.V infusion ( preservative as sulfite ) من يجب ان تخلو المادة من	8132952	100 AMP		32.30	14.75	9.10	
108	06-E00-018	Hydrocortisone as sodium succinate OR (Hydrogen succinate) eq. to 100mg hydrocortisone. Vial with 2ml ampoule solvent for solution for injection OR Act-o-vial system , I.M. , , slow I.V, I.V. Infusion	7509261	1 Vial + 2ml water	1.80	0.96	0.70	0.30	
109	06-F00-020	Norethisterone 5mg Tablet	1476139	30 TAB	2.94	2.30	0.70		
110	06-IA0-001	Calcitonin inj. 100 MRC unit equivalent to 100 IU calcitonin synthetic/1ml (1ml) Ampoule ( I.M , S.C , I.V Infusion )	3439	1 ML AMP	6.25	4.38	2.81	1.56	
111	06-K00-008	Atorvastatin calcium trihydrate or Atorvastatin calcium ≡ Atorvastatin 40mg coated Tablet	3561610	30 tab	48.35	11.54	8.34	2.50	

112	07-A00-009	Methylergometrine (Methylergonovine) maleate 200mcg/ml, (1ml) Ampoule مراكز رعاية صحية اولية + احتياج المستشفيات ج 986 (ج ٩٨٩ مراكز الرعاية الصحية الاولية والمستشفيات)	1059657	10 AMP of 1ml					2.20
113	07-A00-012	Oxytocin 10units/ml slow I.V , I.M , I.V Infusion inj (1ml) Ampoule	2734852	1 AMP	0.47	0.33	0.21	0.15	
114	07-B00-004	Atosiban as acetate inj:7.5mg /ml (5ml )Vial	2709	5ml vial	72.00	50.40	32.40	18.00	
115	07-DA0-004	Ethinylloestradiol 30mcg+ levonorgestrel 150 mcg Tablet	5507446	21 tab	2.30	0.99	1.03	0.57	
116	07-DB0-003	Norethisterone 350mcg Tablet	163272	3*28 tab	3.72	2.60	1.67	0.93	
117	08-AA0-009	Iron-dextran inj 50mg/ml, (2ml Ampoule) by deep I.M or slow I.V or by slow I.V infusion	705096	2-ml amp	1.00	0.68	0.45	0.25	
118	08-B00-005	Hydroxycobalamin 1000mcg/ml (1ml) Ampoule ,I.M inj	1940859	10 amp of 1-ml	2.70	1.94	1.24	0.70	
119	08-B00-015	folinic acid 15mg (as calcium folinate or as calc.leucovorin) capsule or Tablet ج /١٠٢ يحصر استخدامه في و المراكز السرطانية مراكز امراض الدم	34778	20 cap	18.70	13.11	8.42	4.60	
120	08-B00-019	Folinic acid 50mg/5ml ampoule (as calcium folinate or as calc.leucovorin) و المراكز السرطانية ج /١٠٢ يحصر استخدامه في مراكز امراض الدم	105552	10 amp	23.00	16.10	10.35	5.75	
121	08-D00-002	Heparin sodium 5000 IU/ml SC.,I.V. inj ( 5ml) Vial يتم التاكيد على المؤسسات الصحية على حساب الجرعة بالوحدات وليس بالحجم	454967	5-ml vial	3.97	3.00	1.79	0.99	



122	08-D00-003	Protamine sulphate 1400 anti-heparin IU/ml(corresponds to 10mg/ml) slow I.V. over 10 minutes (5ml) Ampoule OR Vial and the giving quantity according to the lab. Analysis over 10 minutes and the giving quantity according to the lab. Analysis مع الاخذ بنظر الاعتبار ادراجة كسموم	16034	1 vial	5.00	3.50	2.25	1.25
123	08-D00-009	Warfarine sodium 1mg Tablet	299725	100 tab	2.75	1.93	1.24	0.69
124	08-D00-010	Warfarine sodium 3mg Tablet	267792	28 tab			0.50	
125	08-D00-011	Warfarine sodium 5mg Tablet	725113	28 tab			0.90	
126	08-D00-013	Enoxaparin sodium 40mg (4000 IU anti Xa(anti thrombotic effect))/0.4ml S.C/ intra arterial Injection prefilled syringe (intravasular i-e intra arterial line only in(extra corporeal circulation)) يؤخذ بنظر الاعتبار قائمة ادوية التخدير	987877	2 syring of 0.4-ml	6.47	4.65	3.38	1.66
127	08-E00-020	Ticagrelor 90 mg film coated tablet نسبة (Clopidogrel 75mg tab): وللاستطبانات التالية احتياج المادة (١٠%) من احتياج العراق من مادة أ-التداخل القسطاري الاولي ( PCI ) Platelet) والمشخصين عن طريق جهاز ( Clopidogrel 75 mg tab) ب- المرضى غير المستجيبين لعلاج ( Agregometer) ويحدد صرفه في مراكز القلب وشعب القسطرة	556963	56 tab	65.0	45.50	29.3	16.3
128	08-F00-009	*Recombinant human tissue type plasminogen activator 50mg/ Vial (Alteplase) set=2vial	19089	2 vial + solvent + transfer device	952.40	666.70	428.50	238.10
129	08-G00-002	Tranexamic acid 100mg/ml inj. (5ml) Ampoule	210418	5-ml amp	1.54	1.08	0.69	0.39

130	08-H00-006	<p>Recombinant Factor VII a (Eptacog alfa) (Activated) I.V. inj, 1mg vial inject slowly over 2 to 5 minutes or tis approved biosimilar</p> <p>لامانع من اعتماد الشكل الجديد (سرنجة تحتوي على المذيب) لضمان النزف الشديدة سرعة حقن العقار عند حالات تعدل دواعي الاستعمال المقره للعامل السابع ويحصر كالاتي ١- نقص العامل السابع الوراثي مع وجود المضادات عالية A) مرض نقص العامل الثامن (هيموفيليا ٢-2- (inhibitors with high responders) - الاستجابة اعتلال عمل الاقراص الوراثي من نوع 3-3- Glanzmans thrombasthenia- -Bernads-soulier</p> <p>والغير المستجيبين لنقل الاقراص مع مراعاة الشروط الواردة في الجلسة ١٠٢٥ و ١٠٢٩ للاعراض الاستيرادية</p> <p>على ان يتم تقديم تقرير عن العامل السابع بعد مرور عام على استخدام الادوية الخاصة بالعامل السابع</p>	41205	1 vial	754.00	527.80	339.30	188.50
131	08-H00-007	<p>Plasma protein fraction (human) 5% i.v. infusion i-e 1ml contains: Human serum protein 50mg of which: Albumin approx 31mg Human Immunoglobulin approx 10mg (Ig G , Ig A, Ig M)</p>	30075	250-ml vial	206.80	148.60	95.55	53.00
132	08-H00-008	<p>Recombinant Factor VIII, 500 IU Injection(HAS Free) لعلاج والوقاية (خالية من اي منشأ بشري او حيواني)</p> <p>٩٨٦ (FOC) توفير كبضاعة مجانية ج ٩٨٦ بنسبة كونها تعتبر جرعة تكملية (recombinant Factor VIII 250 IU) (recombinant Factor VIII 500 IU) ١٠% من احتياج الكلي</p>	164295	1 vial	271.60	178.22	114.57	63.65

133	08-H00-014	<p>VonWillebrand Factor / Coagulation Factor VIII Complex (Human) powder and solvent for solution for injection or infusion :- Vwf400 – 1200 IU + Factor VIII 450- 900 IU For:- In adult &amp; pediatric patients with von willebrand disease -828 ضرورة توفر الفحوصات المختبرية المرفقة بكتاب دائرة مدينة 828 وحسب الجلسة 11/9/2012 الطب ٢٩٤٥٤ في ج/٩٨٦ يحصر صرفه للحالات الاتية indicated in sever cases of VonWillebrand disease a- lifethreating condition ( CNS bleeding, GIT bleeding ,trauma) b- in caseof bleding from other site Necessite urgent blood transfusion c- in case of surgery</p>	14072	1 vial	280.00	196.00	126.00	70.00
134	08-H00-017	<p>Factor XIII concentrate ( Human) Lyophilized concentrate for reconstitution:-1000- 1600 units for reconstitution in 20 ml . Indicated for routine prophylactic treatment of congenital Factor XIII deficiency (828)</p>	619	vial of 20ml	738.00	516.60	332.13	184.52
135	08-I00-002	<p>Sodium chloride 0.8766g (15mmol/l)+Potassium chloride 0.6710g(9mmol/l)+Potassium hydrogen 2-Ketoglutarate0.1842g (1mmol/l)+Magnesium chloride 6H2O 0.8132g (4mmol/l)+Histidine Hcl .H2O 3.7733g(18mmol/l)+Histidine 27.9289g(180mmol/l)+Tryptophan 0.4085g(2mmol/l)+Mannitol 5.4651g(30mmol/l)+Calcium chloride .2H2O 0.0022g(0.015mmol/l)/1000ml ,in Water for inj Osmolality 310mosmol/Kg ,An ion CL- 50mEq ,2000ml</p>	405	4 bags	1,383.96	968.77	622.78	345.99

136	08-I00-003	Cardioplegia infusion 20 ml ampoule: containing in 20 ml : magnesium chloride BP 3.26 g , potassium chloride BP 1.193 g , procaine hydrochloride BP 272.8 mg , also present :disodium edentate BP. sodium hydroxide BP and water for injection	5821	السعر الموجود بدون حجم أو تركيز	485.70	339.99	218.57	121.43
137	09-AA0-004	Vitamin A 4000 units Capsule or tablet لا يعطى اكثر من كبسولة في اليوم لا يعطى للحوامل.	175789	1 cap	0.03	0.02	0.01	0.01
138	09-AB0-002	Vitamin B1- (Thiamine Hcl) 50mg/ml, (2ml) Ampoule	168590	25 amp of 1ml 100mg/ml	25.00	17.50	11.25	6.25
139	09-AB0-004	Vitamin B6 (Pyridoxine Hcl) inj 50mg/ml, (2ml) Ampoule	1033385	100 amp			20.68	5.95
140	09-AD0-002	Alphacalcidol 1mcg soft gelatin Capsule	1687336	30 cap	12.78	8.90	3.99	3.19
141	09-AD0-005	Vitamin D2 (Ergocalciferol or calciferol) 15mg (600000 IU) /1.5ml I.M. , oral solution (1.5ml Ampoule) (for adults only)	58456	1 amp		1.90	0.15	
142	09-AF0-006	Phytomenadione mixed micelles (Vit. K1-MM) 2mg/0.2ml oral and I.M.&I.V.(0.2ml) Ampoule Paediatric	318887	0.2-ml amp	1.00	0.70	0.45	0.25
143	09-AF0-007	Phytomenadione mixed micelles (Vit. K1-MM) 10mg/ml (I.V. inj or slow I.V. inj (withen 30 sec) (1ml) Ampoule	155645	1-ml amp	0.71	0.50	0.32	0.18

144	09-CB0-001	Calcium gluconate injection 10% w/v amp. or vial(10ml) each ml contains anhydrous calcium gluconate(usp) (approximately 0.233 mmol = 0.465 meq. of calcium ) or calcium gluconate monohydrate(Bp) (approximately 0.225 mmol = 0.450 meq. of calcium)(I.V infusion) or (slow I.V inj.,deep I.M) or (slow I.V inj.)(I.M use not for children & adolescent)	825335	20 amp of 10-ml	5.19	3.63	2.33	1.30
145	09-CF0-003	Magnesium sulphate 20% inj (20ml) Ampoule	56813	20-ml amp	30.32	21.23	13.64	7.58
146	09-D00-015	Human albumin 200mg/ml, 100ml low salts-Aids free I.V.Infusion	314349	100-ml bottle	47.00	32.90	21.15	11.75
147	09-D00-067	Sodium chloride 3% hypretonic saline 200ml or 250 ml bottle) ( او توضع علامات تحذيرية لتفريقه ) يثبت على العبوة hypertonic solution عن بقية المغذيات (3%)	16222	250-ml			1.50	
148	09-D00-070	Sodium bicarbonate 8.4% slow I.V. , I.V. infusion inj 100ml Vial	98583	100-ml vial	2.86	2.00	1.29	0.71
149	09-F00-007	Zinc Sulfate monohydrate 54.9mg equivalent 20mg elemental zinc dispersable tablet- تقر حبوب الزنك ٢٠ ملغم كما مدرج ادناه للأطفال من ٦ أشهر إلى ٥ سنوات و ١٠ ملغ للأطفال دون ٦ أشهر للسيطرة على الإسهال والالتهابات التنفسية بالإضافة إلى نقص النمو. (ليس علاج اي) ORS هو برنامج للسيطرة على حالات الإسهال ولا يحل محل -	4182384	125 mg effervescent	22.36/90 tab			
150	10-AC0-006	Penicillamine 250 mg capsule or tablet ضمن ادوية السموم مع الاخذ بنظر الاعتبار ج/١٠١٢ وردت هذه المادة ضمن قائمة الادوية الاساسيه وكذلك ضمن قائمة الادوية النادرة يرجى تثبيت الاحتياج فيما يخص الادوية الاساسية فقط .	65305	50 tab	15.70	11.00	7.07	3.90

151	10-CAa-004	Neostigmine metisulphate 2.5mg/ml,I.V,I.M,S.C inj (1ml) Ampoule ) (note: to be given (i.v.) for anesthesia and to be given(i.m.,s.c.) in case of myasthenia gravis في حالة (I.V) على ان يعطى وريديا I.V,I.M,S.C كون طريقة الزرق والتخدير (I.M,S.C) ضمن قائمة ادوية التخدير (انظر في حالة وهن العضلات الوبيل وادرج ملاحظة Sugammadex ) Presently it's need not more than 10% of prostigmine(neostigmin) need. - Reversal of Rocuronium&Vecuronium. -used in case when prostigmine:- a. Cannot be used . Or b. Can be used with sever side effect.	668906	amp of 1-ml	1.07	0.74	0.48	0.27
152	10-CAa-007	Pyridostigmine Bromide 60mg Tablet	166933	150 tab	25.36	17.75	7.20	
153	11-A00-001	Acyclovir 3% Eye Ointment	50066	4.5 gm	4.40	3.08	1.98	1.10
154	11-A00-009	Fucidic acid 10mg/g viscous Eye Drop	319037	5 gm	2.70	1.89	1.22	0.67
155	11-BC0-002	Diclofenac sodium 1mg/1ml (0.1%)Eye Drop	170350	5 ml			0.50	
156	11-C00-001	Atropine sulphate 0.5% (with or without HPM cellulose) Eye Drop	14685	10 ml			0.70	
157	11-C00-010	Tropicamide 1% Eye Drop	22660	15ml	3.50	1.38		
158	11-D00-001	Acetazolamide (as sodium salt ) 500mg Vial inj. , powder for reconstitution.SEE 11D	1528	1 vial	10.80	7.56	4.86	2.70
159	11-D00-022	Timolol as maleate 0.5% Eye Drop	66250	5 ml	2.00	0.90	0.69	0.50
160	11-E00-023	Amethocaine (tetracaine) hydrochloride 1.0% w/v ph.Eur with purified water &hydrochloric acid Eye Drop	21424	20 × 0.5ml	8.84	6.18	3.98	2.21
161	12-B00-002	Beclomethasone dipropionate 50mcg/ metered inhalation (Aerosol Inhalation) Nasal Spray	229276	200 dose	2.89	2.02	1.60	0.72
162	13-G00-004	Clindamycin as phosphate 1% topical Solution	204733	30 ml	3.10	2.16	1.35	0.77
163	13-J00-001	Acyclovir 5% Cream,	88395	10 gm	2.57	1.80	0.30	0.23
164	14-AA0-036	Ketamine as Hcl 50mg/ml, I.V ,I.M inj (10ml) Vial	174347	10-ml vial	2.30	1.61		

165	14-AA0-039	Thiopentone sodium inj (1g in 40ml) vial	202701	1 vial بدون حجم	5.00	3.50	2.25	1.25
166	14-AA0-043	Propofol 1% ampoule (20ml)((preferable with preservative)) (الافضلية للمستحضر الذي يحتوي على مادة حافظة)	847069	(20 ml)	1.90	1.33	0.86	
167	14-AB0-009	Isoflurane volatile liquid anaesthesia Sevoflorane 20% على ان تجهز في وقت واحد احتياج واحد يقسم الى 80% Isoflorane والى Isoflorane لعمليات الاطفال والحالات التي لا يمكن فيها Isoflorane ويخصص sevoflorane استخدام	221423	100 ml	13.10	8.40	6.24	
168	14-AB0-011	sevoflurane volatile liquid anesthesia Sevoflorane الى 20% و Isoflorane 80% احتياج واحد يقسم الى 20% و Isoflorane 80% على ان تجهز في وقت واحد ويخصص sevoflorane لعمليات الاطفال والحالات التي لا يمكن فيها استخدام Isoflorane ( Sevoflurane ) بنفس كمية مادة ( Adaptor ) تطلب مادة ل وبشكل سنوي "وتجهز بصورة مجانية من قبل الشركة المجهزة للمادة انفا وحسب رأي ( Vaporizer ) حسب نوع ( Adaptor ) ويكون نوع اللجنة الاستشارية للتخدير وثبتت الملاحظة بالقائمة الاساسية .	55918	250 ml	123.00	88.00	55.35	30.75
169	14-AC0-008	Atracurium besilate inj 10mg/ml (5ml) Ampoule احتياج واحد يقسم الى 70% الى Atracurium و 30% الى Rocuronium على ان تجهز في وقت واحد	444597	5 amp	15.42	11.66	4.38	
170	14-AC0-011	Rocuronium bromide inj 10mg/ml (5ml) Vial احتياج واحد يقسم الى 70% الى Atracurium و 30% الى Rocuronium على ان تجهز في وقت واحد	186413	10 vial	35.00	24.50	15.75	8.75

171	14-AC0-012	Suxamethonium chloride 100mg/2ml OR 100mg/5ml Ampoule	172354	2-ml amp	1.98	1.39	0.89	0.50
172	14-AD0-029	Fentanyl as citrate inj 50mcg/ml ( 2ml) Ampoule	148528	2-ml amp	0.40	0.58		
173	14-AD0-032	Remifentanil as Hcl inj 2mg/ vial i.v injection	52113	1 vial	8.49	5.94	3.82	2.12
174	14-AD0-034	Ketorolac trometamol 30 mg / ml iv infusion, IM, slow I.V لايقل عن ١٥ ثانية injection (1ml ampoule)	90152	10 amp	10.70	7.50	2.60	
175	14-B00-015	Lidocaine HCL 2% (20mg/ml) + Epinephrine as bitartrate 1:80000( 0.0125 mg/ ml) ( cartridges(1.7-2.2 ml- Carpule) يكون احتياجها بنسبة ٨٥% من الاحتياج الكلي لل	4140049	50 carpule	14.20	10.00	6.40	3.50
176	14-B00-038	Anhydrous Bupivacain Hcl 5mg + glucose( mg/ml (4ml ) Vial OR ٨٠ (anhydrous monohydrate or for spinal anesthesia Amp ملاحظة:تستعمل المادة للزرق داخل القناة الشوكية وتحت مستوى الحبل الشوكي نهايته Spinal anesthesia وليس عن طريق spinal cord limited it's according to the pharmacopeia that ) ( specifications	160804	5 amp	9.50	6.65	4.28	2.38
177	14-B00-040	Lidocaine Hcl 2% ( 1.8) ml carpule carpule يكون احتياجها بنسبة ١٠% من الاحتياج الكلي لل	367045	25 of 2ml	23.14	16.20	10.41	5.79
178	14-B00-044	Anhydrous lignocaine Hcl 20 mg / ml ( 20 ml vial ) injection	65760	20-ml amp	1.12	0.66	0.50	0.28
179	14-B00-048	Anhydrous Lidocaine Hcl 2 % (20mg/ml) +adrenaline 1:200000 (20 ml vial) للتخدير والجراحة العامة وليس في الطوارئ	23186	20-ml vial	2.21	1.55	1.00	0.55
180	14-B00-055	Anhydrous Lignocaine Hcl 20mg/ml (50 ml vial) (يفضل) طريقة (I.V , I.M)(الطوارئ والجراحة العامه) الاعطاء	200925	1-ml amp	3.75	2.63	1.69	0.94



181	14-DA0-001	Midazolam 5mg/ml( I.V., I.M . Inj) or ( I.V., I.M or rectal adminstration) Ampoule( 1 ml ampoule)	272543	10 amp	8.37	3.92	3.76	
182	14-DB0-002	Glycopyrronium Bromide (Glycopyrrolate) 200mcg/ml inj (3ml) Ampoule	33959	3-ml amp	2.68	1.88	1.21	0.67
183	14-DB0-004	inj (Adrenaline (as acid tartrate ) or (as HCL 1mg/ml(1:1000), (1ml . AMP ) s.c,i.m or I.Vuse after dilution أن مادة الـ Adrenaline المستخدمة في مستحضرات الزرق حسب دساتير الأدوية الأمريكية والبريطانية أما تكون بشكل: Adrenaline أو (Hcl Adrenaline (as Adrenaline base أو (as Acid tartarate وتكون النسبة المطلوبة على ما يكافئها من الـ . Adrenaline base أما مادة الـ Adrenaline borate فلا تستخدم دستوريا في مستحضرات الزرق (٦٩٤) (٧٠٩) وتستخدم في allergic disorders ج ١٠١٢	282642	1-ml disp. syringe + needle for s.c.inj.		0.29	0.25	
184	15-AA0-002	Carmustine 100mg I.V. Injection	200	1 vial	550.00	385.00	247.50	137.50
185	15-AA0-008	Cyclophosphamide 500mg Injection	114751	1 vial	5.70	4.00	2.57	1.43
186	15-AA0-010	Dacarbazine 200mg powder for reconstitution vial for inj (I.V. Infusion or I.V. infusion and Intra-arterial perfusion) Note: the drug after reconstitution and during infusion should be kept out of light	30193	1 vial	14.29	10.00	6.43	3.57
187	15-AA0-013	Ifosfamide 2g powder for reconstitution for I.V injection	29207	1 vial	41.30	28.91	18.59	10.33
188	15-AA0-018	Melphalan 2mg Tablet	15209	25 tab	65.00	45.50	29.25	16.25
189	15-AA0-020	Mesna 100mg/ml, (4ml) Injection	142780	4-ml amp	3.50	2.45	1.58	0.88
190	15-AA0-024	Melphalan 50 mg (as HCl) powder for reconstitution vial ( with solvent-diluent) يخصص في مركز زراعة نخاع العظم في مدينة الطب	300	1 vial + solvent	162.26	150.00	67.50	37.50
191	15-AA0-025	Busulphan 60mg I.V Injection(10 ml vial) يحصر استخدامه في مراكز زرع نخاع العظم	70	10-ml vial	251.56	176.09	113.20	62.89

192	15-AA0-030	Bendamustine hydrochloride 100mg vial powder for reconstitution يحصر استخدامة في مراكز امراض الدم وحسب الاستطبابات 1018 المقرة في الجلسة Bendamustine vial to be use in :- a/ relapse chronic lymphocytic leukemia b/ relapse low grade non – hodykin lymph c/ in chronic lymphocytic leukemia in those not fit for RFC and failed to respond to R leukeran	11076	1 vial			100.00	
193	15-AB0-001	cytarabine (for S.C, I.V. , intrathecal ) 20mg/ml, 5 ml vial	36331	1 vial	8.00	5.60	3.60	2.00
194	15-AB0-008	Gemcitabine as Hcl 1g powder for reconstitution / vial or concentrate for solution for infusion 10 mg / ml (1g )	74750	1 vial	40.00	19.00		
195	15-AB0-009	6- mercaptopurine 50mg Tablet	389690	25 tab	30.00	18.60	11.96	6.64
196	15-AB0-010	Methotrexate 2.5mg Tablet (psoriasis) يصرف للاستخدام في علاج	618282	50 tab	7.86	5.50	3.54	1.96
197	15-AB0-028	5-Fluorouracil 50mg/ml (10 ,20 ,50 ,100) ml vial for I.V inj. Or infusion oR intra-arterial infusion	94747	10-ml vial	7.14	5.00	3.21	1.79
198	15-AC0-002	Bleomycin as sulphate 15000 units per vial dry powder for reconstitution	20661	1 vial	41.69	29.18	18.75	10.43
199	15-AC0-003	Dactinomycin 500mcg (Actinomycin D) I.V Injection	6540	1 vial	25.00	20.00	15.00	10.00
200	15-AC0-004	Daunorubicin 20mg I.V. Injection (as Hcl) powder for reconstitution vial	15054	1 vial	75.00	60.00	40.00	25.00
201	15-AC0-008	Doxorubicin Hcl 50 mg I.V. inj , powder for reconstitution vial OR Doxorubicin Hcl 2mg/ml, 25 ml vial	86323	1 vial	16.50	14.90	10.52	9.00

202	15-AC0-019	Epirubicin Hcl 2mg/ml, 25 ml vial OR Epirubicin Hcl 50 mg (powder for reconstitution ) vial.	10731	25-ml vial	32.00	22.40	13.44	7.46
203	15-AD0-007	Vincristine sulphate Injection 1mg/ml , 1 ml inj. for I.V. administration only not for intrathecal administration. يستعمل عن طريق الوريد فقط وليس بأي طريقة اخرى	37678	1-ml vial	7.20	5.04	3.24	1.80
204	15-AD0-011	Vinorelbine as tartrate , concentrate for I.V. infusion 10 mg/ml, 5 ml vial.	10656	5-ml vial	80.00	56.00	36.00	20.00
205	15-AD0-015	Vinorelbine as tartrate 30 mg capsule	51005	1 cap	85.70	60.00	38.50	21.42
206	15-AF0-003	Cisplatin inj 50mg/vial I.V. infusion -: Cisplatin فيما يخص لا يوجد مستحضر خاص يعطى عن طريق التسريب الوريدي .. ونفس المستحضر (sol. or powder) يستخدم لكلا الطريقتين أي بمعنى أن المستحضر المثبت عليه طريقة الاعطاء بالزرق الوريدي يمكن استعماله عن طريق التسريب الوريدي	45883	1 vial	10.00	7.00	6.96	3.86
207	15-AF0-005	Oxaliplatin 100mg/vial powder for reconstitution I.V. Infusion OR concentrate for I.V. infusion 5mg/ml , 20 ml vial.	33208	1 vial	30.00	32.00		
208	15-AF0-008	Carboplatin 10mg/ml (45ml) Vial i-e 450mg/45ml	43463	45-ml vial	36.00	27.60	18.67	15.00
209	15-AF0-018	Methyl prednisolon (as sod. Succinate) 250 mg IM,slow IV,IV infusion inj	59060	1 vial	10.00	7.00	4.50	2.50
210	15-AF0-031	Tretinoin 10mg capsule (ALL-trans retinoic acid)	135033	100 cap	260.09	182.06	117.04	100.00

211	15-AF0-036	Trastuzumab( HER2)( Recombinant ) 440mg or 420mg/Vial or its approved biosimilar لايستورد الا بعد توفر فحص (CD) الخاص (Cluster of difference = CD )CD مع اي الفحص الخاص بالعقار الخلية لبيان تحسس وهي معلمات اورام خاصة على جدار يوفر هذا المعلم .. الورم الى عقار معين HER/2/neu في المختبرات	42158	1 vial	1,611.00	1127.70	724.95	402.75
212	15-AF0-038	Capecitabine 500mg tablet	2769205	120 tab	199.48	50.16		
213	15-AF0-051	Bortezomib( as mannitol boronic ester )inj.3.5 mg i.v, s.c vial يستعمل للحالات المعقدة للعلاج التقليدي وغير المناسبة لغرس نخاع العظم (multiple myeloma) في ورم ليفي العظم المتعدد الخلايا يحدد صرف العقار للمرضى المصابين بأبيضاض الدم النقاني المتعدد -في الحالات التالية ( Multiple Myeloma ) أ- المرضى الذين لديهم أنتكاسة (relapse) ب- المرضى الذين لديهم قصور كلوي نتيجة للمرض (Refractory disease) أو مرض متعند ت- المرضى الذين لديهم مرض شرس (aggressive disease) والذين قد يستفادون من عملية زرع الخلايا الجذعية الذاتية مستقبلا • أن يحدد الصرف في المستشفيات والمراكز التي يتوفر فيها وحدات متخصصة لعلاج أمراض الدم السريرية	15858	1 vial	1,065.80	746.00	400.00	266.45

214	15-AF0-062	Brentuximab Vedotin 50mg vial يحصّر صرفه في مركز زرع نخاع في دائرة مدينة الطب وتكون الاستطبابات كالاتي ولمدة اربع جرع a-used in patient with hodgkin's lymphoma who has resistance and failed to respond to two lines of chemotherapy and he is fit for autologous transplant b- in fit patient who relapsed after autologous transplant and they are fit for allogeneic transplant and have matched related donor	480	1 vial	3,300.0	2310.00	1485.00	825.00
215	15-AG0-013	Tamoxifen as citrate 20mg Tablet	2319706	30 tab	5.00	3.50	2.25	1.25
216	15-AG0-015	Bicalutamide 50mg tablet Not use in cases of Localize prostatic disease لحالات سرطان البروستات المتقدم	193385	28 tab	60.00	33.60	27.00	10.00
217	15-AG0-021	Abiraterone acetate 250 mg tablet 15-AG0-024 مع قرار في الجلسة ٩٨١ اعتماد قاعدة اقل الاسعار 1033 ( MCRPC ) تستخدم كعلاج اساسي لمرضى سرطان البروستات المنتشر ويحدد منافذ الصرف في اربع مراكز ( بغداد , النجف , البصرة , ( كركوك )	810890	120 tab	3,000.00	2100.00	1350.00	750.00
218	15-AG0-024	Enzalutamide 40mg cap capsule تستخدم كعلاج اساسي لمرضى سرطان البروستات المنتشر (MCRPC) ويحدد منافذ الصرف في اربع مراكز (بغداد,النجف ,البصرة,كركوك) وحسب قاعدة اقل الاسعار مع الرمز الوطني ١٥- AG0-021	818090	112 cap	3,418.34	2392.84	1538.25	854.58
219	15-B00-001	Azathioprine 50mg Tablet ومنها ( Autoimmune disease ) لا مانع استخدامها لـ (الامراض الجلدية (٩٨٩)	1329522	100 tab	18.80	13.16	8.46	4.70
220	15-B00-003	Anti-Thymocytic-Globulin 100mg/5ml (ATG) Vial (Rabbit type)(limited for kidney) م.تخصّصي زرع الكلى	3733	1 vial	591.00	413.70	265.95	147.75
221	15-B00-004	Basiliximab 20mg /Vial	801	vial	1,120.00	784.00	504.00	280.00

222	15-B00-008	Cyclosporine (Microemulsion)100mg/ml oral Solution ومنها ( Autoimmune disease ) لا مانع استخدامها لـ (الامراض الجلدية (٩٨٩)	130616	50 ml	121.50	85.00	54.67	30.38
223	15-B00-027	Interferon Beta 1a 6 million I.U.(30mcg) vial (I.M) مرضى تصلب الاعصاب المنتشرة لمعالجة : single demyelinating يعطى المريض احدى الاشكال التاليه event with active inflammatory procces النوبات الحادة -Interferon Beta-1a (Avonex) -Interferon Beta 1b (Betaferon,Extavia)	19696	4 PFS	823.00	576.10	370.35	205.75
224	15-B00-029	Imatinib as mesylate (Protein – Tyrosine kinase inhibitor) 100mg Capsule OR TAB الشركة المجهزة ملزمة بتوفير الفحوصات التالية لكل "سنويا ( مرات 3 ) ( PCR BCR - ABL210 ) مريض . لمرة واحدة للمرضى المشخصين ( BCR - AB ) ( FISH "حديثا .	769501	120 cap	700.00	495.00	300.40	175.00
225	15-B00-037	Interferon Beta 1a (Recombimant) 12million IU (44mcg) pfs Interferon b -1a (Rebif) يعطى ( Remitting Relapsing) في حالة النوبات المتكررة الهادئة والنتكسة (Avonex) حسب قرار US FDA (Evidece study) او لانه اكثر فعالية من (INCOMIN STUDY)Interferon beta 1a (Betaferon,Extavia) وبنسبة ٢٠% من الاحتياج الكلي لعلاجات (الخط الاول لمرض ( M.S.)	109499	12 PFS	924.00	646.80	448.80	231.00

226	15-B00-050	Imatinib as mesylate (Protein - Tyrosine kinase inhibitor) 400mg Tablet or capsule يحصر في مدينة الطب+المركز الوطني لامراض الدم ( بابل+البصرة+نينوى+النجف+كركوك + كربلاء + + ج) ( ١٠١٢ ) (الكرخ+واسط+الانبار+اربيل+سليمانية الشركة المجهزة ملزمة بتوفير الفحوصات التالية . لكل مريض"سنويا ( 3 مرات ) ( PCR BCR - ABL210 ) "المرءة واحدة للمرضى المشخصين حديثا ( FISH BCR - AB ) .	579382	30 cap	1,576.00	645.00	300.40	
227	15-B00-051	Recombinant Interferon Beta 1b 0.3mg(9.6 million IU) S.C Inj. Vial. (Better to be free from Human blood additives) في مدينة الطب صحة بغداد يحصر(M.S.) الخطاوالمرض سليمانية-النجف-كربلاء ( ) -الرصافة- نينوى- البصرة -دهوك -اربيل من عدد المرضى ) ج ٩٨٦ ج ١٠٠١%70نسبة علاج هي	341796	15 vial+ 15 PFS solvent	600.00	420.00	270.00	150.00
228	15-B00-053	Mycophenolic acid as sod.Salt i.e Mycophenolic acid as mycophenolate sod.360mg Tablet يحصر صرفه لمرضى زرع الكلى ج/ ٩٤٩	7102009	120 tab	238.50	200.00	113.18	62.88
229	15-B00-068	Sorafenib (as tosylate) 200 mg tablet. ج ٩٨٧ لعلاج سرطان الكبد حصرا" المشخص بواسطة Liver Biopsy or ( ↑↑↑ alpha- feto protein with Radiological diagnoses ) ويحدد منفذ الصرف عن طريق م.الامل الوطني ومستشفى الاورام في دائرة مدينة الطب عن طريق لجنة مختصة والاليات المتبعة لديهم ( ج ) ( ٩٨٩ ) الموافقة على اعتماد منفذ صرف المادة في مركز البصرة للاورام على ان يعتمد تقدير الحاجة سنويا" من قبل اللجنة الاستشارية للاشعة العلاجية حصرا" ولكافة منافذ الصرف (المعتمدة . ج ( ١٠١٥ ) ج/ ١٠٣٨ الموافقة على اضافة استطباب علاج مرضى سرطان الغدة الدرقية غير المستجيب لعلاج اليود المشع	125660	60 cap	2,311.00	1617.70	1039.95	577.75

		ج ١٠٥١ في محافظة ( sorafenib ) لا مانع من فتح منفذ صرف لمادة النجف الاشراف على ان يعتمد تقدير الحاجة سنويا" من قبل اللجنة الاستشارية للاشعة العلاجية وبكافة منافذ الصرف . المعتمدة بعد ان يتم توفير المتطلبات الخاصة بصرف المادة						
230	15-B00-070	Nilotinib as Hcl monohydrate 200 mg cap. - يحصر في مدينة الطب+المركز الوطني لامراض الدم ) - +بابل+البصرة+نينوى+النجف+كركوك + كربلاء + ( اربيل + سلیمانیه+الكرخ+واسط+الانبار مع Imatinib cap يستخدم في علاج المرضى الذين لا يستفيدون من الالتزام بالصوابط الموضوعه من قبل اللجنة المركزية بصرف علاج ( ج ٩٨٩ ) في مؤسسة مدينة الطب كخط ثاني Glevic الشركة المجهزة ملزمة بتوفير الفحوصات التالية . لكل مريض"سنويا ( مرات 3 ) ( PCR BCR - ABL210 ) "لمرة واحدة للمرضى المشخصين حديثا ( FISH BCR - AB ) .	1175032	112 cap	3,400.00	2380.00	1530.00	850.00
231	15-B00-076	Lenalidomide 10mg tablet or cap to be used as maintenance post autologus transplant in multiple myelome for 2 years	76599	21 cap	5,149.45	3604.60	420.00	1287.36
232	15-B00-080	Nilotinib as Hcl monohydrate 150 mg cap ج / ٩٨٩ يطلب العقار بنسبة لا تتجاوز ( ١٥ ) ( Nilotinib 200 mg ) من عدد المرضى الذين يستلمون عقار ( % والتي تمثل ( ٩٠ مريض ) غير قابلة للزيادة ( ٣٥ ) منهم تتحملها الشركة المصنعة والباقي يوفر عن طريق كيماديا يتم تثبيت الاحتياج من قبل اللجنة المركزية لعلاج مرضى ابيضاض الدم النقياتي في دائرة مدينة الطب مع بقاء منافذ الصرف السابقة وحسب توزيع مدينة الطب+المركز الوطني لامراض الدم : المرضى (منافذ الصرف + +بابل+البصرة+نينوى+النجف+كركوك + كربلاء (الكرخ+واسط+الانبار+اربيل+سلیمانیه الشركة المجهزة ملزمة بتوفير الفحوصات التالية . لكل مريض"سنويا ( مرات 3 ) ( PCR BCR - ABL210 ) "لمرة واحدة للمرضى المشخصين حديثا ( FISH BCR - AB ) .	131400	112 cap	3,400.35	2380.00	1530.00	850.00



233	15-B00-081	<p>Natalizumab concentrate for I.V. infusion 20mg/ml, 15 ml vial</p> <p>تقرر المادة كخط ثاني على ان تقوم الشركة باجراء الفحوصات وحسب الضوابط المعمول بها عالميا المتعلقة بفايروس</p> <p>اقرت اللجنة الاستشارية لطب الاعصاب البروتوكول العلاجي للمادة وكمايلي: يستعمل العلاج اعلاه في حالة فشل ادوية الخط الاول الانترفيرون بكل انواعه ويعرف الفشل على انه حدوث انتكاسة واحدة او اكثر او ظهور نقاط بيضاء اضافية في فحص الرنين المغناطيسي للمريض خلال مدة لا تقل عن ستة اشهر من استعمال الانترفيرون. يستعمل العلاج اعلاه كعلاج خط اول في حالة المرض الشديد والمعروف بأنه حدوث اعاقه مهمة ومبكرة مع حدوث اكثر من نوبة شديدة واحدة او ظهور اكثر من أفة دماغية في فحص الرنين عند تشخيص المرض يحصر في دائرة مدينة الطب واربيل والنجف</p>	5636	15-ml vial	1,582.00	1107.40	711.90	395.50
234	15-B00-082	<p>Everolimus 10 mg tablet</p> <p>ج/٩٨٩ والتي تشترط توفير المعلومات السرطانية لمدة خمسة سنوات وتدريب الكوادر الطبية التي تقوم باجراء الفحوصات واستحداث "مجانا نظام تسجيل المرضى وتثبيت ( Metastatic pancreatic neuroendocrine tumors ) هذا الشرط كجزء من فقرات العقد فيما يخص مرض</p> <p>( كبضاعة مجانية بنسبة ١٨% من احتياج تركيز ( 10 mg ) Everolimus 5 mg ) ج/٩٨٧ بالنسبة لسرطان الثدي يشترط توفر (مرضى سرطان الثدي وبواقع الف مريضة للسنة الواحدة مع تعهد الشركة المجهزة لوزارة الصحة ( ER,PR,Her2,Ki67 ) بتوفير معلومات الأورام ( exemestine 25mg tab ) كبضاعة مجانية وبكامل الاحتياج وتوفير عقار metastatic HR+ve ,Her2-ve breast cancer after failure of non steroidal aromatase inhibitors ج/٩٨٦ اضافة استطباب</p>	108318	30 tab	3,700.00	2590.00	1665.00	925.00

235	15-B00-104	<p><b>Pembrolizumab I.V inj .100 mg/vial</b>  يحصر استخدامه للحالات التالية فقط-1  . ا-مرضى سرطان الجلد (الميلانوما) المنتشر  ب-مرضى سرطان الغدد اللمفاوية ( هودجكين ) المنتكس بعد الخط الثاني  من العلاج الكيميائي والذي من الممكن ان تجري لهم عملية زراعة نخاع  العظم ويحصر صرفه في دائرة مدينة الطب  من الاحتياج الكلي ( 15%) تلزم الشركة المجهزة على توفير 3-  كبضاعة مجانية على ان لا يكون السعر المقدم في المناقصة اعلى من  الكلفة التخمينية اوسعر التسجيل  في حال تجهيز التركيز ٥٠ ملغم لاستطباب هودجكن وحسب ماورد في  محضر لجنة امراض الدم والذي يحصر صرفه في مدينة الطب وبواقع  (لحين ورود احتياج ٢٠٢١) فيال فيتم خصم ٢٤٠ من تركيز ١٠٠ ملغم  Pembrolizumab I.V inj .100 mg/vial اي يصبح احتياج عقار  هو ٣٠٥٤ فيال وفي حال</p> <p>عدم تجهيز التركيز ٥٠ ملغم يصبح احتياج عقار  Pembrolizumab I.V inj .100 mg/vial  هو ٣٢٩٤ فيال  حسب كتاب قسم تقدير الحاجة ١٠٩٩ في ١٧/٧/٢٠١٩</p>	3294	1 vial	3,419.0	2393.3	1538.6	854.8

236	15-D00-002	Docetaxel (Anhydrous or as Trihydrate) 10mg/1ml ,8ml vial OR 20mg/1ml ,4ml vial OR 80mg/2ml Vial (all with diluent) يتم الخلط حسب النشرة الداخلية للمستحضر في المحاليل الوريدية وعدم خلطها بالاشكال الاخرى	45702	8ml vial	60.00	42.00	27.00	15.00
237	15-D00-004	Paclitaxel 6mg/ml 50ml vial	45215	50-ml vial	65.71	46.00	29.50	16.42
238	15-D00-005	Docetaxel 10mg/1ml, 2ml vial or pfs OR Docetaxel 20mg/ml, 1 ml vial or pfs ( يتم الخلط ) حسب النشرة الداخلية للمستحضر في المحاليل الوريدية وعدم خلطها بالاشكال الاخرى) ج ٩٨٧ اضافة شكل صيدلاني	48509	2ml vial	18.00	12.50	8.10	4.50
239	15-E00-002	Irinotecan Hcl or Hcl Trihydrate 20mg/ml ( 5ml I.V. Infusion Vial )	22178	5-ml vial	57.00	32.00	24.00	17.50
240	17-000-001	Acetylcysteine 10ml amp of 20% w/v aqueous solution (each containing 2g) i.e.(200mg/ml) SEE gp 17 خاص بوحدات العناية المركزة ووحدات الطوارئ ومراكز السموم	4070	10-ml amp	2.81	1.97	1.27	0.70
241	17-000-015	Desferrioxamine mesylate 500mg inj Vial يتم تثبيت الاحتياج للدوائر التي تحتوي مراكز للتلاسيما	1394623	1 vial	4.91	3.44	2.56	1.23
242	17-000-016	Dicobalt edetate 300mg/ (20ml) Ampoule	10	20-ml amp	30.34	21.24	13.65	7.58
243	17-000-018	Dimercaprol in arachis oil (solvent) 50mg/ml 2ml Ampoule injection يتم تثبيت الاحتياج من قبل المركز الاستشاري لاستعلامات السموم + ذي قار	550	1 amp	110.88	77.62	49.90	27.72
244	17-000-028	Naloxone Hcl 400mcg/ml inj (1ml) Amp or Pfs or vial مع الاخذ بنظر الاعتبار استخدامه ضمن قائمة التخدير وقائمة السموم	5204	1-ml amp	6.57	4.60	2.96	1.64

245	04-J00-005	Carbamazepine 100mg/5ml liquid	70000	300 ml	2.945	2.06	1.32	0.73
246	09-AD0-001	Alphacalcidol 0.25mcg (1alphahydroxy cholecalciferol) soft gelatin Capsule	600000	30 cap	5.55		2.85	
247	02-E00-006	Mesalazine 500mg mlr (modified release)Tablet	1896594	100 TAB	38.12	26.68	17.15	9.53
248	04-J00-010	Clonazepam 0.5mg Tablet	727084	50 TAB	3.00	2.05	1.35	0.75
249	06-J00-004	Clomiphene citrate 50mg Tablet	416613	10 tab		2.03	1.40	
250	11-A00-010	Gentamycin as sulphate 0.3% Eye/Ear Drop	415722	5 ml	1.13	0.79	0.51	0.28
251	11-BA0-003	Dexamethasone 1 mg / 1 ml ( 0.1% ) eye drop	303845	5 ml	1.65	1.80	0.65	
252	15-F00-001	<p>2-8x10<sup>8</sup> CFU TICE BCG  مادة BCG المستخدمة لعلاج سرطان المثانة  تختلف عن لقاح BCG العامة المستخدم في دائرة الصحة  intravesicular BCG Instillation  code15- المقدمة وتكون الاحاله حسب افضلية العروض  F00-002 يكون بحتياج ضمني مع  BCG يكون صرف مادة</p> <p>عن طريق المثانة لعلاج اورام المثانة السطحية للمستشفيات 1  مركز علاج الاورام من قبل مركز علاج الاورام التي توفر فيها  المستشفيات التي لايتوفر فيها مركز علاج للاورام بصرف من 2  البولية وبعد استشارة اخصائي الاورام قبل اختصاصي الجراحة  المذكور بعد اجراء وذلك لصعوبة تحديد حاجة المريض للعلاج</p>	11385	1 INJ	80			

		قص للورم من قبل اختصاص الجراحة البولية ومعاونة المريض المستشفيات التي لاتوفر فيها مركز علاج الاورام في						
253	15-F00-002	<p><b>2x108 – 3x109 (RIVM ) BCG</b>  <b>مادة BCG المستخدمة لعلاج سرطان المثانة</b>  <b>تختلف عن لقاح BCG المستخدم في دائرة الصحة العامة</b>  <b>intravesicular BCG Instillation</b>  <b>code15-F00-</b> وتكون الاحاله حسب افضلية العروض المقدمة  <b>001</b> يكون بحتياج ضمني مع  <b>BCG</b> يكون صرف مادة</p> <p>عن طريق المثانة لعلاج اورام المثانة السطحية للمستشفيات 1  مركز علاج الاورام من قبل مركز علاج الاورام التي توفر فيها  المستشفيات التي لايتوفر فيها مركز علاج للاورام بصرف من 2  البولية وبعد استشارة اخصائي الاورام قبل اختصاصي الجراحة  المذكور بعد اجراء وذلك لصعوبة تحديد حاجة المريض للعلاج  قص للورم من قبل اختصاص الجراحة  البولية ومعاونة المريض في المستشفيات التي لاتوفر فيها مركز  الاورام علاج</p>	2300	81-mg vial	99.04	69.33	44.57	24.76
254	05-AA0-007	Amoxycillin as sodium 500mg per Vial. (I.V.I.M)	18257121	1 VIAL		0.75	0.42	0.23

**CONTENTS**  
**PART 1 – BIDDING PROCEDURES**

**Section I. Instructions to Bidders**  
**Section II. Bid Data Sheet**  
**Section III. Evaluation and Qualification Criteria**  
**Section IV.**

**Bidding Forms**

**PART 2 – PROCUREMENT REQUIREMENTS**  
**Section V Schedule of Requirements**

**PART 3 – CONDITIONS OF CONTRACT AND CONTRACT FORMS**  
**Section VI. General Conditions of Contract**



---

**Section VII. Special Conditions of Contract**  
**Section VIII. Contract Forms**







**PART 1  
BIDDING PROCEDURES**

**SECTION I. INSTRUCTIONS TO BIDDERS**  
**TABLE OF CLAUSES**

A. Introduction.....	4	
1. Scope of Bid.....	4	
2. Fraud and Corruption.....	4	
B. The Bidding Documents.....	5	
3. Content of Bidding Documents.....	5	
4. Clarification of Bidding Documents.....	5	
5. Amendment of Bidding Documents.....	6	
C. Preparation of Bids.....	6	
6. Eligibility.....	6	
7. Establishing Eligibility of Goods and Services and Conformity .....	7	
8. Qualifications of the Bidder.....	8	
9. One Bid per Bidder.....	9	
10. Cost of Bidding.....	9	
11. Language of Bid .....	9	
12. Documents Constituting the Bid.....	9	
13. Bid Form.....	10	
14. Bid Prices and Discounts.....	10	
15. Currencies of Bid.....	12	
16. Period of Validity of Bids.....	12	
17. Bid Security.....	12	
18. Format and Signing of Bid.....	14	
D. Submission of Bids.....	14	
19. Sealing and Marking of Bids.....	14	
20. Deadline for Submission of Bids.....	15	
21. Late Bids.....	15	
22. Modification and Withdrawal of Bids.....	15	
E. Opening and Evaluation of Bids.....	16	
23. Bid Opening .....	16	
24. Clarification of Bids.....	18	
25. Confidentiality.....	18	
26. Examination of Bids and Determination of Responsiveness.....	18	
27. Correction of Errors.....	19	
28. Conversion to Single Currency.....	19	
29. Evaluation and Comparison of Bids.....	20	
30. Margin of Preference .....	20	
31. Contracting Entity's Right to Accept Any Bid and to Reject Any or All Bids.....	21	
32. Eligibility and Qualification of bidder.....	21	
F. Award of Contract .....	21	
33. Award Criteria.....	21	
34. Contracting Entity's Right to Vary Quantities at Time of Award .....	21	
35. Notification of Award.....	21	
36. Complaints and Appeals.....	22	
37. Signing of Contract.....	22	
38. Performance Security.....	23	



## PART 1

### BIDDING PROCEDURES Section I. Instructions to Bidders Instructions to Bidders

#### A. INTRODUCTION

- 
- |                                |  |
|--------------------------------|--|
| <b>1. Scope of Bid</b>         | <p>1.1 The Contracting Entity, as specified in the <b>Bid Data Sheet (BDS)</b> and in the <b>Special Conditions of Contract (SCC)</b>, invites bids for the supply of Goods (pharmaceuticals, vaccines, contraceptives, or medical equipment) as specified in the <b>Bid Data Sheet</b> and <b>Schedule of Requirements</b>.</p> <p>1.2 Throughout these bidding documents, the terms “writing” means any typewritten or printed communication, including letters delivered by hand, telex, and facsimile transmission, and “day” means calendar day. Singular also means plural.</p>  |
| <b>2. Fraud and Corruption</b> | <p>2.1 The Contracting Entity requires that bidders, suppliers, and contractors, their subcontractors and their staff shall observe the highest standard of ethics during the procurement and execution of contracts. In pursuance of this policy, the Contracting Entity:</p> <p>(a) defines Fraud and Corruption as per the relevant applicable Iraqi laws. For the purpose of this provision, the Contracting Entity will be guided further by the definition of the terms as set forth here below:</p> <p>(i) “corrupt practice” is the offering, giving, receiving or soliciting, directly or indirectly, of anything of value to influence improperly the actions of another party;</p> <p>(ii) “fraudulent practice” is any act or omission, including a misrepresentation, that knowingly or recklessly misleads, or attempts to mislead, a party to obtain a financial or other benefit or to avoid an obligation;</p> <p>(iii) “collusive practice” is an arrangement between two or more parties designed to achieve an improper purpose, including to influence improperly the actions of another party;</p> <p>(iv) “coercive practice” is impairing or harming, or threatening to impair or harm, directly or indirectly, any party or the property of the party to influence improperly the actions of a party;</p> <p>(v) “obstructive practice” is</p> <p>(aa) deliberately destroying, falsifying, altering or concealing of evidence material to the investigation or making false statements to investigators in order to materially impede a Contracting Entity’s investigation into allegations of a</p> |

- corrupt, fraudulent, coercive or collusive practice in accordance with the applicable Iraqi laws; and/or threatening, harassing or intimidating any party to prevent it from disclosing its knowledge of matters relevant to the investigation or from pursuing the investigation; or
- (bb) acts intended to materially impede the exercise of inspection and audit rights provided for under Sub-Clause 2.1 (d) below in accordance with the applicable Iraqi laws.
  - (b) will reject the Bid if it determines in accordance with the applicable Iraqi laws that the bidder recommended for award has, directly or through an agent, engaged in corrupt, fraudulent, collusive, coercive or obstructive practices in competing for the contract in question;
  - (c) will sanction a firm or individual in accordance with the applicable Iraqi laws, including declaring ineligible, either indefinitely or for a stated period of time, to be awarded contract if it at any time it is determined by the competent Iraqi authorities that the firm has, directly or through an agent, engaged in corrupt, fraudulent, collusive, coercive or obstructive practices in competing for, or in executing, a Contracting Entity financed contract; and
  - (d) will have the right to inspect the accounts and records and other documents relating to the bid submission and contract performance of bidders, suppliers, and contractors and their sub-contractors and to have them audited by the competent authorities in accordance to the applicable Iraq Laws.

## B. THE BIDDING DOCUMENTS

- 
- |  |  |
|--|--|
| <b>3. Content of Bidding Documents</b> | <p>3.1 The Bidding Documents are those stated below and should be read in conjunction with any addendum issued in accordance with ITB Clause 5:</p> <ul style="list-style-type: none"><li>Section I. Instructions to Bidders (ITB)</li><li>Section II. Bid Data Sheet (BDS)</li><li>Section III. Evaluation and Qualification Criteria</li><li>Section IV. Bidding Forms</li><li>Section V. Eligible Countries</li><li>Section VI. Schedule of Requirements</li><li>Section VII. General Conditions of Contract (GCC)</li><li>Section VIII. Special Conditions of Contract (SCC)</li><li>Section IX. Contract Forms</li></ul> <p>3.2 The "Invitation for Bids" does not form part of the Bidding Documents..</p> |
| <b>4. Clarification of</b>             | <p>4.1 A prospective Bidder requiring any clarification of the</p>   |

- Bidding Documents**
- Bidding Documents shall contact the **Contracting Entity** in writing or by cable (the term “cable” is deemed to include electronic mail, telex, or facsimile) at the **Contracting Entity’s address indicated in the Bid Data Sheet**. The **Contracting Entity** will respond in writing to any request for clarification received no later than **fourteen (14) calendar days** prior to the deadline of submission of bids. Copies of the Contracting Entity’s response shall be sent to all prospective Bidders who have purchased the Bidding Documents, including a description of the inquiry but without identifying its source.
- 4.2 In order to maintain the confidentiality of the procedures during the Bid advertisement period, information about the names and addresses of Bidders and their agents shall not be disclosed to any unconcerned party.
- 5. Amendment of Bidding Documents**
- 5.1 At any time prior to the deadline for submission of bids, the **Contracting Entity** may amend the Bidding Documents by issuing Addenda.
- 5.2 Any addendum thus issued shall be part of the Bidding Documents pursuant to ITB Sub-Clause 3.1 and shall be communicated in writing to all purchasers of the Bidding Documents and will be binding on them. Bidders are required to immediately acknowledge receipt of any such amendment, and it will be assumed that the information contained in the amendment will have been taken into account by the Bidder in its bid.
- 5.3 To give prospective Bidders reasonable time in which to take the amendment into account in preparing their bids, the **Contracting Entity shall extend**, at its discretion, the deadline for submission of bids, in which case, the Contracting Entity will notify all Bidders by cable confirmed in writing of the extended deadline. The Contracting Entity shall advertise any extension of the deadline for bid submission in same media as was done for the Short Procurement Notice of this tender.

### C. PREPARATION OF BIDS

- 6. Eligibility**
- 6.1 This bidding process is **open to qualified firms from any Eligible country as specified in Section - V. The Firms may be excluded from bidding if:**
- (a) the firms have a conflict of interest. All Bidders found to have a conflict of interest shall be disqualified. A Bidder may be considered to have a conflict of interest with one or more parties in this bidding process, if :
- (1) they have a controlling partner in common; or
  - (2) they receive or have received any direct or indirect subsidy from any of them; or
  - (3) they have the same legal representative for purposes of this bid; or

- (4) they have a relationship with each other, directly or through common third parties, that puts them in a position to have access to information about or influence on the bid of another Bidder, or influence the decisions of the Contracting Entity regarding this bidding process; or
- (5) a Bidder submits more than one bid in this bidding process, either individually or as a partner in a joint venture. This will result in the disqualification of all such bids. However, this does not limit the participation of a Bidder as a subcontractor in another bid or of a firm as a subcontractor in more than one bid. or
- (6) a firm has been engaged by the Contracting Entity - or a Purchasing Agent that has been duly authorized to act on behalf of the Contracting Entity - to provide consulting services for the preparation of the design, specifications, and other documents to be used for the procurement of the Goods described in these Bidding Documents. or

6.2 Staff of the Government and Public Sector cannot participate directly or indirectly in Public Tenders

6.3 A firm declared Black listed or Suspended by the competent authorities shall be ineligible to bid during the period of time determined. A list in this regard is available on the website **specified in BDS**.

## 7. Documents Establishing Eligibility of Goods and Services and Conformity to Bidding Documents

7.1 Pursuant to ITB Clause 12, the Bidder shall furnish, as part of its bid, documents establishing, to the Contracting Entity's satisfaction, the eligibility of the Health Sector Goods and Medical Equipment and services to be supplied under the Contract.

7.2 The documentary evidence of the eligibility of the Goods and Services shall consist of a statement in the Price Schedule of the country of origin of the Goods and Services offered that shall be confirmed by a certificate of origin to be issued at the time of shipment and approved by the competent Iraqi authorities in the country of origin; such an approval is waived for items of certified Arab origin.

7.3 The documentary evidence of conformity of the Goods and Services as **specified in Section VI Schedule of Requirements** may be in the form of literature, drawings, and data and shall consist of:

- (a) a detailed description of the essential technical and performance characteristics of the Goods;
- (b) an item-by-item commentary on the Contracting Entity's Technical Specifications demonstrating substantial responsiveness of the Goods and Services to those specifications, or a statement of deviations and exceptions to the provisions of the Technical

- Specifications;
- (c) any other procurement-specific documentation requirement as stated in the **Bid Data Sheet**.
- 7.4 Unless the **Bid Data Sheet** stipulates otherwise, the Goods to be supplied under the Contract shall be registered with the competent authority in Iraq. A Bidder who has already registered its Goods by the time of bidding should submit a copy of the Registration Certificate with its bid. Otherwise, the successful Bidder, by the time of Contract signing, shall submit to the Contracting Entity either:
- (a) a copy of the Registration Certificate of the Goods for use in the Iraq.
- OR, if such Registration Certificate has not yet been obtained,
- (b) evidence establishing to the Contracting Entity's satisfaction that the Bidder has complied with all the documentary requirements for registration as specified **in the Bid Data Sheet**.
- (c) **it is permitted to take exception by the health minister.**
- 7.4.1 The Contracting Entity shall at all times cooperate with the successful Bidder to facilitate the registration process within Iraq. The agency and contact person able to provide additional information about registration are identified in the **Bid Data Sheet**.
- 7.4.2 (a): If the Goods of the successful Bidder have not been registered in Iraq at the time of Contract signing, then the Contract shall become effective upon such date as the Certificate of Registration is obtained.
- (b) : **minister of health has the right to take exception for the winner bidder from submitting registration certificate at the time of signing contract.**
- 7.5 For purposes of the commentary to be furnished pursuant to ITB Sub-Clause 7.3 (b) above, the Bidder shall note that standards as well as references to brand names designated by the Contracting Entity in its Technical Specifications are intended to be descriptive only and not restrictive. The Bidder may substitute alternative standards, brand names, and/or catalog numbers in its bid, provided that it demonstrates to the Contracting Entity's satisfaction that the substitutions ensure substantial equivalence to those designated in the Technical Specifications.
- 8.1 The Bidder shall provide documentary evidence to establish to the Contracting Entity's satisfaction that
- (a) the Bidder has the financial, technical, and production capability necessary to perform the Contract, meets the Qualification Criteria **specified in Section III Evaluation and Qualification Criteria**.
- (b) in the case of a Bidder offering to supply Goods,

## 8. Qualifications of the Bidder



- identified in the Bid Data Sheet, that the Bidder did not manufacture or otherwise produce, the Bidder has been duly authorized by the manufacturer or producer of such Goods to supply the Goods in Iraq as per format of Manufacturer's Authorization Form in Section IV;
- (c) in the case of a Bidder who is not doing business within Iraq (or for other reasons will not itself carry out service/maintenance obligations), the Bidder is or will be (if awarded the Contract) represented by a local service/maintenance provider in Iraq equipped and able to carry out the Bidder's warranty obligations prescribed in the Conditions of Contract and/or Technical Specifications; and
  - (d) the Bidder meets the qualification criteria listed in the **specified in Section III Evaluation and Qualification Criteria**(see additional clauses of **Section III** for pharmaceuticals, vaccines and medical equipment).
- The companies should be submitted a letter of no objection issued by the general authority for taxes when participating in the tenders announced .**
- 9. One Bid per Bidder** 9.1 A firm shall submit only one bid as an individual Bidder and in accordance with ITB 6.1.a.
- 10. Cost of Bidding** 10.1 The Bidder shall bear all costs associated with the preparation and submission of its bid, and the Contracting Entity will in no case be responsible or liable for those costs, regardless of the conduct or outcome of the bidding process.
- 11. Language of Bid** 11.1 The bid, **as well as all correspondence** and documents **relating to** the bid exchanged by the Bidder and the **Contracting Entity**, shall be written in the language specified in the **Bid Data Sheet**. Supporting documents and printed literature furnished by the Bidder may be in another language provided they are accompanied by an accurate translation of the relevant passages **in the language specified**, in which case, for purposes of interpretation of the Bid, the translation shall **govern**.
- 12. Documents Constituting the Bid** 12.1 The bid submitted by the Bidder shall comprise the following:
- (a) duly filled-in Bid Form and Price Schedule, in accordance with the forms indicated in Section IV;
  - (b) original form of bid security in accordance with the provisions of ITB Clause 17 (Bid Security);
  - (c) written power of attorney authorizing the signatory of the bid to commit the Bidder;
  - (d) documentary evidence establishing to the Contracting Entity's satisfaction, and in accordance with Documents required as per ITB Clause 7 and that they conform to the Bidding Documents;

- (e) documentary evidence establishing to the Contracting Entity's satisfaction, and in accordance with Qualification of the Bidder as per ITB Clause 8 that the Bidder is qualified to perform the Contract if its bid is accepted.
  - (f) Bidder's voucher of purchasing the Bidding Document.
  - (g) if applicable as per ITB Sub-clause 8.1(b), Manufacturer's Authorization Form as per format in Section IV
  - (h) **Bidder's voucher of purchasing the Tender Document.** Any other required document shall be **specified in the Bid Data Sheet**
- 13. Bid Form**
- 13.1 The Bidder shall complete the Bid Form and the appropriate Price Schedule **provided under Section – IV** indicating the Goods to be supplied, a brief description of the Goods, their country of origin, quantity, and prices.
- 14. Bid Prices and Discounts**
- 14.1 The Bidder shall quote their prices as per format of Price Schedule provided under **Section IV** all the specified components of prices shown therein. All the columns shown in the Price Schedule should be filled up as required. If any column does not apply to a Bidder, same should be clarified as "NA" (means Not Applicable) by the Bidder.
- 14.2 The quoted prices for goods offered for domestic goods or goods of foreign origin located in Iraq shall be quoted in the Price Schedule given under **Section IV** (2). The quoted prices for goods to be imported from abroad, shall be quoted in the Price Schedule given under **Section IV** (3).
- 14.3 While filling up the columns of the Price Schedule, the following aspects should be noted for compliance:
- 14.3.1 For domestic goods or goods of foreign origin located in Iraq, the prices under column 5 in the corresponding Price Schedule in at **Section IV** (2) shall be entered separately in the following manner:
- Column 5(a): The price of goods, quoted ex-factory/ ex-showroom/ ex-warehouse/ off-the-shelf, as applicable, including all taxes and duties like Sales Tax, Custom Duty, Excise Duty etc. already paid or payable on the components and raw material used in the manufacture or assembly of the goods quoted ex-factory etc. or on the previously imported goods of foreign origin quoted ex-showroom etc. This will also include charges towards Packing & Forwarding,
  - Column 5(b): Any sales and other taxes and duties like Excise Duty, Sales Tax etc., which will be payable on the goods in Iraq if the Contract is awarded;
  - Column 5(c): Inland Transportation, Insurance, Loading/ Unloading and other incidental costs till to

delivery of the goods to their final destination as specified in the Schedule of Requirements.

Column 5(d): The Price of Incidental Services including installation, demonstration and onsite training at End-users' site, if applicable, as mentioned in Schedule of Requirements.

- 14.3.2 For goods offered from abroad, the prices under Column 5 in the corresponding Price Schedule as per format in **Section IV** (3) shall be entered separately in the following manner:

Column 5(a): The price of goods quoted CIP at port/airport of destination;

Column 5(b): The price of goods quoted DDP (Delivery Duty Paid) at End-user site in Iraq as specified in the Schedule of Requirements.

Column 5(c): The price of Incidental Services including installation, demonstration and onsite training at End-users' site, if applicable, as mentioned in Schedule of Requirements;

- 14.3.3 For Medical Equipment, Annual Maintenance Contract (AMC) at End-users' site for the stipulated years after warranty period in the Price Schedule as per format in **Section IV** (4), if applicable as specified in Schedule of Requirements. The cost of AMC may be quoted along with taxes applicable on the date of Bid Opening. The taxes to be paid extra, to be specifically stated. In the absence of any such stipulation the price will be taken inclusive of such taxes and no claim for the same will be entertained later. During AMC contract period the Supplier shall keep sufficient stock of spares required during and will to attend to the break down calls promptly. An UPTIME warranty of 'x'% per year during Annual Maintenance Contract, if applicable, **as specified in Section VI Schedule of Requirements** should be provided. In such cases if the Down Time exceeds (100-x) % per year during AMC period, it will extend the AMC period by double the down time period.

- 14.4 The terms EXW, FCA, FOB, CIF, CIP, DDP, etc., shall be governed by the international rules for interpreting trading terms as prescribed in the current edition of INCOTERMS® published by the International Chamber of Commerce, Paris.

- 14.5 The Bidder's separation of price components in accordance with ITB Sub clause 14.3 above will be solely for the purpose of facilitating the comparison of bids by the Contracting Entity and will not in any way limit the Contracting Entity's right to contract on any of the terms offered.

- 14.6 Price quoted by Bidder shall be fixed during the currency of the Contract and not subject to any variation on any account.
- 14.7 If more than one schedule (or lot) has been **specified in Section VI** Schedule of Requirements, these Bidding Documents allow Bidders to quote separate prices for one or more schedules (or lots). The Bidder may quote for one or more schedules (or lots) but are required to quote for all items and its full quantity of the goods of that schedule. The Schedules (or lots) must be listed and priced separately in the Price Schedules. Bids shall be evaluated for each schedule (or lot) separately.
- 15. Currencies of Bid**
- 15.1 Prices shall be quoted in the following currencies:
- (a) The Bidder shall express its prices for such goods to be supplied from Iraq in the Iraqi Dinar.
  - (b) The Bidder may express the bid price of the Goods to be supplied from abroad as indicated in the **Bid Data Sheet**.
- 16. Period of Validity of Bids**
- 16.1 Bids shall remain valid for the period stipulated in the **Bid Data Sheet** after the date of bid submission specified in ITB Clause 20. A bid valid for a shorter period shall be rejected by the Contracting Entity as nonresponsive.
- 16.2 In exceptional circumstances, prior to expiry of the original bid validity period, the Contracting Entity may request that the Bidders extend the period of validity for a specified additional period. The request and the responses thereto shall be made in writing. A Bidder may refuse the request without forfeiting its bid security. The Bidder agreeing to the request will not be required or permitted to modify its bid, but will be required to extend the validity of its bid security for the period of the extension.
- 17. Bid Security**
- 17.1 The Bidder shall furnish as part of its bid a bid security in the form of an unconditional guarantee and payable upon first demand and in any of the following modes:
- (a) a bank guarantee as per format in **Section IV** ; or
  - (b) a cashier's or certified check; or
  - (c) **or any mode depended by the contracting entity in data sheet.**
- The amount of the Bid Security shall be as stipulated in the **Bid Data Sheet** and in the **Schedule of Requirements in Section VI**.
- 17.2 The bid security shall be addressed to the Contracting Entity stating the number and title of the IFB and shall remain valid for a period of 28 days beyond the validity

period for the bid, and beyond any extension subsequently requested under Sub-Clause 16.2.

- 17.3 The bid security shall, at the Bidder's option, be in the form of either or a Bank Guarantee from an accredited bank in Iraq and in accordance with the instructions of Central Bank of Iraq or certified check in the format provided in the Bidding Documents **any mode depended by the contracting entity in data sheet.** In the case of Bank Guarantee furnished from the banks outside Iraq, it should be endorsed and countersigned by accredited bank in Iraq by way of back-to-back counter guarantee.
- 17.4 Any bid not accompanied by an acceptable bid security shall be rejected by the Contracting Entity as nonresponsive **excepting that of the producing drugs company or medical equipment manufacturing companies which are cover by the valid exception of the minister of health .**
- 17.5 Upon the approval of the Contracting Authority, the Contracting Entity has the right to release the Bid Securities of the unsuccessful Bidders that are unlikely to be awarded the Contract before the end of the Bid Validity and after the referral recommendation has been made. In such a case, the Bid Securities of the first three (3) candidates Bidders shall be retained in view of ITB Sub-Clause 38.2
- 17.6 The bid security of the successful Bidder will be returned when the Bidder has signed the Contract and furnished the required performance security.
- 17.7 The bid security may be forfeited
- (a) if the Bidder withdraws its bid, except as provided in ITB Sub-Clauses 16.2 and 22.3; or
  - (b) in the case of a successful bidder, if the Bidder fails within the specified time limit to:
    - (i) sign the contract, or
    - (ii) furnish the required performance security.
  - (c) In the case of Complaint and Appeal as per Clause 36 by an unsuccessful Bidder and when this complaint or appeal is found by the competent authorities to be for false or unjustified reasons. The amount of damage resulting from delaying the contract signature will be recovered from the Bid Security of the here above unsuccessful Bidder. However, such amount **which forfeited from Bid Security which equale to the penalties value limited** in accordance with the applicable Iraqi laws and procedures.
- 17.8 If the bid security is not provided by some Bidders, due to exemption provided by the Iraqi applicable laws, as in the case of Public Companies or others as

- specified in **Bid Data Sheet** Sub-Clause 17.1, and
- a) if such a Bidder withdraws its bid during the period of bid validity specified by the Bidder on the Bid Submission Form, except as provided in ITB Sub-Clause 16.2, or
  - b) if such a Bidder is nominated as a successful Bidder and fails to: sign the Contract in accordance with ITB Clause 37; or furnish a performance security in accordance with ITB Clause 38;
- the Contracting Entity may, if provided for in the **Bid Data Sheet**, declare the Bidder disqualified to be awarded a contract by the Contracting Entity and proceed with the administrative actions as stated in the **Bid Data Sheet**.

#### **18. Format and Signing of Bid**

- 18.1 The Bidder shall prepare an original and it is permitted to be as ( compact disk ) with the technical bid , while the financial bid should be submitted in one written original copy .
- 18.2 The original and all copies of the bid, each consisting of the documents listed in ITB Sub-Clause 12.1, shall be typed or written in indelible ink and shall be signed by the Bidder or a person or persons duly authorized to bind the Bidder to the Contract. The authorization shall be indicated as specified in the **Bid Data Sheet** by those legally authorized to signed, which pursuant to ITB Sub-Clause 12.1 (c) shall accompany the bid. The Bidder has to ensure the signature of the Bid Submission Form and of every page of the Price Schedules and the attached documents to the Bid by the person signing the Bid. Noting that all pages of the bid where entries or corrections on entries have been made by the Bidder shall be signed or initialled by the person signing the bid. Prices shall be incorporated by the Bidder in words and figures as required in the Price Schedules. Any other requirement is specified in the **Bid Data Sheet**.
- 18.3 The Bid shall contain no interlineations, erasures, or modifications to the Bidding Documents, except to correct errors made by the Bidder in preparing the Bid Forms and where accordingly such corrections should be signed and initialled by the authorised person or persons signing the bid.

#### **D. SUBMISSION OF BIDS**

#### **19. Sealing and Marking of Bids**

- 19.1 Bidders may always submit their bids by express mail, express courier or by hand. The Bidder shall enclose the original and each copy of the bid in separate sealed envelopes, duly marking the envelopes as "ORIGINAL" or "COPY." The envelopes containing the

original and copies shall then be enclosed in **stamped outer envelope**.

- 19.2 The inner and outer envelopes shall:
- (a) bear the name and address of the Bidder and Bidder stamp on four corners;
  - (b) be addressed to the Contracting Entity at the address given in the **Bid Data Sheet**;
  - (c) bear the Tender, Tender number, and IFB number indicated in the **Bid Data Sheet**; and
  - (d) bear a statement “DO NOT OPEN BEFORE [23 –2 - 2020]” to be completed with the time and date specified in the Bid Data Sheet relating to ITB Sub-Clause 20.1.

19.3 If the outer envelope is not sealed, stamped and marked as required by ITB Sub-Clause 19.2 and in accordance with the applicable Iraqi laws, the Contracting Entity will assume no responsibility for the misplacement or premature opening of the bid.

## **20. Deadline for Submission of Bids**

- 20.1 Bids must be received by the Contracting Entity at the address specified in ITB Sub-Clause 19.2 (b) no later than the time and date specified in the **Bid Data Sheet**. A receipt will be provided by the Contracting Entity against each Bid submitted. One copy of the receipt will be for the Bidder, and the second copy will be kept by the Contracting Entity for a further reference
- 20.2 The Contracting Entity may, at its discretion and before the deadline, extend the deadline for the submission of bids by amending the Bidding Documents in accordance with ITB Sub-Clause 5.3, in which case all rights and obligations of the Contracting Entity and Bidders previously subject to the deadline will thereafter be subject to the deadline as extended.

## **21. Late Bids**

- 21.1 Any bid received by the Contracting Entity after the deadline for submission of bids prescribed in ITB Clause 20 will be rejected and returned unopened to the Bidder.

## **22. Modification and Withdrawal of Bids**

- 22.1 The Bidder may modify or withdraw its bid after submission, provided that written notice of the modification, or withdrawal of the bids duly signed by an authorized representative with a valid proof of the authorization, is received by the Contracting Entity prior to the deadline prescribed for submission of bids.
- 22.2 The Bidder’s modification or substitution shall be prepared, sealed, marked, and dispatched prior to the deadline for submission of bids and as follows:
- (a) The Bidder shall provide an original and the number of copies specified in ITB Sub-Clause **19.1** of any modifications to its bid, clearly identified as such, in two inner envelopes duly marked “BID MODIFICATION-ORIGINAL” or “BID SUBSTITUTION-ORIGINAL” and “BID MODIFICATION-COPIES” or “BID SUBSTITUTION-COPIES.”

- The inner envelopes shall be sealed in an outer envelope, which shall be duly marked "BID MODIFICATION" or "BID SUBSTITUTION."
- (b) Other provisions concerning the marking and dispatch of bid modifications shall be in accordance with ITB Sub-Clauses 19.2 and 19.3.
- 22.3 A Bidder wishing to withdraw its bid shall notify the Contracting Entity in writing prior to the deadline prescribed for bid submission. A withdrawal notice shall be received prior to the deadline for submission of bids and shall:
- (a) be addressed to the Contracting Entity at the address named in ITB Sub-Clause 19.2 (b)
  - (b) bear the Invitation for Bids (IFB) title and number indicated in named in ITB Sub-Clause 19.2 (c) and the words "BID WITHDRAWAL NOTICE" and
  - (c) be accompanied by a valid written power of attorney authorizing the signatory of the withdrawal notice to withdraw the bid.
- 22.4 Bids requested to be withdrawn in accordance with ITB Sub-Clause 22.3, shall be returned unopened to the Bidders.
- 22.5 No bid may be withdrawn, substituted, or modified in the interval between the bid submission deadline and the expiration of the bid validity period specified in ITB Clause 16. Withdrawal of a bid during this interval may result in the forfeiture of the Bidder's bid security, pursuant to ITB Sub-Clause 17.7.

## E. OPENING AND EVALUATION OF BIDS

### 23. Bid Opening

- 23.1 The Contracting Entity (Bid Opening Committee) will open all bids, including withdrawal notices and modifications, in public, in the presence of Bidders' representatives who choose to attend, at the time, on the date, and at the place specified in the **Bid Data Sheet**. Bidders' representatives shall sign a register as proof of their attendance.
- 23.2 Envelopes marked "WITHDRAWAL" shall be read out and the envelope with the corresponding bid shall not be opened but returned to the Bidder. No bid withdrawal notice shall be permitted unless the corresponding withdrawal notice with a valid authorization is read out at bid opening. Next, envelopes marked "SUBSTITUTION" shall be opened and read out and exchanged with the corresponding bid being substituted, and the substituted bid shall not be opened, but returned to the Bidder. No bid substitution shall be permitted unless the corresponding substitution notice contains a valid authorization to



request the substitution and is read out at bid opening. Envelopes marked "MODIFICATION" with a valid authorization shall be read out and opened with the corresponding bid.

23.3 All other Bids shall be opened one at a time, reading out: the name of the Bidder and the Bid Price of each item or schedule (or lot) including any discounts, and indicating whether there is: the presence or absence of a bid security, if required; the presence or absence of requisite powers of attorney; and any other such details as the Contracting Entity may consider appropriate. No bid shall be rejected at bid opening except for late bids pursuant to Sub-Clause 21.1.

All pages of the original of each Bid shall be stamped with the bid opening committee stamp and the bid opening committee members shall sign on all pages of the price schedules of the original of each Bid.

23.4 Bids (and modifications sent pursuant to ITB Sub-Clause 22.2) that are not opened and read out at bid opening shall not be considered further for evaluation, irrespective of the circumstances.

23.5 The Contracting Entity will prepare minutes of the bid opening at the end of the opening session, with the here above mentioned information of ITB Sub-Clauses 23.1, 23.2, 23.3, and 23.6 and including in minimum the following information about: --sealing and stamping of the envelopes;

- bid prices ( unit price for each lot if it is available ) in addition to any conditional pricing or discounts based on other Bids;

- marking (with the signature of the Chairman of Bids Opening Committee and the members) of any alteration, erasure, correction made by the Bidder on the prices schedules (while slashing un-priced items with horizontal lines);

- Bidder's signature of the Bid Submission Form and other attached Bid Forms and of every page of the price schedules;

- number of pages of each Bid;

- any other relevant remarks and reservations made by the Bidder on the Bid;

- any other remarks and general description and highlights to be made by the Committee on any attachments to the Bid. All Bid's content and attachments will be initialled by the Bids Opening Committee.

23.6 The Bidder's representatives who are present shall be requested to sign the minutes with the right to add any comment on the performance of the Committee. The omission of a Bidder's signature on the minutes shall

- not invalidate the content and effect of the minutes. The minutes should be distributed to all Bidders who wish to retain its copy.
- 23.7 All Bids' prices, technical specifications, and implementation periods will be officially placed on the Contracting Authority's bill board while stating that these are to be analysed and verified further.
- 23.8 The Bids will be referred by an official report to the Bids Evaluation Committee according to the agreement of The Contracting Entity chairman.
- 24. Clarification of Bids**
- 24.1 During evaluation of the bids, only the Contracting Entity (evaluation & analysis committee) may, at its discretion, ask the Bidder for a clarification of its bid. The request for clarification and the response shall be in writing, and no change in the prices or substance of the bid shall be sought, offered, or permitted, except to correct arithmetic errors identified by the Contracting Entity in the evaluation of the bids, in accordance with ITB Sub-Clause 27.1.
- If a Bidder does not provide clarifications of its bid by the date and time set in the Contracting Entity's request for clarification, its bid may be rejected.
- 25. Confidentiality**
- 25.1 Information relating to the examination, clarification, evaluation, and comparison of bids, and recommendations for the award of a Contract shall not be disclosed to bidders or any other persons not officially concerned with such process until the notification of Contract award is made to all Bidders.
- 25.2 Any effort by the bidder to influence the Contracting Entity (evaluation & analysis committee) in the Contracting Entity's bid evaluation, bid comparison, or contract award decisions may result in the rejection of the Bidder's bid.
- 25.3 From the time of bid opening to the time of Contract award, if any Bidder wishes to contact the Contracting Entity on any matter related to its bid, it should do so in writing.
- 26. Examination of Bids and Determination of Responsiveness**
- 26.1 The Contracting Entity (evaluation & analysis committee) will examine the bids to determine whether they are complete, whether any computational errors have been made, whether required Bid Securities have been furnished, whether the documents have been properly signed, and whether the bids are generally in order.
- 26.2 The Contracting Entity (evaluation & analysis committee) may waive any minor informality, nonconformity, or irregularity in a bid that does not constitute a material deviation, provided such waiver does not prejudice or affect the relative ranking of any Bidder.

- 26.3 Prior to the detailed evaluation, pursuant to ITB Clause 29, the Contracting Entity (evaluation & analysis committee) will determine whether each bid is of acceptable quality, is complete, and is substantially responsive to the Bidding Documents. For purposes of this determination, a substantially responsive bid is one that conforms to all the terms, conditions, and specifications of the Bidding Documents without material deviations, exceptions, objections, conditionality, or reservations. A material deviation, exception, objection, conditionality, or reservation is one: (i) that limits in any substantial way the scope, quality, or performance of the Goods and related Services; (ii) that limits, in any substantial way that is inconsistent with the Bidding Documents, the Contracting Entity's rights or the successful Bidder's obligations under the Contract; and (iii) that the acceptance of which would unfairly affect the competitive position of other Bidders who have submitted substantially responsive bids.
- 26.4 If a bid is not substantially responsive, it will be rejected by the Contracting Entity (evaluation & analysis committee) and may not subsequently be made responsive by the Bidder by correction of the nonconformity. The Contracting Entity's determination of a bid's responsiveness is to be based on the contents of the bid itself.
- 27. Correction of Errors**
- 27.1 Arithmetical errors will be rectified as follows. If there is a discrepancy between the unit price and the total price that is obtained by multiplying the unit price and quantity, the unit or subtotal price shall prevail. If there is a discrepancy between subtotals and the total price, the total price shall be corrected. If there is a discrepancy between words and figures, the amount in words will prevail. If a Bidder does not accept the correction of errors, its bid will be rejected. If the Bidder that submitted the lowest evaluated bid does not accept the correction of errors, its bid security shall be forfeited.
- 28. Conversion to Single Currency**
- 28.1 To facilitate evaluation and comparison, the Contracting Entity will convert all bid prices expressed in the various currencies in which they are payable to Iraqi Dinar at the selling exchange rate established for similar transactions by the Central Bank or a commercial bank in Iraq.
- 28.2 The currency selected for converting bid prices to a common base for the purpose of evaluation to common currency in Iraqi Dinar as on the date of Bid submission.

**29. Evaluation and Comparison of Bids**

- 29.1 The Contracting Entity (**evaluation & analysis committee**) will evaluate and compare the bids that have been determined to be substantially responsive, pursuant to ITB Clause 26.
- 29.2 For comparison for ranking purpose for evaluation, the comparison of the responsive Bids shall be carried out on Delivery Duty Paid (DDP) End-users' site basis / Free Delivery at End-users' Site basis. The quoted AMC (**Annual Maintenance Contract**), if applicable as per Schedule of Requirements as per ITB Sub-Clause 14.3.3 for subsequent stipulated years after warranty period will also be added for comparison/ranking purpose for evaluation.
- 29.3 For domestic goods or goods of foreign origin located within Iraq, the various prices as brought out in ITB Sub-Clause 14.3.1 and stipulated in Price Schedule in format in **Section IV(2)**, and for goods offered from abroad, the various prices brought out in ITB Sub-Clause 14.3.2 and stipulated in Price Schedule in format in **Section IV(3)** will be loaded for comparison/ranking purpose for evaluation. In addition, Annual Maintenance Contract (AMC) price, if applicable as per Schedule of Requirements as per ITB Sub-Clause 14.3.3 for stipulated years after Warranty period in Price Schedule in format in **Section IV(4)** will be loaded for comparison/ranking purpose for evaluation.
- 29.4 The rate of quoted Annual Maintenance Contract (AMC), if applicable, as per **Section VI Schedule of Requirements**, will be loaded for comparison/ranking purpose at Net Present Value (NPV) considering discount rate as brought out in **Bid Data Sheet**.
- 29.5 If more than one schedule (or lot) has been specified in Section VI Schedule of Requirements, the Bidders are required to quote as stipulated in ITB Sub-Clause 14.7. Bids shall be evaluated for each schedules (or lots) separately.
- 29.6 The Contracts may be awarded Schedule wise to the lowest responsive Bidder who meets the laid down Qualification Criteria as per ITB Clause 8 subject to Margin of Preference, as per Clause- 30.

**30. Margin of Domestic Preference**

- 30.1 **As not contrary to what** specified in **Bid Data Sheet**. Margin of domestic preference will be deperenede for the domestic bidders.

**31. Contracting Entity's Right to Accept Any Bid and to Reject Any or All Bids**

31.1 The Contracting Entity reserves the right to accept or reject any bid, or to annul the bidding process and reject all bids at any time prior to contract award, without thereby incurring any liability to the affected Bidder or Bidders.

In case of annulment, all bids submitted and specifically, bid securities, shall be promptly returned to the Bidders together with the fees of purchasing the Bidding Documents as paid by the Bidders.

**32. Eligibility and Qualification of bidder**

32.1 The Contracting Entity will determine to its satisfaction whether the Bidder that is selected as being eligible and having submitted the lowest evaluated responsive bid is qualified to perform the Contract satisfactorily, in accordance with the criteria listed in ITB Sub-clause 8.1.

32.2 The determination will evaluate the Bidder's financial, technical, and production capabilities. It will be based on an examination of the documentary evidence of the Bidder's qualifications submitted by the Bidder, pursuant to ITB Sub-Clause 8.1, as well as other information the Contracting Entity deems necessary and appropriate.

32.3 An affirmative Qualification of bidder determination will be a prerequisite for award of the contract to the eligible and lowest evaluated Bidder schedule wise. A negative determination will result in rejection of the Bidder's bid, in which event the Contracting Entity will proceed to the next-lowest evaluated Bidder to make a similar determination of that Bidder's capabilities to perform satisfactorily.

**F. AWARD OF CONTRACT**

**33. Award Criteria**

33.1 Pursuant to ITB Clauses 29, 30 and 32, the Contracting Entity will award the Contract to the eligible Bidder whose bid has been determined to be substantially responsive and has been determined to be the lowest evaluated bid, provided further that the Bidder is determined to be qualified to perform the Contract satisfactorily.

33.2 Before the award, the Contracting Entity has to verify from the competent authorities the validation of the substantial forms provided in the Bids including the Bid Security..

**34. Contracting Entity's Right to Vary Quantities at Time of Award**

34.1 The Contracting Entity reserves the right at the time of Contract award to increase or decrease, by the percentage of 20% the quantity of goods and services beyond that originally specified in the Schedule of Requirements without any change in unit price or other terms and conditions.

**35. Notification of Award**

35.1 Prior to the expiration of the period of bid validity, the Contracting Entity will notify the successful Bidder in writing or by cable, to be subsequently confirmed in writing by registered letter, that its bid has been

accepted. At the same time, the Contracting Entity shall also notify all other Bidders of the results of the bidding, and shall publish the results as per the applicable Iraqi Laws identifying the bid and lot numbers and the following information: (i) name of each Bidder who submitted a Bid; (ii) bid prices as read out at Bid Opening; (iii) name and evaluated prices of each Bid that was evaluated; (iv) name of bidders whose bids were rejected and the reasons for their rejection; and (v) name of the successful Bidder, and the Price and currency it offered, as well as the duration and summary scope of the contract awarded.

35.2 The notification of award will constitute the formation of the Contract subject to settlement of Appeal by unsuccessful bidder as per ITB Clause 36.

35.3 Upon the successful Bidder's furnishing of the signed Contract Form and performance security pursuant to ITB Clause 38, the Contracting Entity will promptly discharge the bid securities of the unsuccessful Bidders, pursuant to ITB Clause 17.

35.4 If, after notification of award, an unsuccessful Bidder wishes to ascertain the grounds on which its bid was not selected, which are not in pursuant to ITB Clause 36, it should address its request to the Contracting Entity. The Contracting Entity will promptly respond in writing to the unsuccessful Bidder.

### 36. Complaints and Appeals

Validation general government implementation contracts procedures represent the dependable criteria in viewing the complaints bidders.

### 37. Signing of Contract

37.1 Promptly after the Contracting Entity notifies the successful Bidder that its bid has been accepted and after lapse of the standstill period and settlement of Appeals as per ITB Clause 36 (as the case may be), the Contracting Entity will send the Bidder the Contract Form provided in **Section IX** of the Bidding Documents, incorporating all agreements between the parties and as indicated in **Bid Data Sheet**. The Contract has to be endorsed as indicated in **Bid Data Sheet**.

37.2 the successful Bidder shall sign, date, and return the Contract Agreement to the Contracting Entity within the permitted period. In case of an unsuccessful Bidder's appeal as per ITB 36.2, the Contracting Entity has still the right to proceed with the Contract with the Successful Bidder upon finding that the contract is fully compliant and it is in the public interest not to delay the commencement of the Contract and where the cancellation of the Contract will impose great damages on the public interest. Nevertheless, the Contracting Entity has to notify the relevant Administrative Court of

### 38. Performance Security

such a decision with all above justifications. The Contracting Entity has the authority to implement the Contract after providing to the approval of the relevant Administrative Court a signed commitment for compensating the future damages resulting from implementing the Contract in case the ruling of the relevant Administrative Court was unfavourable to its decision.

- 38.1 Within fourteen (14) days of the receipt of notification of award from the Contracting Entity, or twenty nine (29) days) in case of complaints as per ITB 36.1, the successful Bidder shall furnish the performance security in accordance with the Conditions of Contract, using the Performance Security Form provided under Contract Forms in **Section IX** of. If rules and regulation of Republic of Iraq grants exemption to Public Companies of the state and public sectors, they are accordingly exempted of submitting Performance Security.
- 38.2 Upon the failure of the successful Bidder to submit the above-mentioned Performance Security or sign the Contract within the period specified under ITB 37.2, the Contracting Entity will send an official notice for the successful Bidder to sign the Contract within fifteen (15) days from receiving this notice, after which the Contracting Entity has sufficient grounds to proceed with the annulment of the award and forfeiture of the bid security of the here above declined Bidder. In that event the Contracting Entity may award the Contract to the next lowest evaluated Bidder whose offer is substantially responsive and is determined by the Contracting Entity to be qualified to perform the Contract satisfactorily. In that case the declined Bidder will be responsible for paying the difference in the bids prices in addition to forfeiture of the bid security. These actions will be taken against the declined bidders provided they decline during their Bid validity.

## SECTION II. BID DATA SHEET

### Bid Data Sheet (BDS)

The following specific data for the Goods to be procured shall complement, supplement, or amend the provisions in the Instructions to Bidders (ITB). Whenever there is a conflict, the provisions in the Bid Data Sheet (BDS) shall prevail over those in the ITB.

#### A. GENERAL

ITB 1.1	<p>Name of Contracting Entity: [Ministry of Health / Environment / The State Company for Marketing Drug and Medical Appliances].</p> <p>Name of authorized Purchasing Agent: authorized by contracting entity : "none"</p> <p>Type of goods: Medicine as mentioned in tender lists</p> <p>Tender: Purchasing medicine</p> <p>Tender Number: <b>Med/ 1 /2020</b> as listed in the Iraqi Federal Budget]</p> <p><u>IFB Number 1</u></p> <p>The number and identification of schedules (lots) comprising this IFB is detailed in Schedule of Requirements are: [Schedule (1)-(4) ] the year of the Federal Budget that certified by the competent authorities is 2018 to purchase the medicines for The Ministry of Health/ Environment / The State Company for Marketing Drug and Medical Appliances (Kimadia)</p> <p>The source of funding for the contract(s) is: [Ministry of Finance ]</p>
---------	--

#### \B. THE BIDDING DOCUMENTS

ITB 4.1	<p>Contracting Entity's Ministry of Health / Environment / The State Company For Marketing Drug and Medical Appliances (kimadia )/Drug Media Department &amp; the Public Relations- 5<sup>th</sup> floor ,position of MOH(Ministry of Health),E-mail (<a href="mailto:dg@kimadia.iq">dg@kimadia.iq</a> ) phone no.(07705419074) Requests for Clarification are to be hand delivered or sent by mail or by express courier and accepted by E-mail</p> <p>Adoption the bidder address which install in the tender &amp; address for correspondence &amp; communications, the bidder should notice the contracting party with any change to this address within seven days of receiving.</p> <p>-additional to ITB :</p> <p>- Specifying the date of conference specialized to answer all the participants in the bid inquiries will be on ( <b>17 / 2 /2020</b>).</p>
---------	---

#### C. PREPARATION OF BIDS



6.3	<p>List of disqualified bidders is available on the following website address: <a href="http://WWW.mop.gov.iq">HTTP://WWW.mop.gov.iq</a></p> <p>In addition to what is stated in the instructions to bidders, the following are added:</p> <ul style="list-style-type: none"><li>-Dilatory or violating the previous contractual obligations according to legal documents with the same contracting party or in other contracting parties.</li><li>- companies are blacklisted in the following cases:<ul style="list-style-type: none"><li>A- when dealing with foreign balcklisted companies.</li><li>B-When it is proved that one of the government staff takes bribery.</li><li>C-When it is proved that there is a forgery in the offer or any tender documents.</li><li>D-When it is proved that they submit incorrect information or matters concerning the work assigned to them for the purpose of harming the public interest.</li><li>E-When there is a violation in the conditions of the tender or technical specifications contracted on, for the purpose of harming the public interest</li><li>F-When it is proved that there is a non-compliance with the profession principles by using unfair methods of competition.</li><li>G- When refrains signing after being informed about the decision of awarding</li><li>H-The withdrawal of work due to the delay in the execution of the tender or the breach of its contractual obligations.</li></ul></li></ul>
7.2	<p>The authentication of the certificate should be according to the instructions of implementing the governmental contracts No. (2) in 2014 concerning the items imported from the Arab country.</p>

7.3 C	<p>Documentation requirements for eligibility of Goods. In addition to the documents stated in Sub-Clauses 7.2 and 7.3 (a) and (b), the following documents should be included with the Bid:</p> <ol style="list-style-type: none"><li>1- The certificate of origin ,of the imported materials in favor of the contracting party issued by the country of manufacture or product or country in which the final assembly takes place or country of shipment (country of export), should be submitted with reference to the origin of imported materials which must be accurate in terms of technical specifications for materials or equipment to be exported to Iraq on condition that there is a duly authenticated undertaking from the company of shipment which provide the imported materials bearing all the financial and legal responsibilities concerning the validity of the information mentioned in the original certificates of origin sent by the manufacturers or producers to the supplier in the last shipping country</li><li>2-To submit certificates of (U.S. FDA, GMP.,EMA,JAP.,MHLW , Canadian AUS - TAG , UK.MHRA , SWISS -MEDIC U.s )</li><li>3- To submit a certificate of company establishment for the manufacturer and supplier companies provided that the certificate should be original , authenticated and new .</li><li>4-Presenting the original and authenticated final balance sheet of the Manufacturer Company for the last five years which shows that there is a profit achieved during the last five years &amp; stating the average rates provided . The final balance should be presented in English and Arabic languages only. In addition, the indicator of the final balance of the last five years should be positive.</li><li>5-The companies that participated in the tender shall submit their prices that are stated in their contracts with other countries and neighboring countries of Iraq provided that such prices should be attached to the tender supported by a confirmation ,stamp and signature of the bidder .</li></ol> <p><b><u>The following should be submitted for products manufactured from blood origin-:</u></b></p> <ol style="list-style-type: none"><li>1A- Certificates for plasma pool data and safety certificates during the</li></ol>
-------	---

	<p>manufacturing process.</p> <p>B- Methods used to get rid of the viruses of HBV, HCV, HIV and others the manufacturing process.</p> <p>C-Method of analysis and the safety certificate of the final product that the final product is free from viruses.</p> <p>2-To submit documents stating that the gelatin which is used in manufacturing capsules is from botanic or animal (halal) origin to Islamic law</p> <p>3- Companies supplying cancer drugs are obliged to re-issue the expired quantities of these medicines and not asking our companies consume them</p> <p>4- The companies that supply the chemotherapeutic products should available all the diagnosis requirements and clinical follow up in accordance with the Iraqi guidance of CMI treatment.</p> <p>-Special condition for medical milk:</p> <p>1-Adopting the weight of 400grn as a unit of measurement. The maximum limit is 1000gm for Kimadia when contracting,</p> <p>2- The milk should be mentioned in (BNF) OR (Martin)-last edition as the specifications can be varied according to the updates that may appear in the future.</p> <p>3-The Milk should to be identical to recently updated British specifications.</p> <p>4-The milk should be packed in the country of origin to avoid contamination during packaging.</p>
7.4	<p>Registration of goods is required in Iraq .</p> <p>{<b>Note</b>: Bid security or performance security will not be confiscated if the bidder fails to register the goods .}</p>
7.4 B	<p>By the time of Contract signing, the successful Bidder shall have complied with the following documentary requirements in order to register the Goods to be supplied under the Contract:</p> <p>The conditions for registration which are approved by the Ministry of Health / Department of technical Affairs / registration section / Eighth floor</p> <p>{<b>Note</b> : Bidders should inquire about the conditions and procedures for registering the goods as soon as possible in order to avoid any delay that may result during the registration process by the various competent governmental bodies .}</p>



---

	<p>-In addition to what has been mentioned , the following shall be considered: 1- The company should register its products before paying their shipped goods dues.</p> <p>2- When the award is made for unregistered material ,the specifications, analysis method and standard material should be submitted upon the confirmation of the award at a maximum one- month period.</p> <p>3- In case the item is not registered, no payment will be made for this contract unless the company proves submitting the documents of the material for the registration department or re- registered it.</p>
7.4. 1	For the purpose of obtaining additional information about the requirements for registration,Bidders may contact { Ministry of Health/ Environment/Department of technical things /Registration section [Eighth floor].
11.1	The language of the bid is: Arabic or English In case the tender documents and contract are received in both languages : Arabic and English, and there is a difference in the interpretation, the Arabic language shall be adopted as it is the official language of the State

12.1	<p>In addition to the documents stated in Paragraphs 12.1 (a) through (f), the following documents must be included with the Bid.</p> <ol style="list-style-type: none"><li>1- The bidder who previously participated in the tender, should submit the prior purchase receipt together with the re-announced tender documents . In case there is an amendment in the prices of the tender documents, the bidder will bear the difference in the price when there is an increasing in the price and should attach the first and the second receipt with his tender.</li><li>2- When contracting ,the beneficiary from the documentary credit should be the same contracted party and the banking details should bear the name of that company . It should exclusively contain (name and address of the bank , name of owner of account (the company contracted with) (swift code and sort code and Iban.... . etc). The account should not bear a person name. Any change in the beneficiary name and address, , bank name and address, account no. and any other bank information after the agreement is considered a violence after informing the supplier about the information stated in the tender, a fine will be imposed on the supplier.</li><li>3-Submitting a the factory license renewal regarding the national factories.</li><li>4- Factories and their materials must be registered in the registration section of the Iraqi Ministry of Health , as the ministry will not market any unregistered product.</li><li>5-The displayed Items or materials should bear its commercial or brand name. In case items are displayed in scientific names, the pharmacopoeia should be stated</li><li>6- The companies should submit a letter permission issued by the general commission for taxes when participating in the announced tenders.</li></ol>
------	--

14	<p>14.6 -In addition to what mentioned in instructions devoted to the bidders, the following will be done:</p> <p>-Neglecting the offer which is based on reduction a percentage or taking out a certain sum from any of the other presented offers in the tender. Any reservation and reduction of the price presented after the closing date of tender will be not accepted. We confirm the condition of not making any change after the notification of awarding. All letters regarding decreasing the offered items prices after the closing date of the tender without a request from KIMADIA will be neglected.</p>
15.1	<p>b) Foreign currencies: In US dollar or by ink or by printed Form in numbers and written forms and should be clear without erasing or scratching</p>
16.1	<p>The bid validity period shall be (365) days so , each bid must be valid until <b>(23/2/2021)</b>          Bid security must be valid twenty-eight (28) days after the end of the bid validity period. Accordingly, a bid with a bid security that expires before<b>(22/3/2021)</b> shall be rejected as nonresponsive.</p>

17.1	<p>Public Companies of the state and public sector are exempted from submitting tender securities in accordance with the valid instructions of implementing the government contracts .</p> <p>The amount of the tender securities shall be 1% from estimated cost of tender in Iraqi Dinar or its equivalent in a convertible currency from the list of currencies from which the Central Bank of Iraq issues the price of exchange of the Iraqi Dinar</p> <p>In addition to what mentioned in 17.1 be (c) or saftaja. Taking into account the following:</p>
	<ol style="list-style-type: none"> <li>1- Bidder should submit Preliminary Insurance (Bid Bond) or any of the share holders of the company or share according to share contract for the benefit of contracting party which should refer to the tender name and number.</li> <li>2-The Guarantee Bond should be issued according to the order of the company with Which we contracted with or with its legal authorized figure who gained the authority to issue the guarantee in accordance with formal authenticated authorization.</li> <li>3-The guarantee Bond should be attached with a letter of authenticity of issuance. (Private &amp; confidential) send to kimadia by the bank who issued the guarantee.</li> <li>-The guarantee should be issued in the Arabic and English languages.</li> <li>4-In addition to what has been mentioned in 17.7 , the following should be taken into account (or refuse to correct his statistical errors in the tender which have an effect on the decision of awarding , All the legal actions written in the instructions of the governmental contract implementation will be applied against him .</li> </ol>

17.4	Concerning the approved companies & according to the approved companies conditions.
17.8	<p>If the Bidder defaults under the actions prescribed in subparagraphs (i) or (ii) of this provision, the Contracting Entity will declare the Bidder in violation and will inform the Ministry of Planning and Economic Development to take the required actions against the violating Bidder (including Suspension or Black Listing) as per the applicable Iraqi laws.</p> <p>In addition to what have been mentioned in the instructions to bidders, the following should be added:-</p> <p>If the participants in the tender reject making the contract after notification by awarding, the following procedures will be taken against bidder</p> <ul style="list-style-type: none"> <li>-Executing the contract on his expense without a need to warn him or take any other legal procedure</li> <li>-In case of breach the two nominees( the first &amp;second) the contracting party has the right to award the tender to a third bidder &amp; each of the two breach will bear the difference of price according to the difference amounts for their nomination confiscating preliminary securities of the two.</li> <li>-In case of the third nominee breaches the tender, his preliminary securities will be confiscated &amp; re-announcing the bid while the three breach bidders will bear the difference of price according to the submitted price of each one of them confiscating the securities of the three breach bidders.</li> <li>-The above procedures should be applied upon the three bidders when breached during the period of tender validity.</li> </ul>
18.1	<p>Required number of copies of the bid in additino to the original bid is: [3 copies].</p> <p>What is mentioned in item 18.1 of the instruction to bidders has been modified to be as following:</p> <ul style="list-style-type: none"> <li>-The offers have to be delivered in the same format as requested for tender in CD &amp; hardcopy (printed out from CD or Disk) . All the papers should be signed and stamped and the information should be compatible. When there are substantial inconsistencies between the hard copy offer and CD, our company (Kimadia) has</li> </ul>





	<p>the right to neglect the offer on CD and depend upon the hard copy offer in case of the availability of simple differences provided that these differences will be specified whether they are simple or not by the committee of analysis and studying offers</p>
18.2	<p>The written confirmation of authorization to sign on behalf of the Bidder shall consist of: a Power of Attorney issued by the Bidder dated no more than 3 month or Company Registration Form (Certificate of establishment showing the authorized signatory).</p> <p>The Offers should be submitted directly by the manufacturing company through the following:</p> <ul style="list-style-type: none"><li>-Director General or his representative.</li><li>-Assistant of Director General or his representative</li><li>-Sales manager (marketing)</li><li>-Commercial manager.</li><li>-Authorized scientific bureau which has a legal authorization.</li></ul> <p>-We can accept the authorization of any representative of the company staff whose title is not stated above provided that his authorization should fulfill the legal form and the required authentications.</p> <p><b>-Special instructions concerning the authorization letters (A.L)</b></p> <p><b>First</b>—The authorization letter should be authenticated officially by:-</p> <ul style="list-style-type: none"><li>A-Chamber of commerce in the country of origin</li><li>B-Ministry of foreign affairs or notary public in the country of origin.</li><li>C -Iraqi embassy its representative in the country of origin.</li><li>D- Iraqi ministry of foreign affairs in Baghdad should fixed its stamp and</li></ul>

signature to authenticate the stamp of the Iraqi embassy in the country of origin.

E-If the Iraqi embassy cannot stamp all the above mentioned documents either because there is no Iraqi embassy or there is no information about the identity of the persons who represented the company, the embassy of the country of origin in Iraq has to authenticate the official authorization letters in order to be legal and Agreed upon.

F- If there is no (diplomatic representation)) between the country of origin the authentication should be made in a third country from the embassy of the country of origin and the Iraqi embassy in the third country then the ministry of foreign affairs has to authenticate the signature and the stamp of the Iraqi embassy.

**Second**-The company should mention in the authorization letter whether it's a manufacturer or supplier (marketing company)

A- In case of being a supplier company, the followings should be clear -:

-names & specialties of the manufacturing companies.

-It should have an authenticated authorization letter from the manufacturing companies as mentioned above item (first)

-your manufacturing company should mention that you are a sole and exclusive (supplier) for all its products in Iraq

B- In case of being a manufacturer company, your specialties (having special knowledge a particular system) should be mentioned and written down and you should mention that you are a sole & exclusive representative to deal with concerning all your products ,also the company should refer to the names of its factories and branches by submitting original authenticated certificates of establishment that proved the company factories & its branches.

C -the A.L should be authenticated as mentioned in item (First).

D —Catalogues with (CD) stating the company's products should be submitted by the manufacturing companies to **Drug Media Department& the Public Relations**. The manufacturing companies should write down their emails on the letters of authorization. Any authorization letter with no emails will be neglected.

**Third** — (A) The company should specify the name of Iraqi scientific bureau & the name of pharmacist who is licensed from Iraqi syndicate of pharmacists for following up and completing the technical data upon request by the committee of study and analysis in case of submitting the tenders through the scientific bureau, or providing an authorization for signing the contract the list of the submitted tender and its documents as an agent. The scientific bureau should be the exclusive representative of all company products or dealing directly with the company through formal authorized figure as it is shown in item no. (6).

B- The scientific bureau will stay responsible till after the expiration of the authorization from foreign companies which authorized him unless the following Authorization has fixed the obligations of the previous foreign companies and its effects.

**Fourth**—The authorization letter must be entitled to kimadia, the state company for marketing drugs and medical appliances, General

**Drug Media Department& the Public Relations** fifth floor —before the closing date.

**Fifth-** The name of scientific bureau should be added in the contract

**Sixth-**The authorization issued by the manufacturer to supplying company, (in case of necessity to make contract with supplying company), the capacities of the supplying company concerning the following should be clarified.

A-Signing the contract &executing all its obligations, provided that it should be signed by the manufacturer company exclusively

B-The negotiation about technical affairs and prices.

C- Specifying clearly and in details the beneficiary applicant from documents L/C& beneficiary from the bank account with the whole banking details noting that the one who signs the contract without company should be the beneficiary party itself.



	<p>D- Specifying the correspondences &amp;the authorities concerning the tenders as for submitting, stamping, signing, opening &amp;submitting the prices without being satisfied by issuing a general authorization which authorizes all these powers.</p> <p>E-Confirming to go on executing all the contracting obligation. The marketing company will bear a legal responsibility for the period of execution the contract even when the period of authorization is expired.</p> <p>Noting that all the procedures including registration the company ,its products . Full address and details of the manufacturing &amp; supplying companies should be fulfilled. In addition, to accomplishing the stamps&amp; legalizations as applicable now.</p>
	<p>F-The contracted companies should submit the legal &amp;required assurances according to the conditions of invitation within stipulated period in these instructions.</p> <p><b>Seventh:</b> Names of the authorized persons of signing &amp;stamping the contracts &amp; offers and their administrative description and samples of their signatures should be mentioned(written down)</p> <p>7-<b>Your offers should include a copy of all original authorization letters issued and legalized producing companies to the marketing ones</b> addition to the original authenticated copies as it is mentioned in item (4) from article (six) to be handed to (3RD bearing all above mentioned authentications).</p>
18.3	<p>In addition to what are mentioned in Instructions to the bidders, the followings are added.</p> <p>The participant has no right to object on any condition of the tender conditions</p>

**D. Submitting Bids**

19.2B	<p>For <u>bid submission purposes</u>, the Contracting Entity's address is :            Attention:Baghdad – Bab Al-Moadham – Ministry of Health /Environment             Ministry of Health / Environment (Kimadia) – sixth floor – receiving and opening tenders committee             CityBaghdad _____            _____            Country: IRAQ _____</p>
19.2C	<p>The Tender, Tender No. and IFB No are:  <u>Tender: Med/ 1 /2020</u>  <u>Tender No. : 1</u>            Contracts of supplying medicine be arranged according to the current balance            .  <u>Reference letter invitation to tender :</u>            In addition to what is mentioned in this article concerning the bids that are submitted through the fast mail, all authorization letters and documents(original and authenticated) should be included in a separated envelope in order to be checked and it should be reached to Kimadia before the closing date, otherwise the offer will be neglected provided that the address of the company inside and outside Iraq and the additional attachments attached with the offer and the number of pages for each offer should be written on the envelope</p>
20.1	<p>Deadline for bid submission is: the date of closing the bid is the end of the official work on 23/ 2 /2020             If the closing day happens to be on an official holiday the new closing date shall be in the first working day following the holiday.</p>

### E. BID OPENING AND EVALUATION

23.1	<p>The bid opening shall take place at:            Street Address: <u>Baghdad-Bab Al moadham -Ministry of Health</u>            _____            Floor/Room number: <u>Ministry of Health /Environment /The state company for drug and medical appliances (Kimadia)-sixth floor -receiving and opening of tenders committee.</u>            _____            City: <u>Baghdad</u>            _____            Country : <u>Iraq</u>            _____            Date: [ 24 -2 -2020            _____            Time: [ _____</p>
------	---

27	<p>In addition to what are mentioned in the instruction to bidders:</p> <ul style="list-style-type: none"> <li>- If an item or items are mentioned in the tender without their price , the cost of the item or items with all their specified quantities will be included within the total price of the tender</li> </ul>
29.4	<p>It is not applicable to medicines supplement</p>
30.1	<p>In case the bid which has been evaluated to be the lowest cost and which meets the demanded Qualification Criteria includes foreign goods according to article 29 of the Instructions to bidders, A preference remark will be given to the responsive bid offered by National Private Sector Factories of the Republic of Iraq provided that the national product price does not exceed that of the foreign product by 10%."</p> <p>-the second party undertakes to prioritize the raw materials manufactured inside Iraq for supplying the contract materials or for implementing the projects through the companies of the Ministry of Industry and Minerals according to the letter of Ministry of Planning no. 16135 dated 3/8/2017.</p>
32	<p>32.2 In addition to what is mentioned in this item of instructions for bidders,the following conditions should be taken into account .</p> <p>Exclusion the bid which is less or greater than 20% or more of the estimated cost allocated for the awarding and in case there is an appropriate price of a bid that meets the required qualifications but there is a rate of diverse in the price analysis of some items (unbalanced) by more than 20% increase or decrease for each item separately and which constitute a total of not more than 10% of the total items , it is possible to accept the awarding and otherwise the bid will be excluded taking into account the exception provided by the office of Prime Minister no. 15773 on 10/11/2015 regarding the acceptance of bid which is less than 20% of the estimated cost .</p>
34	<p>34.1 amending this paragraph of ITB to be :</p> <p>The contracting party may increase the quantity of non-consulting goods or materials or services or modify its technical specifications contracted to no more than the percentage of reserve amount stipulated in the annual budget implementation instructions provided that the financial allocation is available and that the prices of the paragraphs covered are increased in accordance with the quoted paragraphs (20%) of the quantity of the paragraph and the above is subject to the prevailing market prices taking into account the reflection of these variables on the contractual obligations as well as the financial guarantees with a contract attachment and under the same conditions contracted for projects listed in the</p>

	<p>balance sheet Exclusive</p> <p>The contracting party may increase the quantity of non-consulting goods or materials or services, or amend their technical specifications contracted by not more than (20%) of the amount of the contract provided that the financial allocation is available and that the prices of the paragraphs included in the increase are approved in accordance with the paragraphs quoted by the contractor (20%) of the amount of the paragraph and the above is subject to prevailing market prices taking into account the reflection of these variables on contractual obligations as well as financial guarantees with a contract attachment for the projects included in the operating budget and special budgets issued by the approvals of the competent authorities For approval by the Ministry of Finance(</p> <p>The contracting party may deduct the non-advisory goods, materials or services, and not more than (15%) fifteen per cent of the contract amount</p> <p>The contracting entity may partition the awarding of supplying the goods , materials or services required to be supplied .</p>
37.1	<p>The Contract to be signed with the successful Bidder shall be written in the language in which the Bid was submitted, and which will be the language that shall govern the contractual relations between the Contracting Entity and the successful Bidder. A Bidder shall not sign a translated version of its Contract.</p> <p>In addition to that should be written an original contract copy in Arabic language</p> <p>The contract must be ratified in accordance with the procedures adopted in this regard in Iraq .</p>
37.2B	<p>In case that ,the judgment of the specialized court was on the contrary to the contracting party decision which has continued in the procedures of contracting, the bidder who appeal the judgment has to contact the specialized courts to ask for compensation if the appeal was based on true causes.</p> <p>In case the procedures of contracting were stopped by specialized court order &amp; judgment issued by the same court committing the contracting party to fulfill all the contracting procedures with the objecting bidder , contracting party could filled up a suitcase that claim to obligate the objecting bidder to compensate any damage that will appear in the future as a result of the contract execution.</p>

In addition to what mentioned in ITB the following will be added :  
The participant has no right to object **any condition of the tender conditions** .

**Bid Data Sheet (BDS)**  
**VACCINES**  
**(Additional Clauses)**

ITB 7.3 (c)	<p>[ Sample clauses:</p> <ol style="list-style-type: none"><li data-bbox="537 499 1419 1192">1. The Goods to be supplied under the Contract must be licensed both in the country of manufacture and in Iraq by the time of Contract signing by a recognized NCA. An NCA is an organization that performs all six critical functions for control of biological products as defined by the World Health Organization, namely: licensing based on published set of requirements; surveillance of vaccine field performance; system of lot release for vaccines; use of laboratory when needed; regular inspections for good manufacturing practice and evaluation of clinical performance. The license from country of manufacture must state that the Bidder is licensed to manufacture the Goods by the NCA in the manufacturing country. Documentary evidence in the form of a certified copy of the license and a copy of the vaccine license/registration that the offered vaccine has been licensed by the NCAs of the manufacturer's country shall accompany the bid and a copy of the license issued by an NCA in Iraq must be submitted by Contract signing. If there is no NCA with specific biologics expertise in Iraq, the Bidder shall furnish evidence that the Goods meet the qualification criteria in the Technical Specifications.</li><li data-bbox="537 1199 1419 1325">2. If the Goods offered do not meet the specified pharmacopoeia standards as stated in the Technical Specification, the Bidder will provide testing protocols and alternative reference standards.]</li></ol>
-------------	---



### **SECTION III. EVALUATION AND QUALIFICATION CRITERIA**

#### **1. Evaluation Criteria**

The Evaluation Criteria has been specified in Instructions to Bidders(ITB) in Section I and Bid Data Sheet(BDS) in Section II.The specific data Bid Data Sheet(BDS) for the Goods to be procured shall complement, supplement, or amend the provisions in the Instructions to Bidders (ITB). Whenever there is a conflict, the provisions in the Bid Data Sheet (BDS) shall prevail over those in the ITB.

## 2. Qualification Criteria

Qualification requirements for Bidders Goods are:

{Note: Contracting Entity may insert appropriate quantifiable qualification criteria for experience and / or financial viability etc depending upon type of good}

A) {For Health Sector Goods insert}

The following documents must be included with the bid:

Documentary evidence of the Bidder's qualifications to perform the Contract if its bid is accepted:

- (i) that, in the case of a Bidder offering to supply Goods under the Contract that the Bidder manufactures or otherwise produces (using ingredients supplied by primary manufacturers) that the Bidder:
  - (a) is incorporated in the country of manufacture of the Goods;
  - (b) has been licensed by the regulatory authority in the country of manufacture to supply the Goods;
  - (c) has manufactured and marketed the specific goods covered by this Bidding Document, for at least [insert two (2) years or as per market availability], and for similar Goods for at least five (5) years;
  - (d) has received a satisfactory GMP inspection certificate in line with the WHO certification scheme on pharmaceuticals moving in International Commerce from the regulatory authority (RA) in the country of manufacture of the goods or has been certified by the competent authority of a member country of the Pharmaceuticals Inspection Convention (PIC), and has demonstrated compliance with the quality standards during the past two years prior to bid submission;
- (ii) that, in the case of a Bidder offering to supply Goods under the Contract that the Bidder does not manufacture or otherwise produce,
  - (a) that the Bidder has been duly authorized by a manufacturer of the Goods that meets the criteria under (i) above to supply the Goods in Iraq; and
- (iii) The Bidder shall also submit the following additional information:
  - (a) a statement of installed manufacturing capacity;
  - (b) copies of its audited financial statements for the past three fiscal years;
  - (c) details of on-site quality control laboratory facilities and services and range of tests conducted;
  - (d) list of major supply contracts conducted within the last five years and relevant certifications endorsed by respective Clients. }

A1 {For Pharmaceuticals insert the following additional clauses}

Documentary evidence of the Bidder's qualifications to perform the Contract if its bid is accepted:

- (i) (e) has a Good Distribution Practice (GDP) Certificate where appropriate.
- (iii) The Bidder will submit the following additional information:
  - (e) list of pharmaceuticals being manufactured by the Bidder with product registration/license number and date.
  - (f) a Certificate of Pharmaceutical Product as recommended by the WHO for each item offered.]

A2 {For Vaccines insert the following additional clauses}

Documentary evidence of the Bidder's qualifications to perform the Contract if its bid is accepted:

- (i) (e) is certified by a competent authority in the country of manufacture according to resolution WHA 28 65 (2) of the World Health Organization's Certificate Scheme on the Quality of Pharmaceutical Products Moving in International Commerce.
- (iii) The Bidder will submit the following additional information:
  - (e) list of vaccines being manufactured by the Bidder with product registration/license number and date.]

B) In addition to what are mentioned above the Qualification criteria are:

1-Accurate technicality specifications which specify the technical features of Goods and the related services that requested by contracting Entity. They are technical features and quality standards of the Goods ghat requested by contracting Entity and the rate of meeting the specifications and which make the evaluation the bid process easier. They have clear indicators that show the purpose of using Goods and contain work environment details (warmth, wetness, storage condition,.etc) and packing requirements

ratification drug and its degree of meeting the technique specifications stated by the national committee of selecting medicines

2- Financial efficiency and ability

a- the final balance for the last (2) years and (5) years concerning the dependable company authenticated by the auditor and gain profit in the balance

b-annual income: of years from(1-10).

**c--liquid pecuniary :**

- **Liquid pecuniary (large contracts) in proportion of assessment cost to contract.**
- **Liquid pecuniary (medium contracts) range between (70%) to (100%) of assessment cost.**
- **Liquid pecuniary ( small contracts) range between (30%) to (50%) of assessment cost.**

- 3- specialization experience (the Identical works)
  - Number of required work in the document of tender range between (1-3)
  - Number of years required for similar works range between (5-10) years noting that requested similar works is "potential" in small works.
- 4- The kind of commercial sale and the method of supplying( transport, insurance & delivery and delivery place of the items.
- 5- domestic preference.
- 6- The availability of contracts and similar executed works within the specialization and the rate and level of execution and commitment of the company when implementing them.
- 7- certificate of trading in the country of origin.
- 8- manufacturing goods meets the requirement of good manufacturing Practices (GMP) other certifications (FDA) that are mentioned in bid documents and mechanisms of quality control.
- 9- Responding to the legal conditions ,technical specifications, standards of required rehabilitation, table prices meet samples of standard-documents as being the lowest price and balanced with the estimated cost.
- 10- duration of executing the contract.
- 11-company status from registration.

12- Status of the product from registration knowing that instructions that bidder shall begin to register in the specialized authorities and the contract will become effective from the date of receiving the registration certificate in case the product is not registered. If the product is registered or under the exception of the Minister of Health from submitting the registration certificate, the contract shall be effective from the date of its signature.

## SECTION IV. BIDDING FORMS

### NOTES ON THE BIDDING FORMS

The Bidding Forms provided in this SSBD provide standard formats for a number of the key documents that the Contracting Entity and Bidders will exchange in the process of bidding.

**{The Contracting Entity shall fill in the Forms with the needed information relevant to each procurement before launching the Bidding Process. The required place for writing this information is under the paragraphs written in Italic style and shaded in grey. Any notes provided to the Contracting Entity which is underlined and shaded in yellow is for information only and shall be deleted before releasing the Bidding Documents.}**

The Bidder will fill in his part of the form where it is designated between brackets or \_\_\_\_\_.

The Bidders must complete the Forms as indicated on the form, and submit them to the Contracting Entity.

**Price Schedules:** The price breakdown given in the sample Price Schedules generally follows the usual breakdown requested for procurement of Goods in order for the domestic preference procedure to be applied. It is essential that Bidders submit their prices in the manner prescribed by the Price Schedules. Failure to do so may result in loss of the preference, if applicable.

**Manufacturer's Authorization Form:** In accordance with ITB Sub-Clause 8.1 (b), Bidders must submit, as part of their bids, Manufacturer's Authorization Form(s) in the format provided in the SSBD for all items specified in the Bid Data Sheet.

**Bid Security Form:** Regarding ITB Clause 17, the Contracting Entity should include the Bid Security form provided in the SSBD in the Bidding Documents. The Contracting Entity must ensure that the submitted form substantially complies with the features of the form included here in respect to its degree of protection and clarity of conditions under which it can be made effective in accordance with the applicable Iraqi Laws.

**1. Bid Submission Form**

Date: [insert: **date of bid**]  
 {Contracting Entity to insert}: Tender Number: [MED/ 1 /2020 ]"  
 IFB Number: [1 ]"

To: {Contracting Entity to insert: [Name and address of Contracting Entity]}

Dear Sir or Madam:

Having examined the Bidding Documents, including Addenda Nos. [insert **numbers** ], the receipt of which is hereby acknowledged, we, the undersigned, offer to supply and deliver the Goods under the above-named Contract in full conformity with the said Bidding Documents for the sum of:

[ insert: amount of "Iraqi Dinar" in words ]	( [ insert: amount of "Iraqi Dinar" in figures ] )
<b>plus</b> [ insert: amount of "US Dollar" in words ]	( [ insert: amount of "US Dollar" in figures ] )
<b>plus</b> [ insert: amount of "Euro" in words ]	( [ insert: amount of "Euro" in figures ] )

(hereinafter called "the Total Bid Price") or such other sums as may be determined in accordance with the terms and conditions of the Contract. The above amounts are in accordance with the Price Schedules attached herewith and are made part of this bid.

2. We undertake, if our bid is accepted, to deliver the Goods in accordance with the delivery schedule specified in the [ insert "Schedule of Requirements in Section-VI" or "as quoted in Price Schedule in Section-IV" ] (the Bidder may select as appropriate clause).
3. We agree to all General Conditions of Contract in Section-VII read in conjunction with the Special Conditions of Contract in Section-VIII.
4. If our bid is accepted, we undertake to provide an advance payment security and a performance security in the form, in the amounts, and within the times specified in the Bidding Documents.
5. We agree to abide by this bid, for the Bid Validity Period specified in Sub-Clause 16.1 of the Bid Data Sheet in Section II and it shall remain binding upon us and may be accepted by you at any time before the expiration of that period.
6. Until the formal final Contract is prepared and executed between us, this bid, together with your written acceptance of the bid and your notification of award, shall constitute a binding Contract between us.
7. We understand that you are not bound to accept the lowest evaluated bid or any other bid that you may receive.
8. We agree to the following Eligibility Criteria:
  - (a) We have nationality from Eligible countries as per ITB Sub-Clause-6.1 of Section-I.
  - (b) We do not have conflict of interest in accordance with ITB Sub-Clause-6.1 (a) of Section-I.
  - (c) We are not a Government-owned Entity in Republic of Iraq./ We are a Government-owned Entity in the Republic of Iraq and meet the requirement as per Sub-Clause 6.1(b) of Section - I.



- (d) We including any of our subcontractors or manufacturers for any part of the contract, have not been declared ineligible by the Contracting Entity, under the Contracting Entity's country laws or official regulations or by an act of compliance with a decision of the United Nations Security Council.
- (e) We have not been Black listed or Suspended by Republic of Iraq and declared ineligible to bid during the period of time determined as per ITB Clause 6.3 of Section-I.

9. We confirm that our website address is **insert web side** \_\_\_\_\_, and our mail address is: \_\_\_\_\_, and that Mr. /Ms. \_\_\_\_\_ of Job Title: \_\_\_\_\_ and e-mail address: \_\_\_\_\_ will be following up all matters relevant to any Clarifications.

Dated this **[insert: number]** day of **[insert: month]**, **[insert: year]**.

**Signed:** \_\_\_\_\_

**Date:** \_

**In the capacity of** **[insert: title or position]**

Duly authorized to sign this bid for and on behalf of **[insert: name of Bidder]**





## 2. A. Price Schedule for Domestic Goods or Goods of Foreign Origin Located In Iraq

1																				
Brief Description of Goods																				
No. of bid t/precipit committee	Code of manufactur company	Offers submission	National code	Generic name	Generic name related to company that submit the bid	Trade name	Active item	Pharmaceutical from	volume	weight	Registration item no.	Registration item date	Quality certificate	Sample submission	sodium meta bisulfate) existence in this compand or not)	Raw material	Registration product no.	Registration product date	Per unite of package	Per unite of sheet

Grand Total of Bid price in Iraqi Dinar: \_\_\_\_\_ (In figures) \_\_\_\_\_ (In words)

Delivery Period: \_\_\_\_\_ [Bidder may insert quoted delivery period] as per INCOTERMS® current edition \_\_\_\_\_ [Insert Incoterms].

Signature of Bidder \_\_\_\_\_  
Name \_\_\_\_\_ &  
Designation \_\_\_\_\_  
Seal \_\_\_\_\_ of \_\_\_\_\_ the \_\_\_\_\_ Bidder

Date: \_\_\_\_\_

## 2. B. Price Schedule for Domestic Goods or Goods of Foreign Origin Located In Iraq

2		3		4			5					6
Quantity offered		Country of origin		Price per physical unit Iraq currency (NO. , Write)			Price & the transport way					Total Price
Quantity of bid submitted	Free goods	The name of producing company	The origin of producing company	Package price	Per unit price	Currency type	Ex-factory/ex-warehouse/ex-show room/off-the shelf including packing and forwarding charges (a)	Sales and other taxes and duties payable if contract is awarded (b)	Inland transportation insurance loading/unloading and incidental costs till end-users site (c)	Incidental services as definal in schedule of requirement (d)	Price on DDP/free delivery at end-users e=(a+b+c+d)	Total Price on DDP/Free Delivery at End-users' site. (Iraqi Dinar)  quantityX 5 (e)

Grand Total of Bid price in Iraqi Dinar: \_\_\_\_\_ (In figures) \_\_\_\_\_ (In words)

Delivery Period: \_\_\_\_\_ [Bidder may insert quoted delivery period] as per INCOTERMS® current edition \_\_\_\_\_ [Insert Incoterms].

Signature of Bidder \_\_\_\_\_

Name & Designation \_\_\_\_\_

Seal of the Bidder \_\_\_\_\_

Date: \_\_\_\_\_



































				تخدامه في حالات ( التخدي ر والقليد ة والسم وم)																	
			01- G00- 009	Ephe drine Hcl inj 3% 30 mg / ml, slow I.V. injec tion 1ml amp oule ( hypo tensi on prev entio n in epid ural/ spina l anae																	





طريق  
الفم او  
المهبل  
وتعداد  
الجرعة  
كل  
اربع  
ساعات  
ولمدة  
(٢٤)  
ساعة  
كحد  
اقصى  
4- .  
في  
حالات  
الحمل  
من  
(١٣)  
اسبوع  
-26-  
اسبوع  
يستعمل  
كالآتي  
أ- :  
-١٣  
١٧ اسد  
بوع  
(٢٠٠)  
مايكرو  
غرام  
مهلي  
كل  
٦ساعا  
ت  
وبواقع  
اربع  
جرع  
فقط.  
ب-  
-١٨  
٢٦  
اسبوع

(١٠٠)  
مايكرو  
غرام  
مهلي  
كل  
(٦) سا  
عات  
وبواقع  
اربع  
جرع  
فقط .  
ملاحظ  
ة  
يشترط  
عدم  
وجود  
عملية  
قيصر  
ية  
سابقة  
او اي  
عملية  
في  
الرحم  
بالنسبة  
للفقرة  
(٣، ٤)  
الخط  
الثاني  
من  
العلاج  
ت  
التحفظ  
ية cyt  
otic  
tab  
وان  
وجدت  
حينئذ  
تشكل  
لجنة  
طبية  
للبحث





المادة  
لتكون  
كالآتي :  
I.M -  
الزرق  
الوريدي  
البطيء  
slow  
Intrav  
enou  
s  
Injecti  
on  
و يخفف  
mg<sup>٥٠</sup>  
في  
Gluc  
se  
or %<sup>٥</sup>  
Nacl  
0.9 %  
20 ml  
ليصبح  
التركيز  
للمادة  
بعد  
التخفيف  
٢.٥  
mg/m  
l  
ويمكن  
تخفيفه  
ايضا  
في  
محلول  
Com  
poun  
d  
Sodiu  
m  
Lacta  
te  
ويعطى  
بالوريد  
بيطيء)  
خلال  
ثلاث









للأطفال  
أقل من  
سنة  
واحدة  
وذلك  
لزيادة  
خطر  
حدوث  
الآثار  
الجانبية  
)  
extra  
pyrad  
imal  
side  
effect  
(  
ب-  
لا ينصح  
بإستخدام  
م  
مستح  
ضرات  
هذه  
المادة  
التي  
تؤخذ  
عن  
طريق  
الفم  
للأطفال  
والمراه  
قين.  
ج-  
تستخدم  
المادة  
اعلاه  
عن  
طريق  
الزرق  
في  
حالات  
التقيئ  
بعد  
العملية  
posto  
perati

ve  
للاطفال  
فوق  
السنة  
من  
العمر  
د-  
تستخدم  
المادة  
اعلاه  
للفئة  
العمرية  
تحت  
20 سنة  
في  
حالات  
التقيئ  
المصاد  
بة  
للعلاج  
الشعاع  
ي  
والعلاج  
الكيمياء  
ي  
والتقييب  
المعدي  
المعوي  
gastr  
o  
intesti  
nal  
intub  
ation  
وتحسب  
الجرع  
للمرض  
ى في  
هذة  
الحالات  
على  
اساس  
الوزن.  
على ان  
يكون  
التركيز  
مكافئ







Amin  
 ophyll  
 ine  
 base  
 197  
 mg/1  
 0 ml  
 (I.V)  
 inj .  
 (10ml  
 ampo  
 ule)  
 (plast  
 ic or  
 glass  
 amp.)  
 (  
 amin  
 ophyll  
 ine مع  
 العبوة  
 المصنو  
 عة من  
 البلاست  
 ك )  
 مطالية  
 الشركة  
 المنتجة  
 بتقديم ما  
 يثبت  
 عدم  
 تفاعل  
 المادة  
 اتفا مع  
 العبوة  
 المصنو  
 عه من  
 البلاست  
 ك او  
 الزجاج  
 ويعطى  
 بالزرق  
 الوريدي  
 البطيء  
 1030  
 ج

03-  
A00-  
024

Salbu  
tamol  
nebul  
es  
(Res  
pirato  
r  
soluti  
on)  
0.5%  
w/v  
(20ml  
)  
Note:  
Home  
Nebul  
iser  
(port  
Neb  
home  
comp  
resso  
r  
Nebul  
iser  
with  
soluti  
on  
(salb  
utam  
ol)  
(as  
sulph  
ate )

بإشكالها  
الصيدلاني  
يه  
وحسب  
المقر  
دستوريا  
ان يكون  
salbu  
tamol  
لمستح  
ضرات



vial  
of -  
4ml )  
intratr  
ache  
al  
use  
only  
(For  
Inten  
sive  
care  
unite  
s for  
childr  
en)  
- (  
جنون  
البقر )  
TSE  
تطلب  
شهادات  
خلو  
المادة  
من  
-  
تستعمل  
المادة  
في  
ردهات  
حديثي  
الولادة  
والخدج  
في  
المستشد  
فيات  
التعليمية  
التي  
يوفر  
فيها  
:- الاتي  
ا نابيب \*  
القصبا  
ت في  
مختلف  
الحجوم  
(٢,٥/٣)

(٢/  
 جهاز\*  
 ناظور  
 الحنجرة  
 بمختلف  
 القياسات  
 (صفر،  
 \* . (١)  
 جهاز  
 قياس  
 غازات  
 الدم.  
 للخداج  
 Ambu  
 bag  
 &  
 او كسجيد  
 \* .  
 جهاز  
 التنفس  
 الصنعي  
 ي  
 للخدج  
 code  
 03-  
 100-  
 007  
 تخضع  
 لقاعدة  
 اقل  
 الاسعار  
 مع

03-  
 100-  
 007

Calfa  
 ctant  
 35m  
 g/ml  
 ( 3  
 ml )  
 intra  
 trach  
 eal  
 susp  
 ensi



Hcl  
25m  
g/ml,  
I.V ,  
I.M  
(2ml)  
Amp  
oule  
يستعم  
ل  
للزرق  
العضط  
ي  
العميق  
بمعدل  
- ٢٥  
٥٠ مغ  
-٦ كل  
٨  
ساعا  
ت  
ويستع  
ل  
للزرق  
الوريد  
ي  
بصور  
٥  
مخففه  
وبطينة  
للحالا  
ت  
المعدنة

Naus  
ea ,  
Hicc









hard capsule (2 capsules)	على الشركة المجهزة ان تلتزم بتوفير (٥٠%) من الاحتياج الكلي للعراق كإضاعة مجانية على ان لا يكون السعر المقدم في المناقصات اعلى والتي تشمل (highly emetogenic potential chemotherapy)	من الكلفة التخمينية او سعر التسجيل ويحصر استخدام مع 1-Taxol
---------------------------	---	---



/ml  
I.V.  
Infusion  
(50ml  
vial)  
يستعمل  
ل  
للجبار  
بطريقة  
ة  
الاستر  
واء  
الوريد  
ي  
خلال  
١٥  
دقيقة  
وللصغ  
ار  
حسب  
وزن  
(الطفل)  
يستعمل  
ل  
لحديثي  
الولادة  
والر  
ضع  
والاط  
فال  
الذي  
تكون  
اوزانها  
م اقل  
من  
٢٣



تكون  
جميع  
هذه  
الطرق  
مذكور  
ة على  
المستح  
ضر  
او  
بشكل  
منفص  
ل  
(جزء  
(منها  
وتستخ  
دم  
حسب  
ما  
مثبت  
في  
النشرة  
الداخ  
ية  
للمستح  
ضر

04-  
100-  
004

Pizot  
ifen  
as  
hydr  
ogen  
male  
ate  
0.5m  
g  
Tabl  
et  
للمستح  
شفيات



التخ  
صص  
ية في  
الطب  
النفسي  
و  
العص  
بي

04-  
J00-  
017

Phen  
obar  
biton  
e  
sod.  
200  
mg/  
ml  
(1ml)  
.  
Amp  
oule  
المادة  
دواء  
طوار  
ئ ولا  
يعطى  
الا  
بالور  
يد بعد  
التخفيف  
ف  
بنسبة  
واحد  
في  
عشرة  
(مل)  
واحد  
يخلط  
مع







caps  
ule

يستخدم  
كعلاج  
ثاني في  
حاله  
فشل

علاج  
الخط  
الأول

وحسب  
الضوابط

ط  
العالمية

المعتمدة  
لتحديد

الفشل  
Rio )

C  
riteria

(AAN  
&  
(EMA

-٢  
يستخدم

كعلاج  
خط أول

في  
الحالات

الحصر  
ية الآتية

-١  
رهاب

الحقن  
الأكيد

ب-  
بعض

حالات  
التصلب

العصبي  
الشديد

جدا  
وحسب

الضوابط  
ط  
العالمية











m  
يحسب  
الاحتياج  
٦٠ %  
من  
احتياج  
دواء )  
يستعمل  
في  
المراكز  
التخصص  
صحة  
يصرف  
في دار  
التمريض  
ض  
الخاص  
infecti  
ons  
in  
neutr  
openi  
c  
patie  
nts to  
be  
reser  
ve  
antibi  
otics  
يحص  
استخدام  
ه في  
المستشد  
قيات  
الحكوم  
ية  
المركز  
ية  
والمراك  
ز  
التخصص  
صحة  
مراكز )  
الحروق















05-  
B00-  
053Palivi  
zuma  
b 50  
mg  
vial  
injection

مع  
ضوابط  
الصرف  
الواردة  
في  
كتاب  
د.ا.ف  
المرقم  
/٢/٢/٥  
٤٣٢  
في  
/٣/٢٧  
٢٠١١  
ان هذا  
العقار  
يستعمل  
للووقاية  
من  
التهاب  
الجهاز  
التنفسي  
بسبب  
فايروس  
(RIV)  
وخلال  
فترة  
الموسم  
ويعطى  
شهريا  
بالعضلة  
كما  
ويعطى  
لحديثي  
الولادة  
من  
الخدج  
الذين  
يكون  
عمرهم  
الحمل



05-  
C00-  
032

on  
Casp  
ofung  
in as  
(acet  
ate )  
50mg  
I.V.inf  
usion  
Vial  
(pow  
der  
for  
recon  
stituti  
on)

على  
ان تكون  
النسبة  
المطلو  
بة من  
مضادا

ت  
الفطريا  
ت تقسم  
بنسبة  
%٢٥  
لكل  
منهما و  
%٥٠  
تعطى  
لمادة

Amph  
oteric  
in

بنوعية  
و  
المقرتان  
بقاعدة  
اقل  
الاسعار  
ضمن  
المستو  
ى الاول

•  
يكون  
البروتك

ول  
المعتمد  
لاستخدا  
م  
الادوية  
المضاده  
للفطريا  
ت  
كمايلي  
:-  
A-  
First  
line in  
the  
treat  
ment  
of  
undia  
gnos  
ed  
causi  
ng  
agent  
in  
neutr  
openi  
c  
fever  
or in  
the  
RCU:  
-  
1-  
Amph  
oteric  
ine ;  
whet  
her  
lipid  
comp  
lex  
or  
liposo  
mal  
2- If  
the  
patie



nt  
can  
not  
tolera  
te or  
has  
renal  
toxicit  
y ,  
the  
seco  
nd  
choic  
e will  
be  
casp  
ofung  
in  
and  
the  
other  
choic  
e is  
Voric  
onaz  
ole

B-  
When  
the  
funga  
l  
micro  
-  
organ  
isim  
is  
know  
n  
1- in  
muco  
rmyc  
osis ;  
the  
first  
choic  
e will



05-  
C00-  
033

ative  
choic  
e .  
voric  
onaz  
ole  
200  
mg.ta  
blet  
-ا  
يحصر  
استعماله  
في  
مراكز  
امراض  
الدم  
وزرع  
النخاع  
والمراك  
ز  
السرطا  
نية  
في  
الحالات  
الاثية  
(Prop  
hylaxi  
n)-ب  
يستعمل  
هذا  
العلاج  
كعلاج  
وقائي  
من  
الفطريا  
ت  
a-  
high  
risk  
neutr  
openi  
c on  
chem  
other  
apy  
includ  
es







لكل  
منهما و  
%٥٠  
تعطى  
لمادة  
Amph  
oterici  
n  
بنوعية  
و  
المقرتان  
بقاعدة  
اقل  
الاسعار  
ضمن  
المستو  
ى الاول

• يكون  
البروتك  
ول  
المعتمد  
لاستخدا  
م  
الادوية  
المضاده  
للفطريا  
ت  
كمايلي  
:-

A-  
First  
line in  
the  
treatm  
ent of  
undia  
gnose  
d  
causin  
g  
agent  
in  
neutro  
penic  
fever



or in  
the  
RCU:

-  
1- Amph  
oterici  
ne ;  
wheth  
er  
lipid  
compl  
ex or  
liposo  
mal  
2- If  
the  
patien  
t can  
not  
tolerat  
e or  
has  
renal  
toxicit  
y , the  
secon  
d  
choice  
will  
be  
caspo  
fungin  
and  
the  
other  
choice  
is  
Voric  
onazo  
le

B-  
When  
the  
fungal  
micro







الدم.  
- يستعمل  
في  
علاج  
حالات  
الخمج  
بفطريا  
ت  
الكانديدا  
الشديده  
والخمج  
النواتج  
عن  
الفطريا  
ت  
المتغلغله  
والتي  
لا تسنج  
ب لدواء  
الامفوتر  
سين  
العادي  
او  
للادويه  
المضاده  
الاخرى  
او  
عندما  
تتعار  
ض  
تأثيرات  
الامفوتر  
سين  
العادي  
الجانبية  
لذلك او  
عند  
وجود  
عجز  
كلوي  
لدى  
المري  
ض

05-  
C00- Lipos  
omal









(NPH )  
100u  
nits/  
ml  
injection  
10 ml  
/vial  
subcutaneous  
injection.

يتم  
صرفه  
ضمن  
ادوية  
الامراض  
المزمنة  
في  
العيادات  
الشعبية  
و  
المراكز  
التخصصية  
وصحية و  
عيادات  
السكري  
في  
المستشفيات  
في  
العام.  
على  
الشركات  
المنتجة  
للاستيفاء  
بين  
بالوفاء  
بالتزامات  
تها التي  
تعهدت  
بها  
للوزارة

06-  
AA0-  
002

875)  
Insulin  
(Human)  
neutral  
(soluble)  
100  
units  
/ml  
injection 10  
ml/vial  
subcutaneous  
injection,  
intravenous  
infusion,  
intramuscular  
injection.  
حسب  
الحاجة  
بم  
صرفه  
ضمن  
ادوية  
الامراض  
المزمنة  
في  
العيادات  
الشعبية  
و  
المراكز  
التخصصية  
وصية و

عيادات  
السكري  
في  
المستشفى  
فيات  
العامه  
( على )  
الشركا  
ت  
المنتجة  
للانسول  
ين  
بالوفاء  
بالتزاما  
تها التي  
تعهدت  
بها  
للوزارة  
)  
بروتوك  
ول  
( ٨٧٥ )  
-  
-  
Solub  
le  
Insuli  
ne or  
Neutr  
al  
insuli  
n من  
الممكن  
أعطاه  
عن  
طريق  
I.V,  
I.M,  
S.C او  
  
I.V  
Infusi  
on  
حسب  
الحاجة

06-  
AA0-

Insuli  
n

003

(human)  
biphasic  
30% soluble,  
70% isophane  
100 units/ml  
injection 10 ml  
vial subcutaneous  
injection.  
(814)-  
يتم صرفه ضمن  
ادوية الامراض  
المزمنة في  
العيادات الشعبية  
والمراكز  
التخصصية و  
عيادات السكري  
في المستشفى  
فيات العامة.  
على الشركة







06-  
C00-  
021

Recombinant human chorion gonadotropin alpha (250 mcg)/0.5 ml = (6500 IU) pre-filled syringe S.C inj  
من مصدر بشري على ان تلتزم الشركة المجهزة بتقديم الادلة والاثباتات العلمية والتقنية في كل ما ياتي: خلو المنتج من الفايروسات والبكتيريا والبروتينات الغريبة (priun

s  
-  
الكفاءة  
على ان  
تقاس  
بطريقة  
filled  
by  
mass  
يستعمل  
في  
حالات  
قصور  
الغدة  
النخامية  
وبعض  
حالات  
العقم  
لدى  
الكبار  
code  
06-  
C00-  
46  
تخضع  
لقاعدة  
اقل  
الاسعار  
مع  
الاخذ  
بنظر  
الاعتبار  
الفقرة ٧  
في ج  
١٠٤٨

06-  
C00-  
043

Desm  
opres  
sin  
aceta  
te  
150  
mcg/  
dose  
nasal  
spray  
: A  
2.5

ml  
bottle  
containing  
1.5  
mg/ml  
I with  
spray  
pump  
capable  
of  
delivering  
25  
doses.  
- .-

يخص  
ص هذا  
التركيز  
للامراض  
النزفية  
الوراثية  
فقط  
ضرورة  
توفر  
الفحوصات  
المختبرية  
المرفقة  
بكتاب  
دائرة  
مدينة -  
الطب  
٢٩٤٥٤  
في  
/٩/١١  
٢٠١٢  
وحسب  
الجلسة  
٨٢٨  
-  
Patients  
with





تلتزم  
الشركة  
المجهزة  
بتقديم  
الأدلة  
والإثباتات  
العلمية  
والتقنية  
في كل  
ما يأتي:  
خلو  
المنتج  
من  
الفايروسات  
والبيكتيريا  
(والبروتينات  
الغريبة)  
)  
priun  
s  
-  
الكفاءة  
على ان  
تقاس  
بطريقة  
ال  
filled  
by  
mass

06-  
C00-  
045

Urinary  
gonadotrophine  
(FSH/LH)...  
highly purified  
70 IU/75  
amp, I



06-  
C00-  
046

by mass  
Urinary human chorionic gonadotropin (HCG) ... highly purified 5000 IU, vial, amp, I.M., S.C. powder for reconstitutions with solvent or solution  
(من مصدر بشري على ان تلتزم الشركة المجهزة بتقديم الادلة والاثباتات العلمية والتقنية في كل ما ياتي:



خلو  
المنتوج  
من  
الفايرو  
سات  
والبكتير  
يا  
والبرو  
تينات  
الغريبة  
priun  
s  
-  
الكفاءة  
على ان  
تقاس  
بطريقة  
filled by  
mass  
يستعمل  
في  
حالات  
قصور  
الغدة  
النخامية  
وبعض  
حالات  
العقم  
لدى  
الكبار  
code  
06-  
c00-  
021  
تخضع  
لقاعدة  
اقل  
الاسعار  
مع

06-  
D00-  
001

Carbi  
maz  
ole  
5mg  
Tabl  
et



009

haso  
ne  
phos  
phat  
e as  
di  
sodi  
um  
salt  
or  
(as  
sod.  
salt )  
inj  
8mg  
/2ml  
(2ml  
Amp  
OR  
Vial)  
I.V .  
I.M  
or  
I.V  
infus  
ion  
(  
pres  
ervat  
ive  
as  
sulfit  
e  
)  
يجب  
ان  
تخلو  
الماده



06-  
E00-  
018

من  
Hydr  
ocor  
tison  
e as  
sodi  
um  
succ  
inate  
OR  
(Hyd  
roge  
n  
succ  
inate)  
eq.  
to  
100  
mg  
hydr  
ocor  
tison  
e.  
Vial  
with  
2ml  
amp  
oule  
solve  
nt  
for  
solut  
ion  
for  
injec  
tion





hyler  
gono  
vine)  
male  
ate  
200  
mcg/  
ml,  
(1ml)  
Amp  
oule  
مراكز  
رعاية  
صحية  
اولية  
+  
احتياج  
المست  
ششفيات  
986  
ج  
مراكز  
الرعا  
ية  
الصد  
ية  
الاولية  
والمسد  
تشفيا  
ت)  
ج ٩٨٩  
)

07-  
A00-  
012

Oxyt  
ocin  
10un  
its/m















Vial and the giving quantity according to the lab. Analysis over 10 minutes and the giving quantity according to the lab. Analysis مع الاخذ بنظر الاعتبار





التخدي  
ر  
Tica  
grelo  
r 90  
mg  
film  
coat  
ed  
table  
t  
وللاس  
تطببا  
ت  
التالية:  
(Clo  
pido  
grel  
75m  
g  
tab)  
نسبة  
احتياج  
المادة)  
(%١٠  
من  
احتياج  
العراق  
من  
مادة  
(PCI  
) - أ  
التداخل  
القسطا  
ري  
الاولي  
Plate  
let)  
والمشخ  
صين

08-  
E00-  
020



عن طريق جهاز (Clopidogrel 75 mg tab) ب- المرضى غير المستجيبين لعلاج (Agre-gom-eter) ويحدد صرفه في مراكز القلب وشعب القسطرة

08-F00-009

\*Recombinant human tissue plasminogen activator





ت عالية  
الاستجا  
بة -  
(inhib  
itors  
with  
high  
respo  
nders  
2-  
3--  
3  
اعتلال  
عمل  
الأقرا  
ص  
الوراثي  
من نوع  
  
Glan  
nzma  
ns  
throm  
basth  
enia-  
-  
Bern  
ads-  
soulie  
ر  
والغير  
المستجيب  
بن لنقل  
الأقرا  
ص  
مع  
مراعاة  
الشروط  
الواردة  
في  
الجلسة  
١٠٢٥  
و١٠٢٩  
للاغرا  
ض  
الاستيرا  
دية

على ان  
يتم تقديم  
تقرير  
عن  
العامل  
السابع  
بعد  
مرور  
عام  
على  
استخدام  
الادوية  
الخاصة  
بالعامل  
السابع

08-  
H00-  
007

Plas  
ma  
prot  
ein  
fracti  
on  
(hum  
an)  
5%  
i.v.  
infus  
ion  
i-e  
1ml  
cont  
ains:  
Hum  
an  
seru  
m  
prot  
ein  
50m  
g of  
whic



خالية )  
من اي  
منشأ  
بشري  
او  
حيوان  
(ي)  
ج ٩٨٦  
توفير  
كبخا  
عة  
مجانبة  
(FOC  
)  
(reco  
mbin  
ant  
Foct  
or  
vIII  
250  
IU)  
كونها  
تعبر  
جرع  
تكمبلبة  
بنسبة  
١٠%  
من  
احتياج  
(reco  
mbin  
ant  
Foct  
or  
vIII













(15m  
mol/l)  
+Pot  
assiu  
m  
chlori  
de  
0.671  
0g(9  
mmol  
/l)+P  
otassi  
um  
hydro  
gen  
2-  
Ketog  
lutara  
te0.1  
842g  
(1mm  
ol/l)+  
Magn  
esiu  
m  
chlori  
de  
6H<sub>2</sub>O  
0.813  
2g  
(4mm  
ol/l)+  
Histid  
ine  
Hcl  
.H<sub>2</sub>O  
3.773  
3g(18  
mmol  
/l)+Hi  
stidin  
e  
27.92  
89g(1  
80m  
mol/l)  
+Tryp

























حبوب  
الزئبق  
٢٠  
ملغم كما  
مدرج  
ادناه  
للأطفال  
من ٦  
أشهر  
إلى ٥  
سنوات  
و ١٠  
ملغ  
للأطفال  
دون ٦  
أشهر  
للسيطرة  
على  
الإسهال  
والإلتها  
بات  
التنفسية  
بالإضا  
فة إلى  
نقص  
النمو  
هو -  
برنامج  
للسيطرة  
على  
حالات  
الإسهال  
ولا يحل  
محل  
ORS  
(أي  
ليس  
علاج).

10-  
ACO-  
006

Peni  
cilla  
mine  
250  
mg  
caps  
ule



or  
table  
t

/ج  
١٠١٢

مع -  
الاخذ  
بنظر  
الاعتد  
بار  
ضمن  
ادوية  
السموم

-  
وردت  
هذه  
المادة  
ضمن  
قائمة  
الادوية  
الاسا  
سيه  
وكذلك

ضمن  
قائمة  
الادوية  
النادرة

يرجى  
تنبيه  
الاحتيا

ج فيما  
يخص  
الادوية  
الاسا  
سية  
فقط .

10-  
CAa-  
004

Neost  
igmin  
e  
metis  
ulpha  
te  
2.5m  
g/ml,I  
.V,I.M  
,S.C  
inj  
(1ml)  
Ampo  
ule )  
(note:  
to be  
givin  
(i.v.)  
for  
anest  
hesia  
and  
to be  
given  
(i.m.,  
s.c.)  
in  
case  
of  
myas  
theni  
a  
gravi  
s  
كون  
طريقة  
الزرق  
I.V,I.  
M,S.  
C على  
ان  
يعطى  
(I  
وريديا  
في (V  
.V)  
حالة  
التخدير

و  
(I.M,  
S.C)  
في  
حالة  
وهن  
العضلا  
ت  
الوييل  
وادر ج  
ضمن  
قائمة  
ادوية  
التخدير  
(انظر  
ملاحظة  
Suga  
mma  
dex )  
Prese  
ntly  
it's  
need  
not  
more  
than  
10%  
of  
prosti  
gmin  
e(neo  
stigma  
n)  
need.  
-  
Reve  
rsal  
of  
Rocu  
roniu  
m&V  
ecuro  
nium.  
-used  
in  
case  
when

















الاطفال  
والحالات  
التي  
لا يمكن  
فيها  
استخدام

Isorane  
تطلب  
مادة ل

(  
Adaptor)

بنفس  
كمية  
مادة (  
Sevoflurane)

وتجهز  
بصورة  
مجانية  
من قبل  
الشركة  
المجهزة  
للمادة  
"انفا"

ويشكل  
سنوي  
ويكون  
نوع (  
Adaptor)

حسب  
نوع (  
Vaporizer)

وحسب  
رأي  
اللجنة  
الاستشارية  
للتخدير  
وتثبيت  
الملاحظ

ة























(Hcl  
أو  
Adre  
nalin  
e (as  
Acid  
tartar  
(ate  
وتكون  
النسبة  
المطلو  
بة على  
ما  
يكافئها  
من الـ  
Adre  
nalin  
e  
base  
.  
أما مادة  
الـ  
Adre  
nalin  
e  
borat  
e فلا  
تستخدم  
دستور  
يا في  
مستح  
ضرات  
الزرق  
(٦٩٤)  
(٧٠٩)  
وتستخدم  
م في  
allerg  
ic  
disor  
ders  
ج  
١٠١٢

15-  
AA0-  
002

Car  
must  
ine







































بالعقار  
وهي  
معلما  
ت  
اورام  
خاصة  
على  
جدار  
الخلية  
لبيان  
تحسس  
الورم  
الى  
عقار  
معين  
..  
يوفر  
هذا  
المعلم  
في  
المخت  
برات  
HER  
/2/n  
eu

15-  
AFO-  
038

Cape  
citab  
ine  
500  
mg  
table  
t



15-  
AF0-  
051

Borte  
zomi  
b( as  
mann  
itol  
boron  
ic  
ester  
)inj.3.  
5 mg  
i.v,  
s.c  
vial  
يستعمل  
للحالات  
المعددة  
للعلاج  
التقليدي  
وغير  
المناسبة  
لغرس  
نخاع  
العظم  
في ورم  
ليفى  
العظم  
المتعدد  
الخلايا  
(multi  
ple  
mylo  
ma)  
,  
يحدد  
صرف  
العقار  
للمرضى  
المصابين  
بأبيضاض  
الدم  
النقياني  
المتعدد  
(  
Multi  
ple

Mylo  
ma)  
في  
الحالات  
التالية :-  
أ-  
المرض  
الذي  
لديهم  
انتكاسة  
(relap  
se)  
أو  
مرض  
متعدد  
(Refr  
actor  
y  
disea  
se).  
ب-  
المرض  
الذي  
لديهم  
قصور  
كلوي  
نتيجة  
للمرض  
.  
ت-  
المرض  
الذي  
لديهم  
مرض  
شرس  
(aggr  
essiv  
e  
disea  
se)  
والذين  
قد  
يستفادو  
ن من  
عملية  
زرع  
الخلايا





جرع :  
a-  
used  
in  
potie  
nt  
with  
hodg  
kin's  
lymp  
homa  
who  
has  
resist  
ance  
and  
failed  
to  
respo  
nd to  
two  
lines  
of  
chem  
other  
apy  
and  
he is  
fit for  
autol  
ogou  
s  
trans  
plant  
b- in  
fit  
patie  
nt  
who  
relap  
sed  
after  
autol  
ogou  
s  
trans  
plant













الجدلية  
٩٨٩)  
)

Interf  
eron  
Beta  
1a 6  
millio  
n  
I.U(3  
0mcg  
) vial  
(I.M)  
:  
لمعالجة  
مرضى  
تصلب  
الاعصا  
ب  
المنتشرة

15-  
B00-  
027

يعطى  
المريد  
ض  
احدى  
الاشكال  
التاليه  
single  
demy  
elinati  
ng  
event  
with  
active  
infla  
mmat  
ory  
procc  
es  
النوبات  
الحادة

-  
Interf  
eron  
Beta-  
1a



( PCR  
BCR -  
ABL2  
10 ) ( )  
3  
مرات  
)  
"سنويا"  
لكل  
مريض  
ض .  
(  
FISH  
BCR -  
AB )  
لمرة  
واحدة  
للمر  
ضى  
المشخ  
صين  
"حديثا"  
.

15-  
B00-  
037

Inter  
fero  
n  
Beta  
1a  
(Rec  
ombi  
mant  
)  
12mi  
llon  
IU  
(44m  
cg)

pfs

Inter  
feron b -  
1a(Rebi  
f )

يعطى

(Rem  
ittingRela  
psing

في )

حالة

النوبا

ت

المتكر

رة

الهادئة

والنتك

سة

او

(Evid

ece

stud

y )US

FDA

حسب

قرار

(Avo

nex

لانه )

اكثر

فعالية

من

(INC



or)  
400m  
g  
Table  
t or  
caps  
ule  
( يحصر )  
في  
مدينة  
الطب+ا  
لمركز  
الوطني  
لامرا  
ض الدم  
+  
بابل+ا  
بصرة+  
نينوى+ا  
لنجف+  
كركوك  
+  
كربلاء  
+  
الكرخ+  
واسط+ا  
لانباء+ا  
ربيل  
+سليمان  
ج (ية  
١٠١٢)  
)  
الشركة  
المجهزة  
ملزمة  
بتوفير  
الفحوصات  
التالية  
(  
PCR  
BCR  
-  
ABL2  
10 ) (  
3  
(مرات)









+بابل+  
لبصرة  
+نينوى  
+النحف  
+كركو  
+ك  
كربلاء  
+  
الكرخ+  
واسط+  
لانبار  
+اربيل  
+سليمان  
ية)  
يستخدم  
في  
علاج  
المرض  
ى الذين  
لا  
يستفيدو  
ن من  
Imati  
nib  
cap  
مع  
الالتزام  
بالضوا  
بط  
الموضو  
عة من  
قبل  
اللجنة  
المركز  
ية  
بصرف  
علاج  
Glevi  
في  
c  
مؤسسة  
مدينة  
الطب  
كخط  
ثاني  
(ج  
٩٨٩)  
الشركة

المجهزة  
ملزمة  
بتوفير  
الفحوصات  
التالية  
(  
PCR  
BCR  
-  
ABL2  
10 ) (  
3  
مرات )  
"سنويا"  
لكل  
مريض  
.  
(  
FISH  
BCR  
- AB )  
لمرة  
واحدة  
للمرضى  
فى  
المشيد  
صين  
"حديثا".

15-  
B00-  
076

Lenal  
idom  
ide  
10m  
g  
table  
t or  
cap  
to be  
used  
as  
main  
tena  
nce

post  
autol  
ogus  
trans  
plant  
in  
multi  
ple  
myel  
ome  
for 2  
year  
s

15-  
B00-  
080

Niloti  
nib  
as  
Hcl  
mono  
hydra  
te  
150  
mg  
cap  
(  
Niloti  
nib  
200  
mg )  
/ج  
٩٨٩  
يطلب  
العقار  
بنسبة  
لا تتجاوز  
١٥ )  
ز  
( %  
من عدد  
المرضى  
الذين  
يستلمون  
عقار  
والتي  
تمثل

٩٠)  
مريض)  
غير  
قابلة  
للزيادة  
( ٣٥)  
منهم  
تتحمّلها  
الشركة  
المصنعة  
والباقي  
يوفر  
عن  
طريق  
كيماديا  
يتم  
تثبيت  
الاحتياج  
من قبل  
اللجنة  
المركزية  
لعلاج  
مرضى  
ابيض  
ض الدم  
النقياتي  
في  
دائرة  
مدينة  
الطب  
مع بقاء  
منافذ  
الصرف  
السابقة  
وحسب  
توزيع  
المرضى  
ى  
(منافذ  
الصرف  
:  
مدينة  
الطب+١  
لمركز  
الوطني

لامرا  
ض الدم  
+بايل+  
لنصرة  
+نينوى  
+النحف  
+كركو  
+ك  
+كربلاء  
+  
+الكرخ  
+واسط+  
+لانباء  
ربيل  
+سليمان  
(ية  
الشركة  
المجهزة  
ملزمة  
بتوفير  
الفحو  
صات  
التالية  
(  
PCR  
BCR  
-  
ABL2  
( ) (10)  
3  
(مرات  
"سنويا  
لكل  
مريض  
.  
(  
FISH  
BCR  
- AB )  
لمرة  
واحدة  
للمرض  
ى  
المشخ  
صين  
". حديثا

15-  
B00-  
081

Nata  
lizu  
mab  
conc  
entr  
ate  
for  
I.V.  
infus  
ion  
20m  
g/ml,  
15  
ml  
vial  
تقر  
المادة  
كخط  
ثاني  
على  
ان  
تقوم  
الشرك  
ة  
باجراء  
الفحو  
صات  
وحسد  
ب  
الضوا  
بط  
المعمو  
ل بها  
عالميا  
المتعط  
قة  
بفايرو  
س





وتتبيبت  
(  
Meta  
static  
pancr  
eatic  
neuro  
endo  
crine  
tumor  
s ) هذا  
الشرط  
كجزء  
من  
فقرات  
العقد  
فيما  
يخص  
مرضى  
(10  
mg )  
كإضاءة  
مجانية  
بنسبة  
%١٨  
من  
احتياج  
تركيز  
(  
Evero  
limus  
5 mg  
) / ج  
٩٨٧  
بالنسبة  
لسرطان  
الثدي  
يشترط  
توفر  
لمرضى  
سرطان  
الثدي  
وبواقع  
الف  
مريضة  
للسنة

(الواحدة  
ER,P  
R,Her  
2,Ki6  
7) مع  
تعهد  
الشركة  
المجهزة  
لوزارة  
الصحة  
بتوفير  
معلومات  
الأورام  
كإضاعة  
مجانية  
ويكامل  
الاحتياج  
(exe  
mesti  
ne  
25mg  
tab )  
وتوفير  
عقار  
meta  
steati  
c  
HR+v  
e  
,Her2  
-ve  
breas  
t  
canc  
er  
after  
failur  
e of  
non  
steroi  
dal  
arom  
atase  
inhibit  
ors  
ج/٩٨٦  
إضافة

استطبا  
ب15-  
B00-  
104

Pembrolizumab I.V inj .100 mg/vial  
1- يحصر استخدام الحالات التالية فقط:  
- ا- مرضى سرطان الجلد (الميلانوما) (وما المنتشر)  
- ب- مرضى سرطان الغدد اللمفاوية (هودجكين) (المنتكس)  
بعد الخط الثاني من العلاج الكيميائي والذي من الممكن

ان تجري لهم عملية زراعة نخاع العظم ويحصر صرفه في دائرة مدينة الطب  
3- تلزم الشركة المجهزة على توفير (15% من) الاحتياج الكلي كإضاءة مجانية على ان لا يكون السعر المقدم في المناقص ة اعلى من الكلفة التخمينية اوسعر التسجيل

15-  
D00-  
002

Doce  
taxel  
(Anh  
ydro  
us or  
as  
Trihy  
drat









ous  
solut  
ion  
(eac  
h  
cont  
ainin  
g 2g)  
i.e(2  
00m  
g/ml  
)  
SEE  
gp  
17  
خاص  
بوحدا  
ت  
العناية  
المرك  
زة  
ووحدا  
ت  
الطوار  
ئ  
ومراك  
ز  
السموم

17-  
000-  
015

Desf  
errio  
xami  
ne  
mesy  
late  
500  
mg  
inj











r  
BCG  
Instil  
latio  
n

وتكون  
الاحاله  
حسب  
افضالية  
العرو  
ض

المقدمة  
code

15-  
F00-  
002

يكون  
بحتياج  
ضمني  
مع

BCG

يكون  
صرف  
مادة

عن 1  
طريق  
المثانة

لعلاج  
اورام  
المثانة

السطح  
ية  
للمست

شفيات  
التي  
توفر

فيها  
مركز  
لاج  
الاورام  
من قبل  
مركز  
علاج  
الاورام  
2  
المست  
شفيات  
التي  
لايتوفر  
فيها  
مركز  
علاج  
للاورام  
يصرف  
من قبل  
اختصاصي  
الجراد  
ة  
البولية  
وبعد  
استش  
رة  
اخصاص  
ي  
الاورام  
وذلك  
لصعو  
بة  
تحديد  
حاجة  
المري  
ض



للعلاج  
المذكور  
بعد  
اجراء  
قص  
للورم  
من قبل  
اختصاص  
ص  
الجراد  
ة  
البولية  
ومعانة  
المريض  
ض في  
المست  
شفيات  
التي  
لا توفر  
فيها  
مركز  
علاج  
الاورام

15-  
F00-  
002

2x10  
8 -  
3x10  
9  
(RIV  
M )  
BCG  
المستخ  
دمة  
لعلاج  
سرطان  
المثانه  
BCG

مادة  
المستخد  
دم في  
دائرة  
الصحة  
العامه  
BCG  
تختلف  
عن  
لقاح  
intra  
vesi  
cula  
r  
BCG  
Instil  
latio  
n  
وتكون  
الاحاله  
حسب  
افضلية  
العرو  
ض  
المقدمة  
code  
15-  
F00-  
001  
يكون  
بححتاج  
ضمني  
مع  
BCG  
يكون  
صرف  
مادة

عن 1  
طريق  
المئات  
لعلاج  
اورام  
المئات  
السطح  
ية  
للمست  
شفيات  
التي  
توفر  
فيها  
مركز  
لاج  
الاورام  
من قبل  
مركز  
علاج  
الاورام  
2  
المست  
شفيات  
التي  
لايتوفر  
فيها  
مركز  
علاج  
للاورام  
يصرف  
من قبل  
اختصاصي  
الجراد  
ة  
البولية  
وبعد

استش  
رة  
اخصا  
ي  
الاورام  
وذلك  
لصعو  
ية  
تحديد  
حاجة  
المري  
ض  
للعلاج  
المذكو  
ر بعد  
اجراء  
قص  
للورم  
من قبل  
اختصا  
ص  
الجارح  
ة  
البولية  
ومعانة  
المري  
ض في  
المست  
شفيات  
التي  
لا توفر  
فيها  
مركز  
علاج  
الاورام

05-

Amo



AA0-007  
xycil  
lin  
as  
sodi  
um  
500  
mg  
per  
Vial.  
(I.V.I  
.M)

Grand Total of Bid price: [Bidders may insert permissible Currency] \_\_\_\_\_ (In figures) \_\_\_\_\_ (In words)

Delivery Period: \_\_\_\_\_ [Bidder may insert quoted delivery period] as per INCOTERMS® current edition \_\_\_\_\_ [Insert Incoterms].

Agent Name & Address: \_\_\_\_\_ [Bidder may insert, if applicable]

Agency Commission: \_\_\_\_\_ [Bidder may insert, if applicable]

Place: \_\_\_\_\_

Date: \_\_\_\_\_

Signature of Bidder \_\_\_\_\_

Name & Designation \_\_\_\_\_

Business address \_\_\_\_\_

Seal of the Bidder \_\_\_\_\_

### 3.B. Price Schedule for Goods to be imported from Abroad

4											5										6				
.....Country origin											Unit price (CIP)										Total Price (CIP)				
Date of registration of offer submitting company	Name of offer submitting company	Origin of offer submitting company	Manufacturer company name	Certificates obtained	Registration no of manufacturer company	Registration date of manufacturer company	Company address	Company phone no	Company email	Company website	Name of scientific bureau in Iraq that represent the company	Beneficiary name	Bank name	Bank address	Bank phone no	Account no	Price per pack	Price per unit (CIP)(A)	Currency type	Secondary services as defined in table(B)	Free goods	Payment method	Price CIP {C=(A+B)}	Total price CIP of the offered Qty. (CxQty.)	

Grand Total of Bid price: [Bidders may insert permissible Currency] \_\_\_\_\_ (In figures) \_\_\_\_\_ (In words)

Delivery Period: \_\_\_\_\_ [Bidder may insert quoted delivery period] as per INCOTERMS® current edition \_\_\_\_\_ [Insert Incoterms].

Agent Name & Address: \_\_\_\_\_ [Bidder may insert, if applicable]

Agency Commission: \_\_\_\_\_ [Bidder may insert, if applicable]

Place: \_\_\_\_\_

Date: \_\_\_\_\_

Signature of Bidder \_\_\_\_\_

Name & Designation \_\_\_\_\_

Business address \_\_\_\_\_

Seal of the Bidder \_\_\_\_\_



#### 4. Bid Security Form (Bank Guarantee)

[The Bank shall fill in this Bank Guarantee Form in accordance with the instructions indicated.]

[insert **Bank's Name**, and **Address** of Issuing Branch or Office]

**Beneficiary:** \_\_\_\_\_ [insert **Name and Address of Contracting Entity**]

**Date:** \_\_\_\_\_

**BID GUARANTEE No.:** \_\_\_\_\_

We have been informed that [insert **name of the Bidder**] (hereinafter called "the Bidder") has submitted to you its bid dated (hereinafter called "the Bid") for the execution of [insert **name of tender/project**] under Invitation for Bids No. [insert **IFB number**] ("the IFB").

Furthermore, we understand that, according to your conditions, bids must be supported by a bid guarantee.

At the request of the Bidder, we [insert **name of Bank**] hereby irrevocably undertake to pay you any sum or sums not exceeding in total an amount of [insert **amount in figures**] ([insert **amount in words**]) upon receipt by us of your first demand in writing accompanied by a written statement stating that the Bidder is in breach of its obligation(s) under the bid conditions, because the Bidder:

- (a) has withdrawn its Bid during the period of bid validity specified by the Bidder in the Form of Bid; or
- (b) having been notified of the acceptance of its Bid by the Contracting Entity during the period of bid validity, (i) fails or refuses to execute the Contract Form, if required, or (ii) fails or refuses to furnish the performance security, in accordance with the Instructions to Bidders.
- (c) has complained or appealed as per ITB clause 36 and it is decided by the competent authorities for this Bidder to compensate all damages resulting from delaying the contract signature for false or unjustified reasons.

This guarantee will expire: (a) if the Bidder is the successful bidder, upon our receipt of copies of the contract signed by the Bidder and the performance security issued to you upon the instruction of the Bidder; or (b) if the Bidder is not the successful bidder, upon the earlier of (i) our receipt of a copy of your notification to the Bidder of the name of the successful bidder and the bidder has not complaint or appeals to the Contracting Entity; or (ii) twenty-eight days after the expiration of the Bidder's Bid and the bidder has not complaint or appeals to the Contracting Entity.

Consequently, any demand for payment under this guarantee must be received by us at the office on or before that date.

This guarantee is subject to the Uniform Rules for Demand Guarantees, ICC Publication No.758.

[signature(s)]



### 5. Manufacturer's Authorization

[The Bidder shall require the Manufacturer to fill in this Form in accordance with the instructions indicated. This letter of authorization should be on the letterhead of the Manufacturer and should be signed by a person with the proper authority to sign documents that are binding on the Manufacturer. The Bidder shall include it in its bid, if so indicated in the BDS.]

Date: [insert: **date** (as day, month and year) **of Bid Submission**]  
IFB No.: [insert: **number of bidding process**]

To: [insert: complete name of Contracting Entity]

WHEREAS

We [insert: **complete name of Manufacturer**], who are official manufacturers of [insert: **type of goods manufactured**], having factories at [insert: **full address of Manufacturer's factories**], do hereby authorize [insert: **complete name of Bidder**] to submit a bid the purpose of which is to provide the following Goods, manufactured by us [insert: **name and or brief description of the Goods**], and to subsequently negotiate and sign the Contract.

We hereby extend our full guarantee and warranty in accordance with Clause 15 of the General Conditions of Contract, with respect to the Goods offered by the above firm.

Signed: [insert: **signature(s) of authorized representative(s) of the Manufacturer**]

Name: [insert: **complete name(s) of authorized representative(s) of the Manufacturer**]

Title: [insert: **title**]

Duly authorized to sign this Authorization on behalf of: [insert: **complete name of Bidder**]

Dated on \_\_\_\_\_ day of \_\_\_\_\_, \_\_\_\_\_ [insert: **date of signing**]







**PART 2  
PROCUREMENT REQUIREMEN**



---

**SECTION VI SCHEDULE OF REQUIREMENTS**

**NOTES ON THE SCHEDULE OF REQUIREMENTS**

---

The Schedule of Requirements provides a concise description of each product and the quantity required, along with any technical specifications unique to that item.





SCHEDULE OF REQUIREMENTS

Schedule: I List of Goods, Delivery Schedule and Terms of Delivery:

1	2					3	4	5	6	
Schedule No.	Item No.	Brief Description of Goods [Insert for Pharmaceuticals, Product, Strength, Dosage form, Pharmacopoeia Standard and Unit pack size. For Medical Equipment only Brief Description of goods may be mentioned]					Quantity and physical unit	Bid security amount in Iraqi Dinar [Note Insert Bid Security amount Schedule wise as one percent of Estimated Value ]	Final Destination [Note Insert End-users' address ]	Required Delivery period as per [ insert Incoterms® current edition]
		Product	Strength	Dosages form	Pharmacopoeia Standard	Unit pack size				
(a)	(b)	(a)	(b)	(c)	(d)	(e)				
[Insert]	[Insert]	[Insert]	[Insert]	[Insert]	[Insert]	[Insert]	[Insert]	[Insert]	[Insert]	[Insert]
[Insert]	[Insert]	[Insert]	[Insert]	[Insert]	[Insert]	[Insert]	[Insert]	[Insert]	[Insert]	[Insert]
[Insert]	[Insert]	[Insert]	[Insert]	[Insert]	[Insert]	[Insert]	[Insert]	[Insert]	[Insert]	[Insert]

**Terms of Delivery:** The Bidders are required to quote prices as per the terms of delivery stipulated in Price Schedule in Section -IV

## ScheduleII: Scope of Incidental Services:

[Insert: "Nil" for Health Sector Goods

OR "Required Installation, Demonstration and onsite Training" for Medical Equipment]

## ScheduleIV. Technical Specifications

---

The purpose of the Technical Specifications (TS) is to define the technical characteristics of the Goods and Related Services required by the Contracting Entity

**Technical Specifications**

- 1-the items offer should be stated by it's commercial name if it offer in it's scientific name should be stated in pharmacopoeia standards. **PHARMACEUTICALS**
- 2-stat the shelf life.
- 3-stat the origin of a material.



**Technical Specifications  
PHARMACEUTICALS**

- 1. Product and Package Specifications**
- 1.1 The Goods to be purchased by the Contracting Entity under this Invitation for Bids are included in Iraq's current national essential drugs list or national formulary. The required packing standards and labeling must meet the latest requirements of the World Health Organization (WHO) good manufacturing practices (GMP) standards in all respects. (These standards are contained in "Good Practices in the Manufacture and Quality Control of Drugs.")
- 1.2 Product specifications indicate dosage form (e.g., tablet, capsules, dry syrup, liquid, ointment, injectable, emulsion, suspension, etc.) and the drug content (exact number of mg or international units [IU] or % v/v, w/w or v/w acceptable range). The Goods should conform to standards specified in the following compendia: [The Contracting Entity should specify an acceptable pharmacopoeia standard from one of the following: the British Pharmacopoeia, the United States Pharmacopoeia, the French Pharmacopoeia, the International Pharmacopoeia, or the European Pharmacopoeia, the latter particularly for raw materials.] The standards will be the latest edition unless otherwise stated by the Contracting Entity or other if applicable. In case the pharmaceutical product is not included in the specified compendium, but included in the Iraq's national essential drug list, the Contracting Entity should clearly indicate acceptable limits and the Bidder (Supplier), upon award of the Contract, must provide the reference standards and testing protocols to allow for quality control testing.
- 1.3 Not only the pharmaceutical item, but also the packaging and labeling components (e.g., bottles, closures, and labeling) should also meet specifications suitable for distribution, storage, and use in a climate similar to that prevailing in Iraq. All packaging must be properly sealed and tamper-proof and packaging components must meet the latest compendium standards and be approved for pharmaceutical packaging by the manufacturer's national regulatory authority (RA). The Contracting Entity should specify any additional special requirements.

- 1.4 All labeling and packaging inserts shall be in the language requested by the Contracting Entity or English if not otherwise stated.
- 1.5 Goods requiring refrigeration or freezing or those that should not fall below a certain minimum temperature for stability must specifically indicate storage requirements on labels and containers and be shipped in special containers to ensure stability in transit from point of shipment to port of entry.
- 1.6 Upon award, the successful Bidder(Supplier) shall, on demand, provide a translated version in the language of the bid of the prescriber's information for any specific goods the Contracting Entity may request.
- 2. Labeling Instructions**
- 2.1 The label of the primary container for each pharmaceutical and vaccine products shall meet the W210 GMP standard and include:
- (a) The international nonproprietary name (INN) or generic name prominently displayed and above the brand name, where a brand name has been given. Brand names should not be bolder or larger than the generic name;
  - (b) dosage form, e.g., tablet, ampoule, syrup, etc.;
  - (c) the active ingredient "per unit, dose, tablet or capsule, etc.;
  - (d) the applicable pharmacopoeia standard;
  - (e) the Purchaser's logo and code number and any specific color coding if required;
  - (f) content per pack;
  - (g) instructions for use;
  - (h) special storage requirements;
  - (i) batch number;
  - (j) date of manufacture and date of expiry (in clear language, not code);
  - (k) name and address of manufacture;
  - (l) any additional cautionary statement.
- 2.2 The outer case or carton should also display the above information.
- 3. Case Identification**
- 3.1 All cases should prominently indicate the following:
- (a) Purchaser's line and code numbers;
  - (b) the generic name of the product;
  - (c) the dosage form (tablet, ampoule, syrup);
  - (d) date of manufacture and expiry (in clear language not code);
  - (e) batch number;
  - (f) quantity per case;
  - (g) special instructions for storage;
  - (h) name and address of manufacture;
  - (i) any additional cautionary statements.
- 3.2 No case should contain pharmaceutical products from more than one batch.
- 4. Unique Identifiers**
- 4.1 The Contracting Entity(Purchaser) shall have the right to request the Supplier to imprint a logo, if the quantity so justifies it, on the labels of the containers used for packaging and in certain dosage forms, such as tablets,

- and ampoules and this will be in the Technical Specifications. The design and detail will be clearly indicated at the time of bidding, and confirmation of the design of such logos shall be provided to the Bidder (Supplier) at the time of contract award.
- 5. Standards of Quality Control for Supply**
- 5.1 The successful Bidder (Supplier) will be required to furnish to the Contracting Entity:
- (a) With each consignment, and for each item a WHO certificate of quality control test results concerning quantitative assay, chemical analysis, sterility, pyrogen content uniformity, microbial limit, and other tests, as applicable to the Goods being supplied and the manufacturer's certificate of analysis.
  - (b) Assay methodology of any or all tests if requested.
  - (c) Evidence of bio-availability and/or bio-equivalence for certain critical Goods upon request. This information would be supplied on a strictly confidential basis only.
  - (d) Evidence of basis for expiration dating and other stability data concerning the commercial final package upon request.
- 5.2 The Supplier (Bidder) will also be required to provide the Contracting Entity (Purchaser) with access to its manufacturing facilities to inspect the compliance with the GMP requirements and quality control mechanisms.]

**[Sample:  
Technical Specification  
VACCINES**

**1. Product  
Qualification  
Requirements**

Option A

- 1.1 The Goods to be purchased by the Contracting Entity under this Invitation for Bids must be produced under the control of a recognized, well-functioning National Control Authority (NCA) for biologicals, which performs all six critical functions as defined by the World Health Organization (WHO):
- (a) licensing based on published set of requirements
  - (b) surveillance of vaccine field performance
  - (c) system of lot release for vaccines
  - (d) use of laboratory when needed
  - (e) regular inspections for Good Manufacturing Practices (GMP)
  - (f) evaluation of clinical performance

Or state the following:

Option B

- 1.1 The Goods under this Invitation for Bids should be purchased from WHO-approved sources only.
- 1.2 The Goods to be purchased by the Contracting Entity under this Invitation for Bids must be produced in accordance with the GMP recommendations of WHO for biological products.
- 1.3 The Goods to be purchased by the Contracting Entity under this Invitation for Bids must be registered by the National Control Authority (NCA) of Iraq.

**2. Product  
Specifications**

- 2.1 Dosage form (e.g.: oral or injectable; liquid or freeze dried with sterile diluents packed separately, etc.).
- 2.2 Type (e.g.: “live attenuated,” “manufactured from purified inactivated (...) obtained from human plasma or manufactured using recombinant DNA technology,” etc.).
- 2.3 Administration (e.g.: “intended for intramuscular injection,” etc.).
- 2.4 Description of intended use (e.g.: “immunization of newborn infants,” etc.).
- 2.5 Dosage size (if not restrictive), or expected immunogenic reaction (e.g.: each dose shall contain that amount of Hbsag protein with micrograms/ml specified by the manufacturer for newborn dosage, that when given as part of a primary immunization series [3 doses] is capable of producing specific humoral antibody [anti HBs] at a level of at least 10 milli international units in >-90 percent of recipients,” etc.).
- 2.6 Dose package (e.g.: “5 infant dose sterile glass vials,” etc.).
- 2.7 Filling volume (e.g.: “final product should contain 15% overfill,” etc.).
- 2.8 Closures (e.g.: “vaccine vials shall be fitted with closures that conform to ISO standard 8362-2”).
- 2.9 Storage temperature (e.g.: “2–8 degrees C. Do not freeze,” or as appropriate, etc.).

**3. Labeling Requirements**

- 2.10 The product should remain stable up to the indicated test expiry date if kept according to the required storage temperature.
- 2.11 Standards (e.g.: “The vaccine should conform to standards established by Iraq or, where no standard has been adopted, meet current requirements published by the WHO Expert Committee on Biological Standardization, or requirements of an established body of equivalent stature such as the U.S. Pharmacopoeia, the British Pharmacopoeia, the French Pharmacopoeia, or the International Pharmacopoeia”).
- 3.1 Each vial or ampoule shall carry the manufacturer’s standard label in Iraqi language, if available at no extra charge; otherwise, the label shall be in English.
- 3.2 Each vial or ampoule label shall state the following:
- (a) name of the vaccine;
  - (b) name of the manufacturer;
  - (c) place of manufacture;
  - (d) lot number;
  - (e) composition;
  - (f) concentration;
  - (g) dose mode for administration;
  - (h) expiration date;
  - (i) storage temperature;
  - (j) any other information that is appropriate.
- 3.3 All labeling shall withstand immersion in water and remain intact.

**4. Packing Requirements**

- 4.1 Inner boxes: Inner Boxes shall contain not more than (number) individual vials/ampoules and shall be constructed of sturdy white cardboard outfitted with individual segments for protecting and separating each vial/ampoules.
- 4.2 Printed materials: Each inner box shall contain at least (number) manufacturer’s standard package inserts in the Iraqi language if available at no extra charge; otherwise, package insert shall be in English.
- 4.3 Over packing: Inner boxes shall be over packed so that the vaccine remains refrigerated as designated in Sub-Clause 2.9. The over packing must be suitable for export handling and be in accordance with WHO Expanded Program of Immunization (EPI) Guidelines on International Packaging and Shipping of Vaccines including all measures needed to maintain required temperatures for seventy-two (72) hours. It must have adequate insulation and sufficient refrigerant to ensure that the warmest storage temperature of the vaccine does not rise above that designated in Sub-Clause 2.9 when exposed to continuous outside temperature of +43 degrees C, nor fall below that specified of -20 degrees C during transit and for a period of at least twenty-four (24) hours after arrival at the airport destination. Additional cushioning shall be provided sufficient to protect the vials/ampoules from breakage during transit and handling.

4.4 Exterior shipping cartons: Product and printed materials, packaged as described above, shall be packed in weather-resistant, triple-wall corrugated fiberboard cartons with a bursting test strength of not less than 1,900 kPa. The overall dimensions of the exterior shipping cartons should be such that the product does not become damaged during transportation and storage.

No shipping carton should contain vaccine from more than one lot.

4.5 Cold chain monitor cards: Each insulated shipping container must include appropriate temperature-monitoring devices designated by the Contracting Entity.

(a) At least two suitable cold chain monitor cards, as approved by the Contracting Entity, shall be packed in each transport case of vaccine.

(b) Freeze watch indicators shall be included in each transport case at the direction of Contracting Entity.

## 5. Marking Requirements

5.1 All containers and invoices must bear the following information:

- (a) the name of the vaccine;
- (b) expiration date of the vaccine;
- (c) appropriate storage temperature.

5.2 Inner boxes: The inner boxes containing vaccine vials or ampoules shall be marked with the following information in a clearly legible manner that is acceptable to the Contracting Entity:

- (a) Generic name and trade name of the vaccine;
- (b) Manufacturer's name and trade registered address;
- (c) Manufacturer's national registration number;
- (d) Lot or batch number;
- (e) Composition and concentration;
- (f) Number of vials contained in box;
- (g) Expiration date (month and year in clear language, not code);
- (h) Instructions for storage and handling;
- (i) Place of manufacture (Made in \_\_\_\_\_).

5.3 Exterior Shipping Cartons: The following information shall be stenciled or labeled on the exterior shipping cartons on two opposing sides in bold letters at least 30mm high with waterproof ink in a clearly legible manner that is acceptable to the Contracting Entity.

- (a) Generic name and trade name of the vaccine;
- (b) Lot or batch number;
- (c) Expiration date (month and year in clear language, not code);
- (d) Manufacturer's name and registered address;
- (e) Manufacturer's national registration number;
- (f) Destination airport and routing;
- (g) Consignee's name and address in full;
- (h) Consignee contact name and telephone number;

- (i) Number of vials or ampoules contained in the carton;
- (j) Gross weight of each carton (in kg);
- (k) Carton #\_\_\_\_\_ of \_\_\_\_\_;
- (l) Instructions for storage and handling;
- (m) Contract number;
- (n) Place of manufacture (Made in\_\_\_\_\_).

## 6. Quality Control for Supply

- 6.1 All goods must:
  - (a) meet the requirements of manufacturing legislation and regulation of vaccines in the country of origin;
  - (b) meet internationally recognized standards for safety, efficacy, and quality;
  - (c) conform to all the specifications and related documents contain herein;
  - (d) be fit for the purposes expressly made known to the Bidder by the Contracting Entity;
  - (e) be free from defects in workmanship and materials; and
  - (f) be certified by a competent authority in the manufacturer's country according to resolution WHA 28-65(2), of the WHO release certificate.
- 6.2 The Supplier will be required to furnish to the Contracting Entity with each consignment:
  - (a) A certificate of quality control and test results in conformity with the WHO release certificate.
  - (b) Assay methodology of any or all tests if required.
  - (c) Evidence of basis for expiration dating and other stability data concerning the commercial final package upon request.
- 6.3 Pre-shipment inspection and testing: The Supplier will be required to provide the Purchaser or his representative with access to the product as packed for shipment at the sellers' factory and/or warehouse at a mutually agreeable time prior to shipment of the product.
  - (a) The Purchaser may inspect and sample, or cause to be sampled, such product.
  - (b) The Purchaser may cause independent laboratory testing to be performed as deemed necessary to ensure that the Goods conform to prescribed requirements. The testing laboratory shall be of the Purchaser's choice and suitably equipped and qualified to conduct quality control test on biological products.



الله أكبر

Republic of Iraq

**PART 3  
CONDITIONS OF CONTRACT AND CONTRACT FORMS**



## **SECTION VII. GENERAL CONDITIONS OF CONTRACT**

### **NOTES ON THE GENERAL CONDITIONS OF CONTRACT**

---

The General Conditions of Contract (GCC) in Section VII, read in conjunction with the Special Conditions of Contract (SCC) in Section VIII and other documents listed in the Contract Agreement, should be a complete document expressing all the rights and obligations of the parties.

GCC must remain unaltered. Contract-specific information, deletions, extensions, and modifications to the GCC shall be introduced only by the Contracting Entity through the SCC.

---

**TABLE OF CLAUSES**

---

1. Definitions
2. Application
3. Country of Origin
4. Standards
5. Use of Contract Documents and Information; Inspection and Audit
6. Certification of Goods in Accordance with Laws of Republic of Iraq
7. Patent Rights
8. Performance Security
9. Inspections and Tests
10. Packing
11. Delivery and Documents
12. Insurance
13. Transportation
14. Incidental Services & AMC
15. Warranty
16. Payment
17. Prices
18. Change Orders
19. Contract Amendments
20. Assignment
21. Delays in the Supplier's Performance
22. Liquidated Damages
23. Termination for Default
24. Force Majeure
25. Termination for Insolvency
26. Termination for Convenience
27. Settlement of Disputes
28. Limitation of Liability
29. Governing Language
30. Applicable Law
31. Notices
32. Taxes and Duties
33. Withholding and lien in respect of sums claimed

**General Conditions of Contract****1. Definitions**

- 1.1 In this Contract, the following terms shall be interpreted as indicated:
- (a) "The Contract" means the agreement entered into between the Contracting Entity and the Supplier, as recorded in the Contract Form signed by the parties, including all attachments and appendices thereto and all documents incorporated by reference therein.
  - (b) "The Contract Price" means the price payable to the Supplier under the Contract for the full and proper performance of its contractual obligations.
  - (c) "Day" means calendar day.
  - (d) "Effective Date" means the date on which this Contract becomes effective pursuant to GCC Sub-Clause 6.2.
  - (e) "End User" means the organization(s) where the goods will be used, as named in the Schedule of Requirements.
  - (f) "GCC" means the General Conditions of Contract contained in this section.
  - (g) "The Goods" means all of the pharmaceuticals including nutritional supplement and oral and injectable forms of contraception, vaccines, condoms and medical equipment that the Supplier is required to supply to the Contracting Entity under the Contract.
  - (h) "The Purchaser" means the organization or the Contracting Entity purchasing the Goods, as **named in the SCC.**
  - (i) "Registration Certificate" means the certificate of registration or other documents in lieu thereof establishing that the Goods supplied under the Contract are registered for use in the Iraq in accordance with the Applicable Law.
  - (j) "SCC" means the Special Conditions of Contract.
  - (k) "The Services" means those services ancillary to the supply of the Goods, such as transportation and insurance, and any other incidental services, such as installation, demonstration and onsite training at End-users' site, and other such obligations of the Supplier covered under the Contract.
  - (l) "The Site," where applicable, means the place or places of End-users' site as per Schedule of Requirements
  - (m) "The Supplier" means the individual or firm supplying the Goods and Services under this Contract, as **named in the SCC.**
  - (n) **Fraud and Corruption :**  
The Purchaser defines Fraud and Corruption as per the relevant applicable Iraqi laws. For the purposes of this Sub-Clause, the Purchaser will be guided further by the definition of the terms as set forth here below:
    - (i) "corrupt practice" is the offering, giving, receiving or soliciting, directly or indirectly, of anything of value to influence improperly the actions of another party;
    - (ii) "fraudulent practice" is any act or omission, including a misrepresentation, that knowingly or recklessly misleads, or attempts to mislead, a party to obtain a financial or

- other benefit or to avoid an obligation;
- (iii) “collusive practice” is an arrangement between two or more parties designed to achieve an improper purpose, including to influence improperly the actions of another party;
  - (iv) “coercive practice” is impairing or harming, or threatening to impair or harm, directly or indirectly, any party or the property of the party to influence improperly the actions of a party;
  - (v) “obstructive practice” is
    - (aa) deliberately destroying, falsifying, altering or concealing of evidence material to the investigation or making false statements to investigators in order to materially impede a Purchaser’s investigation into allegations of a corrupt, fraudulent, coercive or collusive practice in accordance with the applicable Iraqi laws; and/or threatening, harassing or intimidating any party to prevent it from disclosing its knowledge of matters relevant to the investigation or from pursuing the investigation, or
    - (bb) acts intended to materially impede the exercise of the Purchaser’s inspection and audit rights as per the applicable Iraqi laws and as per Sub-Clause 5.4.

## 2. Application

- 2.1 These General Conditions shall apply to the extent that they are not superseded by provisions of other parts of the Contract.

## 3. Country of Origin

- 3.1 For purposes of this Clause, “origin” means the place where the Goods were mined, grown, or produced, or from which the Services are supplied. Goods are produced when, through manufacturing, processing, or substantial and major assembly of components, a commercially recognized new product results that is substantially different in basic characteristics or in purpose or utility from its components.
- 3.2 The origin of Goods and Services is distinct from the nationality of the Supplier.

## 4. Standards

- 4.1 The Goods supplied under this Contract shall conform to the standards mentioned in the Technical Specifications and, when no applicable standard is mentioned, to the authoritative standards appropriate to the Goods’ country of origin. Such standards shall be the latest issued by the concerned institution.

## 5. Use of Contract Documents and Information; Inspection and Audit

- 5.1 The Supplier shall not, without the Purchaser’s prior written consent, disclose the Contract, or any provision thereof, or any specification, plan, drawing, pattern, sample, or information furnished by or on behalf of the Purchaser in connection therewith, to any person other than a person employed by the Supplier in the performance of the Contract. Disclosure to any such employed person shall be made in confidence and shall extend only as far as may be necessary for purposes of such performance.
- 5.2 The Supplier shall not, without the Purchaser’s prior written consent, make use of any document or information enumerated in GCC Sub-Clause 5.1 except for purposes of performing the Contract.

5.3 Any document, other than the Contract itself, enumerated in GCC Sub-Clause 5.1 shall remain the property of the Purchaser and shall be returned (all copies) to the Purchaser on completion of the Supplier's performance under the Contract if so required by the Purchaser.

5.4 In accordance with the applicable Iraqi laws, the Supplier shall permit the Purchaser through the competent authorities to inspect the Supplier's offices and/or the accounts and records of the Supplier and its sub-contractors relating to the performance of the Contract, and to have such accounts and records audited by auditors. The Supplier's attention is drawn to Clause 23, which provides, inter alia, that acts intended to materially impede the exercise of the Purchaser's inspection and audit rights provided for under this Sub-Clause constitute a prohibited practice subject to contract termination as well as to a determination of ineligibility pursuant to the Iraqi's prevailing sanctions procedures in Iraq.

## 6. Certification of Goods in Accordance with Laws of Republic of Iraq

6.1 If required under the Applicable Law, Goods supplied under the Contract shall be registered for use in the Iraq. The Purchaser undertakes to cooperate with the Supplier to facilitate registration of the Goods for use in the Iraq.

6.2 Unless otherwise **specified in the SCC**, the Contract shall become effective on the date ("the Effective Date") that the Supplier receives written notification from the competent authority in Iraq that the Goods have been registered for use in Iraq.

## 7. Industrial ownership or Patent Right

7.1 The Supplier shall indemnify the Purchaser against all third-party claims of infringement of patent, trademark, or industrial design rights arising from use of the Goods or any part thereof in Iraq.

## 8. Performance Security

8.1 Within 14 days, or twenty-nine (29) days in case of Complaints and Appeals raised by unsuccessful Bidders, of receipt of the notification of Contract award, the successful Bidder shall furnish to the Purchaser the performance security of 5% of Contract Price. If rules and regulations of Republic of Iraq grant exemption to Public Companies of State and Public Sector, they are accordingly exempted of submitting Performance Security.

8.2 The proceeds of the performance security shall be payable to the Purchaser as compensation for any loss resulting from the Supplier's failure to complete its obligations under the Contract.

8.3 The performance security shall be denominated in the currency or currencies of the Contractor in a freely convertible currency acceptable to the Purchaser and chosen from the list of currencies from which the Central Bank of Iraq quotes the rate of exchange to the Iraqi **Dinar**. The Security shall be an unconditional guarantee payable upon first demand and in one of the following forms:

(a) A bank guarantee issued by accredited bank in Iraq in

accordance with the instructions of Central Bank of Iraq in the format provided in the Bidding Documents. In the case of a Bank Guarantee furnished from the banks located outside Iraq, it shall be endorsed and countersigned by an accredited bank in Iraq by way of back-to-back counter guarantee. Or

- (b) an irrevocable letter of credit or
- (c) Republic of Iraq bonds

8.4 The performance security will be discharged by the Purchaser and returned to the Supplier not later than thirty (30) days following the date of completion of the Supplier's performance obligations under the Contract, including any warranty obligations. The performance security shall be released after the final certificate regarding satisfactory completion of Supplier's performance obligations has been issued and final payment settlements have been done.

## 9. Inspections and Tests

9.1 The Purchaser or its representative shall have the right to inspect and/or to test the Goods to confirm their conformity to the Contract specifications. **The SCC** and the Technical Specifications shall specify what inspections and tests the Purchaser requires and where they are to be conducted. The Purchaser shall notify the Supplier in writing, in a timely manner, of the identity of any representatives retained for these purposes.

9.2 As **specified in the SCC**.

9.3 Nothing in GCC Clause 8 shall in any way release the Supplier from any warranty or other obligations under this Contract.

## 10. Packing

10.1 The Supplier shall provide such packing of the Goods as is required to prevent their damage or deterioration during transit to their final destination, as indicated in the Contract. The packing shall be sufficient to withstand, without limitation, rough handling during transit and exposure to extreme temperatures, salt, and precipitation during transit and open storage. Packing case size and weights shall take into consideration, where appropriate, the remoteness of the Goods' final destination and the absence of heavy handling facilities at all points in transit.

10.2 The packing, marking, and documentation within and outside the packages shall comply strictly with such special requirements as shall be expressly provided for in the Contract, including additional requirements, if any, **specified in the SCC** or Technical Specifications, and in any subsequent instructions ordered by the Purchaser.

## 11. Delivery and Documents

11.1 Delivery of the Goods shall be made by the Supplier in accordance with the terms specified in the Schedule of Requirements. The details of shipping and/or other documents to be furnished by the Supplier are **specified in the SCC**.

11.2 For purposes of the Contract, "EXW," "CIF," "CIP," "DDP" and other trade terms used to describe the obligations of the parties shall be governed by the

international rules for interpreting trading terms as prescribed in the current edition of INCOTERMS® published by the International Chamber of Commerce, Paris.

11.3 Documents to be submitted by the Supplier are **specified in the SCC.**

## 12. Insurance

12.1 The Goods supplied under the Contract shall be fully insured in a freely convertible currency chosen from the list of currencies from which the Central Bank of Iraq quotes the rate of exchange to the Iraqi Dinar, against loss or damage incidental to manufacture or acquisition, transportation, storage, and delivery. Where delivery of Goods is required by Purchaser on a CIF or CIP basis, the supplier shall assure the insurance of an amount equal to 110 percent of the CIF or CIP value of the Goods from “warehouse” to “warehouse” on “All Risks” basis, including war risks and strikes.

12.2 Where delivery of the Goods is required by the Purchaser on a CIF or CIP basis, the Supplier shall arrange and pay for cargo insurance, naming the Purchaser as beneficiary. Where delivery is on an FOB or FCA basis, insurance shall be the responsibility of the Purchaser.

## 13. Transportation

13.1 Where the Supplier is required under Contract to deliver the Goods FOB, transport of the Goods, up to and including the point of putting the Goods on board the vessel at the specified port of loading, shall be arranged and paid for by the Supplier, and the cost thereof shall be included in the Contract Price. Where the Supplier is required under the Contract to deliver the Goods FCA, transport of the Goods and delivery into the custody of the carrier at the place named by the Purchaser or other agreed point shall be arranged and paid for by the Supplier, and the cost thereof shall be included in the Contract Price.

13.2 Where the Supplier is required under Contract to deliver the Goods CIF or CIP, transport of the Goods to the port of destination or such other named place of destination in the Purchaser’s country, as shall be specified in the Contract, shall be arranged and paid for by the Supplier, and the cost thereof shall be included in the Contract Price.

13.3 Where the Supplier is required under the Contract to transport the Goods to a specified place of destination within Iraq, defined as the Site, transport to such place of destination in Iraq, including insurance and storage, as shall be specified in the Contract, shall be arranged by the Supplier, and related costs shall be included in the Contract Price.

13.4 Where the Supplier is required under Contract to deliver the Goods CIF or CIP, no restriction shall be placed on the choice of carrier.

## 14. Incidental Services & AMC

14.1 The Supplier shall provide such incidental services, if any, as are **specified in the Schedule of Requirements.**

**15. Warranty****16. Payment**

14.2 The Supplier shall provide Annual Maintenance Contract (AMC), if any, after warranty period for number of years as specified in the Schedule of Requirements.

15.1 Warranty shall be as **specified in the SCC**.

16.1 The method and conditions of payment to be made to the Supplier under this Contract shall be **specified in the SCC**.

16.2 The Supplier's request(s) for payment shall be made to the Purchaser in writing, accompanied by an invoice describing, as appropriate, the Goods delivered and Services performed, and by documents submitted pursuant to GCC Clause 11, and upon fulfillment of other obligations stipulated in the Contract.

16.3 Payments shall be made promptly by the Purchaser, but in no case later than sixty (60) days after submission of an invoice or claim by the Supplier. In case of delay beyond 60 (sixty) days, the resolution of this delay shall be settled as **specified in the SCC**.

When applicable, the advance security shall be payable upon an on demand and unconditional guarantee issued by an accredited bank in Iraq as per the official publication of the Iraqi Central Bank. If the security is issued by a Bank located outside Iraq, the issuer shall have a correspondent accredited financial institution located in Iraq to make it enforceable. In the case of a bank guarantee, the security shall be submitted using the Bid Security Form included in Section IX (Contract Forms) or in another substantially similar format with the prior approval of the Purchaser as per the applicable Iraqi laws.

16.4 Payment will be made in the currency or currencies in which the payment has been requested in the Supplier's bid.

16.5 Irrevocable non – transferable and unconfirmed Letter of Credit (LC) shall be opened by the Purchaser in accordance with the applicable Iraqi regulations. However, if the Supplier requests specifically to open confirmed LC, the extra charges would be borne by the supplier. If LC is required to be extended and/or amended for reasons not attributed to the Purchaser, the charges thereof shall be borne by the Supplier. However, if the LC is amended to make LC as per Contract requirements then charges thereof shall be borne by the Purchaser.

**17. Prices**

17.1 Prices charged by the Supplier for Goods delivered and Services performed under the Contract shall not vary from the prices quoted by the Supplier in its bid, prices shall be fixed and firm for the duration of Contract.

**18. Change Orders**

18.1 No changes shall be introduced to the contract unless for the circumstances (a-e) listed herebelow. In such case, the Change should be limited to minimum and would be applicable for the following reasons:

- a) If the change is not introduced, a major damage will result economically and technically;
- b) If the change is not introduced, the Goods cannot be useful upon completion;



- c) If the change will realize savings in the cost of the Project;
- d) If the change does not result in a major modification to the pre-determined scope of supply;
- e) If the change will result in earlier time for completion but not to result in inferior technical specification or scope of supply

The Purchaser may as per the applicable Iraqi laws, by a written order given to the Supplier pursuant to GCC Clause 31, make changes within the general scope of the Contract in any one or more of the following:

- (a) specifications, where Goods to be furnished under the Contract are to be specifically manufactured for the Purchaser;
- (b) the method of shipment or packing;
- (c) the place of delivery; and/or
- (d) the Services to be provided by the Supplier.

18.2 If any such change causes an increase or decrease in the cost of, or the time required for, the Supplier's performance of any provisions under the Contract, an equitable adjustment shall be made in the Contract Price or delivery schedule, or both, and the Contract shall accordingly be amended. Any claims by the Supplier for adjustment under this clause must be asserted within fifteen (15) days from the date of the Supplier's receipt of the Purchaser's change order.

## 19. Contract Amendments

19.1 Subject to GCC Clause 18, no variation in or modification of the terms of the Contract shall be made except by written amendment signed by the parties.

## 20. Assignment

20.1 The Supplier shall not assign, in whole or in part, its obligations to perform under this Contract, unless specified otherwise **in the SCC**.

## 21. Delays in the Supplier's Performance

21.1 Delivery of the Goods and performance of Services shall be made by the Supplier in accordance with the time schedule prescribed by the Purchaser in the Schedule of Requirements.

21.2 If at any time during performance of the Contract, the Supplier or its subcontractor(s) should encounter conditions impeding timely delivery of the Goods and performance of Services, the Supplier shall promptly notify the Purchaser in writing of the fact of the delay, its likely duration, and its cause(s). As soon as practicable after receipt of the Supplier's notice, the Purchaser shall evaluate the situation and may at its discretion extend the Supplier's time for performance, with or without liquidated damages, in which case the extension shall be ratified by the parties by amendment of Contract.

21.3 Except as provided under GCC Clause 24, a delay by the Supplier in the performance of its delivery obligations shall render the Supplier liable to the imposition of liquidated damages pursuant to GCC Clause 22, unless an extension of time is agreed upon pursuant to GCC Sub-Clause 21.2 without the application of liquidated damages.

**22. Delay penalties  
( reduced  
according the  
achievement  
percentage**

22.1 Subject to GCC Clause 24, if the Supplier fails to deliver any or all of the Goods or to perform the Services within the period(s) specified in the Contract, the Purchaser shall, without prejudice to its other remedies under the Contract, deduct from the Contract Price, as liquidated damages as per following formula:

$\text{Total Contract Price} \times 10\% - 25\% = \text{delay penalty per day}$

$\text{Total validity contract (days)}$

OR could be deducted as following formula :

$\text{Unperformed Contract Price} \times 10\% = \text{Liquidated damages per day}$

$\text{Delivery period (days)}$

In the above formula the unperformed Contract Price applicable will be a sum equivalent to delivered price of the delayed Goods or unperformed Services until actual delivery or performance, up to a maximum deduction of the 10% percentage of Contract Price. Once the maximum is reached, the Purchaser may consider termination of the Contract pursuant to GCC Clause 23.

**23. Termination for  
Default**

23.1 The Purchaser, without prejudice to any other remedy for breach of Contract, by written notice of default sent to the Supplier, may terminate this Contract in whole or in part in accordance with the Iraqi applicable laws:

- (a) if the Supplier fails to deliver any or all of the Goods within the period(s) specified in the Contract, or within any extension thereof granted by the Purchaser pursuant to GCC Clause 21; or
- (b) if the Goods do not meet the Technical Specifications stated in the Contract **within 30 days from date of receiving the written notification issued by the purchaser;**  
**or**
- (c) if the Supplier fails to provide any registration or other certificates in respect of the Goods within the time specified in the Special Conditions.
- (d) if the Purchaser determines as per the applicable Iraqi laws that the Supplier has engaged in corrupt, fraudulent, collusive, coercive or obstructive practices in accordance with GCC Sub-Clause 1.1.n, in competing for or in executing the Contract, then the Purchaser may, after giving **15** days notice to the Supplier, terminate the Supplier's employment under the Contract and cancel the contract, and the provisions of Clause 23 shall apply as if such expulsion had been made under Sub-Clause 23.1.
- (e) should any employee of the Supplier be determined to have engaged in corrupt, fraudulent, collusive, coercive, or obstructive practice in accordance with GCC Sub-Clause 1.1.n during the purchase of the Goods, then that employee shall be removed.
- (f) if the Supplier fails to perform any other obligation(s) under the Contract.
- (g) if the supplier withdraw completely or partially from the contract to another supplier or sign un-official contract with another supplier

23.2 In the event the Purchaser terminates the Contract in whole or in part, pursuant to GCC Sub-Clause 23.1, the Purchaser may procure, upon such terms and in such manner as it deems appropriate, Goods or Services similar to those undelivered, and the Supplier shall be liable to the Purchaser for any excess costs for such similar Goods or Services. However, the Supplier shall continue performance of the Contract to the extent not terminated.

#### 24. Termination for Insolvency

-The Purchaser may at any time terminate the Contract by giving written notice within 15 days to the Supplier if the Supplier becomes bankrupt or otherwise insolvent. Without returning to the court as following cases :

- (a) if the supplier has been insolvency , poverty, or subjected to dissolution his assets or submit a request to become under Insolvency or poverty.
- (b) if the relevant court issued a judgment to put the supplier assets under the hand of Insolvency secretary .
- © if the supplier has agreed to carryout his contractual obligations under the observation of inspection committee consist of his creditors.
- (d) if the supplier assets have been holding ( blocked) by the relevant court which lead to inability to commit with his contractual obligations.

In this case , the contract will be under determination without any compensation to the supplier & without exceed to the purchaser rights or compensations according to the contract or what are resulted beyond.

#### 25. Force Majeure

25.1 Notwithstanding the provisions of GCC Clauses 21, 22, and 23, the Supplier shall not be liable for forfeiture of its performance security, liquidated damages, or termination for default if and to the extent that it's delay in performance or other failure to perform its obligations under the Contract is the result of an event of Force Majeure.

25.2 For purposes of this clause, "Force Majeure" means an event beyond the control of the Supplier and not involving the Supplier's fault or negligence and not foreseeable. Such events may include, but are not restricted to, acts of the Purchaser in its sovereign capacity, wars or revolutions, fires, floods, epidemics, quarantine restrictions, and freight embargoes.

25.3 If a Force Majeure situation arises, the Supplier shall promptly notify the Purchaser in writing of such condition and the cause thereof. Unless otherwise directed by the Purchaser in writing, the Supplier shall continue to perform its obligations under the Contract as far as is reasonably practical and shall seek all reasonable alternative means for performance not prevented by the Force Majeure event.

#### 26. Termination for Convenience

26.1 The Purchaser, by written notice sent to the Supplier, may terminate the Contract, in whole or in part, at any time for the following cases :

- (a) for general benefit .

(b) in case there is no way to achieve the contract for any reason agreed which are outside the will of the two parties, which lead to impossible supplying.

For its convenience. The notice of termination shall specify that termination is for the Purchaser's convenience, the extent to which performance of the Supplier under the Contract is terminated, and the date upon which such termination becomes effective.

26.2 For the remaining goods, the Purchaser may elect:

- (a) to have any portion completed and delivered at the Contract terms and prices; and/or
- (b) to cancel the remainder and pay to the Supplier an agreed amount for partially completed Goods and Services and for materials and parts previously procured by the Supplier.

26.3 If the Contract is terminated for convenience of the Purchaser, the rights, duties and obligations of the parties, including all dues to the Supplier, shall be in accordance with the procedure set forth in Clause 27.

## 27. Settlement of Disputes

27.1 If any dispute or difference of any kind whatsoever shall arise between the Purchaser and the Supplier in connection with or arising out of the Contract, the parties shall make every effort to resolve amicably such dispute or difference by mutual consultation.

27.2 If, after thirty (30) days, the parties have failed to resolve their dispute or difference by such mutual consultation, then either the Purchaser or the Supplier may give notice to the other party of its intention to commence arbitration, as hereinafter provided, as to the matter in dispute, and no arbitration in respect of this matter may be commenced unless such notice is given.

27.2.1 Any dispute or difference in respect of which a notice of intention to commence arbitration has been given in accordance with this Clause shall be finally settled by arbitration. Arbitration may be commenced prior to or after delivery of the Goods under the Contract.

27.2.2 Arbitration proceedings shall be conducted in accordance with the rules of procedure **specified in the SCC**.

27.3 Notwithstanding any reference to arbitration herein,

- (a) the parties shall continue to perform their respective obligations under the Contract unless they otherwise agree; and
- (b) the Purchaser shall pay the Supplier any monies due the Supplier.

## 28. Limitation of Liability

28.1 Except in cases of criminal negligence or willful misconduct, and in the case of infringement pursuant to Clause 7,

- (a) the Supplier shall not be liable to the Purchaser, whether in contract, tort, or otherwise, for any indirect or consequential loss or damage, loss of use, loss of production, or loss of profits or interest costs, provided that this exclusion shall not apply to any obligation of the Supplier to pay liquidated damages to the Purchaser

## 29. Governing

29.1 The language of the Contract shall govern its

- Language** interpretation. All correspondence and other documents pertaining to the Contract that are exchanged by the parties shall be written in the same language.
- 30. Applicable Law** 30.1 The Contract shall be interpreted in accordance with the Iraqi Law and guardianship of Iraqi judicial system.
- 31. Notices** 31.1 Any notice given by one party to the other pursuant to this Contract shall be sent to the other party in writing or by cable (the term "cable" is deemed to include electronic mail, telex, or facsimile) and confirmed in writing to the other party's address **specified in the SCC.**
- 31.2 A notice shall be effective when delivered or on the notice's effective date, whichever is later.
- 32. Taxes and Duties** 32.1 A Supplier supplying Goods from abroad shall be entirely responsible for all taxes, stamp, duties, license fees, and other such levies imposed outside Iraq.
- 32.2 A Supplier supplying Goods offered from within Iraq shall be entirely responsible for all taxes, duties, license fees, etc., incurred until delivery of the contracted Goods to the Purchaser.
- 32.3 **The awarded company bears (the 2<sup>nd</sup> part that contracted with our company ) all customs fees.**
- 33. Withholding and lien in respect of sums claimed** 33.1 Whenever any claim or claims for payment of a sum of money arises out of or under the Contract of Republic of Iraq against the Supplier, the Purchaser shall be entitled to withhold and also have a lien to retain such sum or sums in whole or in part from the security, if any, deposited by the Supplier and for the purpose aforesaid, the Purchase shall be entitled to withhold the said cash security deposit or the security, if any, furnished as the case may be and also have a lien over the same pending finalization of any such claim. In the event of the security being insufficient to cover the claimed amount or amounts or if no security has been taken from the Supplier, the Purchaser shall be entitled to withhold and have lien to retain to the extent of the such claimed amount or amounts referred to supra, from any sum or sums found payable or which at anytime thereafter may become payable to the Supplier under the same Contract or any other Contract with the Purchaser or the Republic of Iraq, pending finalization of any such claim and that The Supplier shall have no claim for interest or damages whatsoever on this account or on any other ground in respect of any sum of money withheld or retained under this clause and duly notified as such to the Supplier.

**SECTION VIII. SPECIAL CONDITIONS OF CONTRACT****NOTES ON THE SPECIAL CONDITIONS OF CONTRACT**

{Similar to the Bid Data Sheet in Section II, the clauses in this Section are intended to assist the Purchaser in providing Contract-specific information in relation to corresponding clauses in the General Conditions of Contract (GCC).

The provisions of Section VIII complement the GCC included in Section VII, specifying contractual requirements linked to the special circumstances of the Purchaser Iraq, the sector, and the Goods purchased.

In preparing this section, the following aspects should be checked:

- (a) The correct version of the Special Conditions of Contract must be used as a base, dependent upon the type of Goods being procured.
- (b) Information that complements provisions of Section VII, GCC, must be incorporated
- (c) Amendments and/or supplements to provisions of Section VII, GCC, as necessitated by the circumstances of the specific purchase, must also be incorporated.

**Special Conditions of Contract**

The following Special Conditions of Contract shall supplement the General Conditions of Contract. Whenever there is a conflict, the provisions herein shall prevail over those in the General Conditions of Contract. The corresponding clause number of the GCC is indicated in parentheses.

GCC 1.1 (h)	The Purchaser is: [Ministry of Health / Environment / The State Company for Marketing Drugs and Medical Appliances (Kimadia) ].
GCC 1.1 (m)	The Supplier is: [insert: <b>name of Supplier</b> ].
GCC5	<p>5.3 In addition to what has mentioned in ITB(instructions to bidders) the following will be added.</p> <p>1-Provide the second party with the official letters related to contract execution and first party will never be responsible about the results of these correspondences.</p> <p>2- adoption the original copy of the contract which is signed by the two parties and which is saved at the first party as it is the copy that will refer to in case of any misunderstanding.</p> <p>3- Submit the original commercial lists to the import department before shipment are sent for each shipment otherwise, the 1<sup>st</sup> party will impose an import penalty according to the text of article GCC 22</p>
GCC6.2	<p>The Effective Date of the Contract starts from date of signing the contract when .</p> <p>1-Goods have already been registered.</p> <p>2- excluded from registration</p> <p>It will be effective starting from the date of receiving the registration certificate if the goods to be submitted by the successful bidder upon signing the contract are not registered</p>
GCC8	<p><b>- Presentation of Performance bond:</b></p> <p>Submit the banking guarantee after the issuance of the letter of awarding and keep valid all the period of the contract. The guarantee should not be cancelled unless there is a notification from Kimadia. A pledge should be submitted with the offer according to this matter.</p> <p>b-The Bank guarantee Should be issued by Iraqi governmental or private Iraqi Bank. These</p>

Tender/Number: MED/ 1/2020

Contracting Entity: Ministry of Health / Environment / The State Company For Marketing Drugs Medical Appliances (kimadia )

reliable government banks do not have the right to

issue bank guarantee to foreign company unless submitting a guarantee issued by foreign Bank (Back to Back) which has classification Issued by one of International classification organizations (Moody's standard and poor) and others or against monetary insurance not less than guarantee amount without the help of T.B.I . The guarantee should be in Arabic and English and the Arabic languages and the Arabic version should be the effective one.

C- performance guarantee should be issued by the order of the company which contracted with or with its legal authorized person for issuing the guarantee in accordance with an official authenticated authorization submitted to the bank and included in the term of guarantee or attached letter issued by the issuing bank .

d- The submission of the guarantee should be attached with an authentication letter of issuance (personal and confidential) send to kimadia by the bank who issued the guarantee. This guarantee should be unconditional and for the favor of (kimadia). Kimadia has the right to extend or confiscate the guarantee if required to do so, without any objection of correspondents or suppliers started from the first written claim

e- The companies and scientific bureaus should take in consideration the following when issued the good performance guarantee:-

1-The letters of guarantee should be issued by the name of the company which signed the contract exclusively.

2-Be sure that the contract no. is mentioned in the letter of guarantee .

3-the following statement should be written in the letter of guarantee (this guarantee is subject and explain in all matters according to the Iraqi laws).





	<p>4-The letter of guarantee should financially covered by the bank.</p> <p>5-Any letter of guarantee will not be received unless attaché with a formal letter issued by the bank who issued the letter of guarantee signed by the director of the bank or the one who represents him.</p> <p>6-The letter of guarantee should be written in (Arabic &amp;English) and the Arabic language is the one to rely upon when having any dispute.</p> <p>7-It should be valid for one year from date of issuing.</p> <p>8-It should not be direct or conditional.</p> <p>9- In case the supplier doesn't accept to make the modifications or extensions to the letters of performance guarantee or the supplier breaches, the amount of guarantee will be confiscated and deposit it in the account of our company.</p> <p>10-The letters of guarantee issued by the approved banks shall be received in accordance with a(bulletin —brochure) issued by central bank of Iraq.</p> <p>11-The letter of guarantee must be the same as the contract currency .</p>
GCC8.3	<p>The guarantee formula in item A of the general conditions of the contract is adopted , item (8.3) .</p>
GCC9.1	<p>In addition to what have been mentioned in the general conditions of the contract, the following are added:</p> <p>Receiving items will never be considered as confirmation for compliance to the specifications and technical conditions but it will relay on the results of laboratory tests issued by labs of Iraqi public health (National Center for control and medical research, Central Health Laboratory). After issuing the acceptance and testing decision by the central committee formed for that purpose and not only the result of lab analysis.</p> <p>-Samples will be sent to national center for control and medical research, for test and evaluation and their results are reliable.</p>



	<p>-Standard analysis substances (i.e. B.P.C Rst U.S.P Rst E.U.C Rst) not working standard together with method and authenticated certificate of analysis are to be sent with the request to our national center for medicine control &amp; research</p> <p>Any material or quantity that fails in the analysis as confirmed by our national center for control and medical research should be compensated by the supplier</p>
GCC9.2	<p>“9.2.1. (a) Said inspection and testing is for the Purchaser’s account. In the event that inspection and testing is required prior to dispatch, the Goods shall not be shipped unless a satisfactory inspection and quality control report has been issued in respect of those Goods.</p> <p>(b) The Supplier may have an independent quality test conducted on a batch ready for shipment. The cost of such tests will be borne by the Supplier.</p> <p>(c) Upon receipt of the Goods at place of final destination, the Purchaser’s representative shall inspect the Goods or part of the Goods to ensure that they conform to the condition of the Contract and advise the Purchaser that the Goods were received in apparent good order. The Purchaser will issue an Acceptance Certificate to the Supplier in respect of such Goods (or part of Goods). The Acceptance Certificate shall be issued at the earliest within fifteen (15) days from the date of supplying material entrance to the place of supplying specified by the first party</p>
	<p>9.2.2. In case the supplier objection with the results of test carried out by the labrotatories referred to in pharagraph GCC9.1 the test shall be repeated at the central labrotatories of the public health and the results will be conclusive.</p>
GCC10.2	<p>Medical items should be shipped in a form of palette covered by nylon and placed on a wooden basis.</p> <p>- on the outside cover of the pack (pallet or big carton) the national code, order no., and the quantity should be printed and on inside pack and small Pharmaceutical unit (ampoule or bottle or sheet) on good the mark of (MOH-Iraq) , beneficiary name and shelf life(MF&amp;Exp. Date) and to print (Batch no.) on all inside and outside packs as well as the smallest pharmaceutical unit.</p> <p>-Pallets should be with the following dimension in order to facilitate the process of</p>

receiving and storage of the arrived shipments.

\*Length 1200 M.M

\*Width 1000 M.M

\*Height 1000 M.M (Including the height of pallet based(

\*The weight of each pallet should be not more than 800 kilos

-All materials must be shipped in a cool condition and for all transporting ways till it reaches MOH/Kimadia stores. The seller will be responsible for the compensation of any material which fails in the analysis because of the unsuitable temperature degree during the transportation

In addition to what mentioned, the following are added:

-All shipments should be attached with commercial shipping lists packing lists and a true authenticated copy of certificate of origin.

-The supplier should submit the shipping documents before the arrival of the consignment within a period not less than 15 days and be responsible for any shortage or any delay caused by the lack of shipping documents.

-Delivery shall be as soon as possible within the period of credit validity and the shipping schedule shall be as required of Kimadia

-Receiving the supplied items upon their arrival to MOH/ Kimadia stores and the insurance of it (CIP) and not to be free from this obligation till organizing a formal minute of finishing in the place of delivery agreed upon.

-The contract should be supplied with a limited number of lots and the quantity of each lot should mentioned in the shipping list along with the manufacturing and expiry date.

-In case the item failed in the analysis of the national center for medicine control & research or any specialized party, the administrative charges will be added as equal to



15% from the total value of failed item with a delay fine in case the company will not ship the compensation item within the agreed period in the contract and with the agreed percentage.

- The supplier has to compensate the exp. QTY which are not used in stores of MOH and Kimadia stores at ratio 100% of the total QTY of exp. items.

-The seller should compensate the items failed in the analysis and the exp.. For technical reasons to the supplier at ratio 100% with 15% administrative charges from the total QTY of exp. items and impose a delay penalty in case not shipping the compensation QTY with same period and ratio which agreed upon in contract.

**-The compensation for the expired materials shall be within aperiod determined by the order of the 1<sup>st</sup> party (the buyer / kim).**

**-Compensation for material failing to be analyzed shall be during the processing period &for the period stipulated in the contract from the date of notification thereof.**

-The second party has to ensure the hidden defects or any failure in the product in duration parallel to shelf life of the product concerning the products subject for shelf life the and the products that do not subject for shelf life, the 2nd party has to ensure above defects for five years starting from the date of receiving tests results.

-in case the company does not ship the compensation products within the same agreed period in the contract starting from the date of notifying him . The calculation of the shipping period per 2nd shipment will be started after the arrival of the compensated shipment if the contract was multiple shipments otherwise a delay penalty will be imposed according to the ratio that mentioned on the agreed penalties articles and in case the company has not compensate within the mentioned period,



kimadia has the right to buy the products from another source on contractor expense and making him bear the difference in price and confiscate all insurance. In addition, it has the right to go to the concerned court in order to obtain its rights

-The seller is responsible to compensate the buyer for the defected items or shortage that appear after the distribution, usage of goods in the hospital and after the necessary checking and analysis and if it is due to a manufacturing defect.

-the seller should compensate the damaged , failed in analysis, missing, shortage items, and the items which not comply with specification required within delivery period stated in contract provided that the period starts from the date of notifying the company about the fail or shortage or missing taken into consideration that the period must be within the period of execution the contract and the other shipments must be shipped within the same shipping schedule from the date of shipping the compensation QTY otherwise the delay penalty will be imposed at the same percentage stated in penalties terms which agreed upon in case the company does not compensate within mentioned period, kimadia has the right to buy the products from another source on contractor expense and making him bear the difference in price and confiscate all insurance.

In addition, it has the right to go to the concerned court in order to obtain its rights.

-The seller must stamp the phrase (failed and not fit to consumption MOH-KIMADIA) on the failure qty. or not compliance to specification in MOH/ Kimadia stores on. The supplier shall bear all the expenses.

Any item or quantity that fails in analysis of the national center for medicine control & research is to be compensated by the manufacturer.

In case the item failed in the analysis or have been expired and the company does not respond for compensation within 15 days after sending a warning letter including the compensation & draw the failed or expired item, kimadia has the right to destroy the



	failed or expired items & dropping the right of the company for getting back the item or its value.
GCC 11.1	{ <b>Sample provision (CIF/CIP/DDP terms)</b> <b>For Goods supplied from abroad:</b>
& 11.3	<p>Upon shipment, the Supplier shall notify the Purchaser and the insurance company in writing the full details of the shipment including Contract number, description of the Goods, quantity, date and place of shipment, mode of transportation, and estimated date of arrival at place of destination. In the event of Goods sent by airfreight, the Supplier shall notify the Purchaser a minimum of forty-eight (48) hours ahead of dispatch, the name of the carrier, the flight number, the expected time of arrival, and the waybill number. The Supplier shall fax and then send by express courier the following documents to the Purchaser, with a copy to the insurance company:</p> <ul style="list-style-type: none"> <li>(i) three originals and two copies of the Supplier’s invoice, showing Purchaser as [enter correct description of Purchaser for customs purposes]; the Contract number, Goods description, quantity, unit price, and total amount. Invoices must be signed in original, stamped, or sealed with the company stamp/seal;</li> <li>(ii) one original and two copies of the negotiable, clean, on-board through bill of lading marked “freight prepaid” and showing Purchaser as [enter correct name of Purchaser for customs purposes] and Notify Party as stated in the Contract, with delivery through to final destination as per the Schedule of Requirements and two copies of non-negotiable bill of lading, or three copies of railway consignment note, road consignment note, truck or air waybill, or multimodal transport document, marked “freight prepaid” and showing delivery through to final destination as per the Schedule of Requirements;</li> <li>(iii) four copies of the packing list identifying contents of each package;</li> <li>(iv) copy of the Insurance Certificate, showing the Purchaser as the beneficiary; in case CIP , CIF .</li> <li>(v) one original of the manufacturer’s or Supplier’s Warranty Certificate covering all items supplied;</li> <li>(vi) one original and six copies of the Supplier’s Certificate of country of Origin covering all items supplied and associated trading lists endorsed by the relevant Iraqi Commercial Agencies outside Iraq. For items originating from countries member of the Arab Common Market, the certificates of origin and associated trading lists endorsed by the competent country of origin authority shall be sufficient;</li> <li>(vii) original copy of the Certificate of Inspection furnished to Supplier by the nominated inspection agency and six copies (where inspection is required);</li> <li>(viii) any other procurement-specific documents required for delivery/payment purposes.</li> </ul> <p><b>For Goods from within Iraq:</b> Upon or before delivery of the Goods, the Supplier shall notify the Purchaser in writing and deliver the following documents to the Purchaser:</p> <ul style="list-style-type: none"> <li>(i) two originals and two copies of the Supplier’s invoice, showing Purchaser, the Contract number; Goods’ description, quantity, unit price, and total amount. Invoices must be signed in original and stamped or sealed with the company</li> </ul>

Tender/Number: MED/ 1/2020

Contracting Entity:Ministry of Health / Environment / The State Company For Marketing

Drugs Medical Appliances (kimadia )



	<p>stamp/seal;</p> <p>(ii) two copies of delivery note, railway consignment note, road consignment note, truck or air waybill, or multimodal transport document showing Purchaser as [ enter correct name of Purchaser] and delivery through to final destination as stated in the Contract;</p> <p>(iii) copy of the Insurance Certificate, showing the Purchaser as the beneficiary;</p> <p>(iv) four copies of the packing list identifying contents of each package;</p> <p>(v) one original of the manufacturer’s or Supplier’s Warranty certificate covering all items supplied;</p> <p>(vi) one original of the Supplier’s Certificate of country of Origin covering all items supplied and associated trading lists endorsed by the relevant Iraqi Commercial Agencies outside Iraq. For items originating from countries member of the Arab Common Market, the certificates of origin and associated trading lists endorsed by the competent country of origin authority shall be sufficient;</p> <p>(vii) original copy of the Certificate of Inspection furnished to Supplier by the nominated inspection agency and six copies (where inspection is required)</p> <p>(viii) other procurement-specific documents required for delivery/payment purposes.</p> <p><b>Note:</b> In the event that the documents presented by the Supplier are not in accordance with the Contract, then payment will be made against issue of the Acceptance Certificate, to be issued in accordance with SCC 9 (GCC 9) above.</p>
GCC 15	<u>15.1</u>
	<p>“15.1 All goods must be of fresh manufacture and must bear the manufacture and expiry dates. The Supplier further warrants that all Goods supplied under this Contract unless otherwise specified by the contract , will have remaining a minimum of five-sixths (5/6) of the specified shelf life upon arrival to KIMADIA stores for goods with a shelf life of more than two years and the items with a shelf life of two years not more than 3 months (maximum) passed upon their manufacturing ; otherwise a financial penalty will be imposed according to the ratios mentioned in pharagraph GCC22.</p>
	<p>15.2 The Purchaser shall have the right to make claims under the above warranty for three months after the Goods have been delivered to the final destination indicated in the Contract. Upon receipt of a written notice from the Purchaser, the Supplier shall, with all reasonable speed, replace the defective Goods without cost to the Purchaser. The Supplier will be entitled to remove, at his own risk and cost, the defective Goods</p>



	once the replacement Goods have been delivered.
	15.3 Not applicable (In the event of a dispute by the Supplier, a counter analysis will be carried out on the manufacturer’s retained samples by an independent neutral laboratory agreed by both the Purchaser and the Supplier. If the counter analysis confirms the defect, the cost of such analysis will be borne by the Supplier as well as the replacement and disposal of the defective goods. In the event of the independent analysis confirming the quality of the product, the Purchaser will meet all costs for such analysis.)
	15.4 If, after being notified that the defect has been confirmed pursuant to GCC Sub-Clause 15.2 above, the Supplier fails to replace the defective Goods within the period for the replacement of defective goods of [insert <b>period for replacement of defective goods</b> ], the Purchaser may proceed to take such remedial action as may be necessary, including removal and disposal, at the Supplier’s risk and expense and without prejudice to any other rights that the Purchaser may have against the Supplier under the Contract. The Purchaser will also be entitled to claim for storage in respect of the defective Goods for the period following notification and deduct the sum from payments due to the Supplier under this Contract.
	15.5 Recalls. In the event any of the Goods are recalled, the Supplier shall notify the Purchaser within fourteen (14) days, providing full details of the reason for the recall and promptly replace, at its own cost, the items covered by the recall with Goods that fully meet the requirements of the Technical Specification and arrange for collection or destruction of any defective Goods. If the Supplier fails to fulfill its recall obligation promptly, the Purchaser will, at the Supplier’s expense, carry out the recall.”}
GCC16.1	<p>{Sample provision: The method and conditions of payment to be made to the Supplier under this Contract shall be as follows: {In case the Supplier is a Public Entity (Public Sector Company), then the Contracting Entity may increase the Advance Payment to x% from the value of contract.and according to instructions }</p> <p><b>A. Payment for Goods supplied from abroad:</b> Payment of foreign currency portion shall be made in [ USD and ID]in special exception cases in the following manner:</p> <p>(i) <b>Advance Payment:</b>( not applied) section VIII</p> <p>(ii) <b>On Shipment:</b>the purchaser should pay to the supplier according to percent of the Contract Price of the Goods shipped shall be paid through irrevocable confirmed letter of credit opened in favor of the Supplier in a bank in its country, upon submission of documents specified in GCC Clause 11 . Opening charges and charges for amendment of the letter of credit at the request of or due to a fault or default of the Purchaser are for the account of the Purchaser. Confirmation charges and</p>

Tender/Number: MED/ 1/2020

Contracting Entity:Ministry of Health / Environment / The State Company For Marketing

Drugs Medical Appliances (kimadia )





	<p>charges for amendment to letters of credit at the request of or due to a fault or default on behalf of the Supplier are for the account of the Supplier.</p> <p>- Payment terms:</p> <ul style="list-style-type: none"> <li>- .50% upon submitting shipping documents.</li> <li>- 50% after the arrival of materials to the warehouses of kimadia and acceptance.</li> </ul> <p style="text-align: center;">and release award</p> <p>shall be paid within [thirty (30)] days of receipt of the Goods upon submission of an invoice (showing Purchaser's name; the Contract number, description of payment and total amount, signed in original, stamped or sealed with the company stamp/seal) supported by the Acceptance Certificate issued by the Purchaser.</p> <p>B. Payment for Goods and Services supplied from within the Iraq: Payment for Goods and Services supplied from within Iraq shall be made in Iraqi Dinar, as follows upon receiving the financial allocation:</p> <ol style="list-style-type: none"> <li>1 -It is 100% after examination and acceptance and after financial allocation has been recieved</li> <li>2-the conditions which are mentioned above will be agreed on by the two parties as per kind of item &amp; contract amount.</li> </ol>
GCC16.3	The payment or payments will be settled as soon as possible after receiving the result of the laboratory tests according to the conditions of the announcement
GCC18	18.2 the contracting entity may increase the quantity of goods or materials or non-consulting services or amend its technical specifications which contracted upon by not more than 20% of the contract amount .
GCC19	19.1 - In addition to what have been mentioned in the general conditions of the contract, the following are added:  any change is not allowed in contract by the supplier unless there is an agreement between the two parties otherwise the 2nd party considered a breach of his contractual



	<p>commitments and kimadia has the right to take the legal procedures or impose penalty at ratio not less than 1% and not more than 5% for shipping quantity of the arrival item which not comply with our contractual conditions.</p>
GCC 20.1	<p>can not be waived of contract or apart of it</p>
GCC21	<p>21.2in addition to what mentioned in the general conditions of contract , the following reasons should be taken into consideration upon extension the contract:</p> <p><u>First:</u></p> <p>A. If any increase or change occurred in The required supplying quantity(qualitative, quantitative) which may effect the executing program which has been agreed upon as it can not be fulfilled within the agreed period in the original contract.</p> <p>B. If the delay of executing the contract related to reasons or procedures of the contracting party or any authorized legal party or to any reason of other contactors which the company owner used.</p> <p>C.If an exceptionable condition have occurred after contracting which is out of contractors control and which can't be avoided or expected upon contracting and which caused a delay in completing the works or supplying the required items according to the contract.</p> <p><u>Second:</u></p> <p>The application of the provisions of this article stipulated that the supplier should submit a written request for contracting party within 15 days started from the date of the cause arising which accordingly the extend has been requested indicating in it the accurate and complete details for any request to extend the period, Any request for extension will not be accepted if presented after issuing the primary receiving certificate mentioned in the contract conditions</p>



GCC22

22.1 First: contract penalties:

1- KIMADIA has the right to impose penalty not less than 1% and not more than 5% from the amount of material shipped in case of :

a-Any change in the contract by the supplier without the consent of the first party as mentioned in paragraph GCC 19.1

b-In case of any shortage in any document required from the supplier

c-In case of contrary to paragraph 15.1 regarding to life of material

d-In case of contrary to paragraph GCC regarding to packaging

e- In case of contravention by the supplier (second party) need to impose penalty from the first party

second: Delay penalties

a- delivery in accordance with the scheduling of shipping and delivery mentioned in the paragraph of delivery and shipping and otherwise impose a delay day without prior notice and according to the following equation:

Amount of contract (original amount of contract + any amendment in amount) / the total duration of contract (original duration of contract + any change in duration) x 10% = fine per day that does not exceed 10% from amount of contract . After the delay penalty reaches its maximum , legal actions can be used according to articles 10,3 from the instructions of implementing the governmental contracts no.(2) year 2014

b-The delay penalty shall be deducted upon expiry of the original contract period with any additional period or upon desert in case of partial shipment

c- Penalties are reduced according to the completion rates of the contractual obligation specified in the text of implementing the contracts which has a certificate of first delivery according to the following equation :-

The value of not implemented commitment /total duration of contract X

	<p style="background-color: yellow;">10% =fine per day</p> <p>-When the contracted company hide any essential information which will be discovered later on , legal procedures will be taken or imposing a penalty at rate not less than 1% and not more than 5% of the quantity shipped for the arrived material and violated of our contractual conditions.</p>
GCC23	<p>23.1 In addition to what is stated in this item of the general condition: In case the supplier does not respond during the warning period and through the approved email which is written down in the contract the legal procedures shall be taken in accordance with the provisions of article 10 of the instruction of implementing the governmental contractno.2 in 2014 with respect to the confiscation or retention of legal insurance provided that the contract is executed on his expense according to the conditions of article 3 of the above instruction and according to the methods of implementation</p>
GCC24	<p>Item 24 G of the general conditions does not apply</p>
GCC27.2.2	<p>This cluse from general conditions contract it should be as:</p>
	<p><b>for contracts with Supplier national of Iraq:</b>          “In the case of a dispute between the Purchaser and a Supplier who is a national of Iraq, the dispute shall be referred to conciliation or arbitration in accordance with the laws of the Iraqi Laws and guardianship of the Iraqi judicial system and according to adopted procedures.”]          -Any amount in the second party account which resulted from breaching any contractual commitment the first party has the right to claim the amount in the specialized court as well as the confiscation in case the requirements have been achieved          - In case of the bidder has not complied with executing the conformed order and according to the agreed conditions a legal procedure will be taken against him.</p>
GCC28	<p><b>Deleted</b></p>
GCC31.1	<p>Kimadia email is: dg@kimadia.iq          Insert :the supplier's address for the purpose of notifying and if by cable is acceptable provided that it should be followed by a written letter          -The scientific bureau which represents the company and authorized representative of the company ( Trade manager, manager...etc) is the one to which the Judicial notifications will be sent.</p>



	<p>-email is considered one of the approved methods of directing warning</p>
GCC32	<p>The Government debts are picked up in accordance with the Iraqi Law for collecting government debts No.56 of year 1977</p> <p>-The Contract is subject to Iraqi laws including laws of tax No. 113 for the year 1982 ,instruction of accounting tax of contracts between Iraqi contracting entry with foreign parties N02 for the year 2008 , the stamp fee N071 for the year 2012 , Notary fees and re-announcement charges.</p> <p>1- Earning an amount of (100) hundred thousand Iraqi Dinars upon request for exchanging the border outlet.</p> <p>2- Earning an amount of (25) twenty five thousand Iraqi Dinars for each unloaded and loading receipt for each shipment that arrived to the target store</p> <p>3- Earning an amount of (10) ten thousand Iraqi Dinars for parking and parking overnight for the trucks that specified for transporting the drug and appliances to the stores of kimadia/Ministry of Health.</p> <p>4- Earning an amount of (250) two hundred fifty thousand Iraqi Dinars for each objection request presented by the Scientific Bureau or company for any Importing status.</p> <p>- All bank charges (opening, issuing for L/C and amendments fees ...etc) inside and outside Iraq are on the seller expenses till reaching the company stores</p> <p><b>The awarded company bears (the 2<sup>nd</sup> part that contracted with our company ) all customs fees.</b></p>



**Special Conditions of Contract  
PHARMACEUTICALS  
(Additional Clauses)**

{ Note: The below data should be included in the Special Conditions of Contract used in Bidding Documents for the procurement of pharmaceuticals, otherwise, delete }

GCC 11.1 & 11.3	<p><b>For Goods supplied from abroad:</b></p> <ul style="list-style-type: none"> <li>(ix) One original of the Certificate of Pharmaceutical Product as recommended by the WHO for each of the items supplied.</li> <li>(x) Certificate of quality control test results in conformity with the World Health Organization “Certification Scheme on the Quality of Pharmaceutical Products Moving in International Trade” stating quantitative assays, chemical analysis, sterility, pyrogen content, uniformity, microbial limit, and other tests as appropriate to the Goods.</li> <li>(xi) Original copy of the certificate of weight issued by the port authority/licensed authority and six copies.</li> </ul>
-----------------	--

**Special Conditions of Contract**  
**VACCINES**  
 (Additional Clauses)

GCC 11.1 & 11.3	<p><b>For Goods supplied from abroad:</b></p> <ul style="list-style-type: none"> <li>(ix) one copy of the Lot Release Certificate issued by the NCA of the country of manufacture for each lot shipped.</li> <li>(x) Certificate of quality control test results in conformity with the World Health Organization "Certification Scheme on the Quality of Pharmaceutical Products Moving in International Trade" stating quantitative assays, chemical analysis, sterility, pyrogen content, uniformity, microbial limit, and other tests as appropriate to the Goods.</li> <li>(xi) Original copy of the certificate of weight issued by the port authority/licensed authority and six copies.</li> </ul> <p><b>For Goods from within the Purchaser's country:</b></p> <ul style="list-style-type: none"> <li>(x) one copy of the Lot Release Certificate issued by the NCA of the country of manufacture for each lot shipped.</li> </ul>
GCC 15.1	<p><b>[Sample clauses:</b></p> <p>The Purchaser reserves the right to request evidence of bio-availability and/or bio-equivalence data and/or evidence of the basis for expiration dating and other stability data concerning the Goods to verify shelf life claimed for the Goods.</p> <p>If an adverse event following immunization (AEFI) occurs in the Purchaser's country and the cause of such event cannot be immediately established, the Purchaser will, with all urgency and in accordance with the procedures laid down by the NCA of the Purchaser's country, take steps to advise the Supplier in order that an investigation may be launched immediately. If the vaccine has been supplied through an agency of the United Nations, the most current procedures laid down by the WHO for such situations will be used.]</p>
	<p><b>The awarded company bears (the 2<sup>nd</sup> part that contracted with our company ) all customs fees.</b></p>



## SECTION IX. CONTRACT FORMS

### NOTES PREPARING THE CONTRACT FORMS

The Sample Contract Forms provided in this SSBD provide standard formats for a number of the key documents that the Purchaser and Supplier will exchange in the process awarding and implementing the Contract.

**Form of Contract Agreement:** Except as indicated by blanks and/or instructions to fill in information, the text of the Contract Agreement should be left unaltered in the Bidding Documents from how it appears in this SSBD. It would be at the time of Contract award when the Contracting Entity has an opportunity to add the final details needed in the Contract Agreement form, by making any necessary insertions or changes to paragraph 2.

**Performance Security Form:** Pursuant to GCC Sub-Clause 8.1, the successful Bidder is required to provide the performance security within fourteen (14) days of notification of Contract award, or twenty-nine (29) days in case of Complaints and Appeal as per ITB 36.1.

**Advance Payment Bank Guarantee:** Pursuant to GCC Sub-Clause 16.1, the successful Bidder is required to provide a bank guarantee securing the advance payment, if SCC related to GCC Sub-Clause 16.1 requests for one.





الله أكبر

Republic of Iraq

### CONTRACT FORMS

---

1. Form of Contract Agreement
2. Performance Security Bank Guarantee
3. Bank Guarantee Form for Advance Payment

---

Tender/Number: MED/ 1/2020

Contracting Entity:Ministry of Health / Environment / The State Company For Marketing

Drugs Medical Appliances (kimadia )

---

**1. Form of Contract Agreement**

THIS CONTRACT AGREEMENT is made

the [ insert: **number** ] day of [ insert: **month** ], [ insert: **year** ].

BETWEEN

(1) [ The State Company For Marketing

Drugs Medical Appliances represent by the general manager and chairman of the board in addition to his job ], a [ insert: **description of type of legal entity**, for example, an agency of the Ministry of ... of the Government of Iraq, or corporation incorporated under the laws of Iraq and having its principal place of business at [ insert: **address of Purchaser** ] (hereinafter called "the Purchaser"), and

(2) [insert: **name of Supplier**], a corporation incorporated under the laws of [insert: **country of Supplier**] and having its principal place of business at [insert: **address of Supplier**] (hereinafter called "the Supplier").

WHEREAS the Purchaser invited bids for certain goods and ancillary services, viz., [insert: **brief description of goods and services**] and has accepted a bid by the Supplier for the supply of those goods and services in the sum of [insert: **contract price in words and figures**] (hereinafter called "the Contract Price").

NOW THIS AGREEMENT WITNESSETH AS FOLLOWS this agreement confirm that the two parties are agreement as follow :

1. In this Agreement words and expressions shall have the same meanings as are respectively assigned to them in the Conditions of Contract referred to.
2. The following documents shall constitute the Contract between the Purchaser and the Supplier, and each shall be read and construed as an integral part of the Contract:
  - (a) This Contract Agreement
  - (b) Special Conditions of Contract
  - (c) General Conditions of Contract
  - (d) Technical Requirements (including Technical Specifications)
  - (e) The Supplier's bid and original Price Schedules
  - (f) Schedule of Requirements
  - (g) The Purchaser's Notification of Award
  - (h) [Add here: **any other documents**]
3. In consideration of the payments to be made by the Purchaser to the Supplier as hereinafter mentioned, the Supplier hereby covenants with the Purchaser to provide the Goods and Services and to remedy defects therein in conformity in all respects with the provisions of the Contract.
4. The Purchaser hereby covenants to pay the Supplier in consideration of the provision of the Goods and Services and the remedying of defects therein, the Contract Price or such other sum as may become payable under the provisions of the Contract at the times and in the manner prescribed by the Contract.

For and on behalf of the Purchaser

Signed: \_\_\_\_\_

in the capacity of [insert: **title or other appropriate designation**]

in the presence of \_\_\_\_\_

For and on behalf of the Supplier

Signed: \_\_\_\_\_

in the capacity of [ insert: **title or other appropriate designation**]

in the presence of \_\_\_\_\_

Tender/Number: MED/ 1/2020

Contracting Entity:Ministry of Health / Environment / The State Company For Marketing

Drugs Medical Appliances (kimadia )



الله أكبر

Republic of Iraq

CONTRACT AGREEMENT

Dated the [ insert: **number**] day of [ insert: **month**], [ insert: **year**]

BETWEEN

[Insert: **name of Purchaser**], “the Purchaser”

and

[insert: **name of Supplier**], “the Supplier”

---

Tender/Number: MED/ 1/2020

Contracting Entity:Ministry of Health / Environment / The State Company For Marketing

Drugs Medical Appliances (kimadia )

---



2. Performance Security Bank Guarantee

[The Bank shall fill in this Bank Guarantee Form in accordance with the relevant conditions of Contract.]& it prefer us the central Iraqi Bank form .

\_\_\_\_\_ [insert: Bank's Name and Address of Issuing Branch or Office]

Beneficiary: \_\_\_\_\_ [insert: Name and Address of Purchaser]

Date: \_\_\_\_\_

PERFORMANCE GUARANTEE No.: \_\_\_\_\_

We have been informed that [insert: name of Supplier] (hereinafter called "the Supplier") has entered into Contract No. [insert: reference number of the contract] dated \_\_\_\_\_ with you, for the supply of [insert: description of goods] (hereinafter called "the Contract").

Furthermore, we understand that, according to the conditions of the Contract, a performance guarantee is required.

At the request of the Supplier, we [insert: name of Bank] hereby irrevocably undertake to pay you any sum or sums not exceeding in total an amount of [insert: amount in figures] (\_\_\_\_) [insert: amount in words] upon receipt by us of your first demand in writing accompanied by a written statement stating that the Supplier is in breach of its obligation(s) under the Contract, without your needing to prove or to show grounds for your demand or the sum specified therein.

This guarantee shall expire no later than the \_\_\_\_ day of month \_\_\_\_\_, 2\_\_\_\_\_, and any demand for payment under it must be received by us at this office on or before that date.

This guarantee is subject to the Uniform Rules for Demand Guarantees, ICC Publication No. 458, except that subparagraph (ii) of Sub-article 20(a) is hereby excluded.

\_\_\_\_\_  
[signature(s)]

### 3. Bank Guarantee Form for Advance Payment

[The Bank shall fill in this Bank Guarantee Form in accordance with the relevant conditions of Contract.] & it prefer us the central Iraqi Bank form .

\_\_\_\_\_ [insert: **Bank's Name and Address of Issuing Branch or Office**]

**Beneficiary:** \_\_\_\_\_ [insert: **Name and Address of Purchaser**]

**Date:** \_\_\_\_\_

**ADVANCE PAYMENT GUARANTEE No.:** \_\_\_\_\_

We have been informed that [insert: **name of Supplier**] (hereinafter called "the Supplier") has entered into Contract No. [insert: **reference number of the contract**] dated \_\_\_\_\_ with you, for the supply of [insert: **description of goods**] (hereinafter called "the Contract").

Furthermore, we understand that, according to the conditions of the Contract, an advance payment in the sum [insert: **amount in figures**] (\_\_\_\_\_) [insert: **amount in words**] is to be made against an advance payment guarantee.

At the request of the Supplier, we [insert: **name of Bank**] hereby irrevocably undertake to pay you any sum or sums not exceeding in total an amount of [insert: **amount in figures**] (\_\_\_\_) [insert: **amount in words**] upon receipt by us of your first demand in writing accompanied by a written statement stating that the Supplier is in breach of its obligation under the Contract because the Supplier used the advance payment for purposes other than toward delivery of the goods.

It is a condition for any claim and payment under this guarantee to be made that the advance payment referred to above must have been received by the Supplier on its account number \_\_\_\_\_ at \_\_\_\_\_ [insert: **name and address of Bank**].

This guarantee shall expire, at the latest, upon our receipt of copy (ies) of \_\_\_\_\_<sup>1</sup>, or on the \_\_\_ day of \_\_\_\_\_, 2\_\_\_\_,<sup>2</sup> whichever is earlier. Consequently, any demand for payment under this guarantee must be received by us at this office on or before that date.

This guarantee is subject to the Uniform Rules for Demand Guarantees, **in Iraq**

[Signature]

<sup>1</sup> Insert documents establishing "delivery" of the goods in accordance with the particular INCOTERMS® selected. (See SCC 11.)

<sup>2</sup> Insert the delivery date stipulated in the original delivery schedule. The Purchaser should note that in the event of an extension of the time to perform the Contract, the Purchaser would need to request an extension of this guarantee from the Guarantor. Such request must be in writing and must be made prior to the expiration date established in the guarantee. In preparing this guarantee, the Purchaser might consider adding the following text to the form, at the end of the penultimate paragraph: "The Guarantor agrees to a one-time extension of this guarantee for a period not to exceed [six months/one year], in response to the Purchaser's written request for such extension, such request to be presented to the Guarantor before the expiry of the guarantee."